Entwicklung und Charakterisierung von gefriergetrockneten Tabletten mittels Lyoc® Technologie by Hernandez, Faustine
  
Entwicklung und Charakterisierung von 
gefriergetrockneten Tabletten mittels Lyoc® 
Technologie 
 
 
 
 
 
 
 
 
Dissertation 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Eberhard Karls Universität Tübingen 
zur Erlangung des Grades eines  
Doktors der Naturwissenschaften  
(Dr. rer. nat.) 
 
 
 
 
 
 
vorgelegt von 
Faustine Hernandez 
aus Colmar/Frankreich 
   
 
 
 
Tübingen 
2018  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der 
Eberhard Karls Universität Tübingen. 
 
 
Tag der mündlichen Qualifikation:  23.04.2019 
Dekan: Prof. Dr. Wolfgang Rosenstiel 
1. Berichterstatter: Prof. Dr. Rolf Daniels 
2. Berichterstatter: Prof. Dr. Stephan Reichl  
  
  
Acknowledgements  
 
The realization of the present dissertation could become true thanks to Prof. Dr. Rolf Daniels. 
Before beginning my dissertation, I would like to offer my sincere appreciation and gratitude 
to Prof. Dr. Rolf Daniels, who accepted me in his team, and allowed me to achieve and complete 
my PhD at the University of Tübingen, in collaboration with TEVA. I am deeply grateful for 
his support and his constructive comments, which enabled the progress of my work.  
I am also thankful to Prof. Dr. Martin A. Wahl who accepted to be the co-rapporter of my 
dissertation.  
This collaboration with TEVA could not happen without the help of Dr. Dieter Swatschek, 
Head of Formulation Development Department at TEVA and of my supervisor Dr. Michael 
Rottke, Formulation scientist, who offered me the chance to perform my PhD within TEVA. I 
am also thankful to my supervisor, Dr. Michael Rottke, who gave me all the tools to understand 
the aspects of lyophilization and for his exemplary guidance, monitoring and constant 
encouragement throughout the course of the project I was assigned to. It has been a rewarding 
experience to work with him and to learn the galenic environment on his side. I also thank Dr. 
Tanja Westphal-Mirzad who supported me for the achievement of my PhD. 
A special thank goes to Dr. Dominique J. Lunter, Klaus Weyhing and Irina Eck who kindly 
contributed to my work and helped me by the diverse measurements at the University of 
Tübingen. 
I also would like to thank all the staff members of TEVA who also helped me during my 
experimental work. 
To finish, I would like to particularly thank my family who unconditionally supported me 
during this whole years. 
I 
 
Table of Contents 
1 Introduction and Goal ........................................................................................................ 1 
2 Theory and Scientific Knowledge ..................................................................................... 2 
2.1 Orally Disintegrating Tablets .......................................................................................... 2 
2.1.1 Definition, Advantages and Drawbacks of ODTs .................................................... 2 
2.1.2 System of Action of ODTs ....................................................................................... 4 
2.1.2.1 Absorption ......................................................................................................... 4 
2.1.2.2 Distribution ........................................................................................................ 6 
2.1.2.3 Metabolism ........................................................................................................ 7 
2.1.2.4 Excretion ........................................................................................................... 7 
2.1.3 Manufacturing Technologies of ODTs ..................................................................... 7 
2.1.3.1 Zydis® Technology ........................................................................................... 9 
2.1.3.2 Lyoc® Technology.......................................................................................... 10 
2.1.3.3 QuickSolv® Technology ................................................................................. 12 
2.1.3.4 Zydis® vs. Lyoc® ........................................................................................... 12 
2.2 Freeze-drying in ODTs .................................................................................................. 13 
2.2.1 Generalities (Jennings, 2008d) ................................................................................ 13 
2.2.2 Lyophilization Cycle ............................................................................................... 13 
2.2.2.1 Freezing step ................................................................................................... 14 
2.2.2.2 Primary Drying (P.D) ...................................................................................... 21 
2.2.2.3 Secondary Drying (S.D) .................................................................................. 26 
2.2.3 Equipment Presentation (AzbilTelstar, 2015; Jennings, 2008c) ............................. 28 
2.2.3.1 Drying Chamber .............................................................................................. 28 
2.2.3.2 Condenser Chamber ........................................................................................ 29 
2.2.3.3 Vacuum Pump ................................................................................................. 29 
2.2.3.4 Sensors ............................................................................................................ 29 
2.2.4 Product Formulation ............................................................................................... 29 
2.2.4.1 Formulation Development ............................................................................... 30 
2.2.4.2 Suspension ....................................................................................................... 32 
3 Materials and Methods ..................................................................................................... 35 
3.1 Materials ................................................................................................................... 35 
3.1.1 Fillers Used ....................................................................................................... 35 
3.1.2 Hardness Builders ................................................................................................... 35 
II 
 
3.1.3 APIs ......................................................................................................................... 36 
3.1.4 Other Excipients ...................................................................................................... 36 
3.2 Equipments and Software ......................................................................................... 36 
3.2.1 Manufacturing Process Flow Chart ........................................................................ 38 
3.2.2 Manufacture of the Suspension ............................................................................... 38 
3.2.3 IPC on the Suspension ............................................................................................ 39 
3.2.3.1 Determination of the Critical Temperature ..................................................... 39 
3.2.3.2 Viscosity Measurement ................................................................................... 39 
3.2.3.3 Degree of Sedimentation ................................................................................. 40 
3.2.4 Lyocs® Manufacture .............................................................................................. 40 
3.2.5 In Process Control on Lyocs® ................................................................................ 42 
3.2.5.1 Visual Aspect .................................................................................................. 42 
3.2.5.2 Weight, Dimension and Resistance to Crushing (Hardness) .......................... 42 
3.2.5.3 Disintegration Time ......................................................................................... 42 
3.2.5.4 Moisture Content ............................................................................................. 42 
3.2.5.5 Scanning Electron Microscopy (SEM) ........................................................... 43 
3.2.5.6 Solid State Determination ............................................................................... 43 
3.2.5.7 Raman Microscopy ......................................................................................... 44 
3.2.5.8 Porosity ............................................................................................................ 45 
3.2.5.9 API Release – Paracetamol Lyocs® ............................................................... 46 
3.2.5.10 Uniformity of Dosage Form – Paracetamol Lyocs® .................................... 46 
3.2.5.11 Statistical Analysis ........................................................................................ 47 
4 Results and Discussion .................................................................................................... 49 
4.1 Excipient Screening ....................................................................................................... 49 
4.1.1 Study on Diluents .................................................................................................... 49 
4.1.1.1 Substance Description ..................................................................................... 49 
4.1.1.2 Suspension Characterization ........................................................................... 51 
4.1.2 Study on Binders ..................................................................................................... 53 
4.1.2.1 Substance Description ..................................................................................... 54 
4.1.2.2 Suspension Characterization ........................................................................... 56 
4.1.3 Pre-formulation of Lyocs® ..................................................................................... 56 
4.1.3.1 Test on Mannitol ............................................................................................. 57 
4.1.3.2 Type of Mannitol ............................................................................................. 62 
III 
 
4.1.4 Conclusion .............................................................................................................. 78 
4.2 Influence of Binder on Suspension and Lyoc® (DoE) .................................................. 78 
4.2.1 DoE Mannitol/Hypromellose .................................................................................. 79 
4.2.1.1 Definition of Formulation Factors and Responses .......................................... 79 
4.2.1.2 DoE Trial ......................................................................................................... 79 
4.2.1.3 Statistical Analysis .......................................................................................... 80 
4.2.2 DoE Mannitol/Dextran ............................................................................................ 87 
4.2.2.1 Definition of Formulation Factors and Responses .......................................... 87 
4.2.2.2 DoE Trial ......................................................................................................... 87 
4.2.2.3 Statistical Analysis .......................................................................................... 88 
4.3 Influence of water soluble and limited-water soluble APIs on Lyocs® ........................ 96 
4.3.1 Study on Water-Soluble APIs ................................................................................. 96 
4.3.1.1 Metoclopramide HCl Lyocs® ......................................................................... 96 
4.3.1.2 Metamizol Sodium Lyocs® .......................................................................... 105 
4.3.2 Study on Less-Water Soluble APIs ....................................................................... 111 
4.3.2.1 Paracetamol Lyocs® ..................................................................................... 111 
4.3.2.2 Sildenafil Citrate Lyocs® .............................................................................. 114 
4.3.3 Microscopic Characteristics .................................................................................. 117 
4.3.4 Conclusion ............................................................................................................ 121 
4.4 Case Study: Development of Paracetamol 100 mg Lyocs® ....................................... 121 
4.4.1 Influence of Mannitol Grade ................................................................................. 121 
4.4.1.1 Tested Formulations ...................................................................................... 121 
4.4.1.2 API Release ................................................................................................... 127 
4.4.1.3 Content of Uniformity ................................................................................... 130 
4.4.1.4 Study of Sedimentation Within The Pipette .................................................. 132 
4.4.1.5 Study of Sedimentation Within The Suspension Placed in The Blister Cavity
 ................................................................................................................................... 134 
4.4.1.6 Conclusion ..................................................................................................... 136 
4.4.2 Process Optimization ............................................................................................ 136 
4.4.2.1 Initial Process ................................................................................................ 136 
4.4.2.2 Optimization 1 ............................................................................................... 140 
4.4.2.3 Optimization 2 ............................................................................................... 142 
4.4.2.4 Final Process Optimization ........................................................................... 143 
4.4.2.5 Conclusion ..................................................................................................... 145 
IV 
 
5 Summary ........................................................................................................................ 146 
6 Annex ............................................................................................................................. 149 
6.1 DSC Measurements ..................................................................................................... 149 
6.1.1 DSC Measurements of Diluent/Water Suspensions ............................................. 149 
6.1.2 DSC Measurements of Mannitol/Binder Suspensions .................................... 152 
6.2 TGA Measurements ..................................................................................................... 153 
6.2.1 Metoclopramide HCl ............................................................................................ 153 
6.2.2 Metamizol Na ........................................................................................................ 153 
6.3 API Release ................................................................................................................. 154 
6.3.1 Measurement ............................................................................................................ 154 
6.3.2 Dissolution Profile Comparison ............................................................................... 155 
6.4 Content of Uniformity ................................................................................................. 155 
6.4.1 Measurement conditions ....................................................................................... 155 
6.4.2 Statistical Analysis ................................................................................................ 157 
6.5 Sedimentation Study .................................................................................................... 158 
6.5.1 Sedimentation Within The Pipette ............................................................................ 158 
6.5.2 Sedimentation Within The Lyocs® .......................................................................... 158 
7 Bibliography .................................................................................................................. 159 
 
  
List Of Abbreviations  
Abbreviation Meaning 
A 
API 
Absorbance 
Active Pharmaceutical Ingredient 
DoE 
DSC 
D.T 
Design of Experiment 
Differential Scanning Calorimetry 
Disintegration Time 
ECF  
F 
f1 
f2 
FD 
Extra Cellular Fluid 
Degree of Sedimentation 
Difference Factor  
Similarity Factor  
Freeze-Dryer 
GF Glass Filter 
GIT Gastro-Intestinal Tract 
H Hardness 
IPC 
λ 
LADME 
In Process Control 
Wavelength 
Liberation, Absorption, Distribution, Metabolism, and Excretion 
LoD Loss on Drying 
η Viscosity 
ODT Orally Disintegrating Tablet 
P 
Pc 
Pressure 
Pressure in the Chamber 
ρ 
Ph. Eur. 
Density of the Lyoc® 
European Pharmacopeia 
P.D Primary Drying  
S.D 
SEM 
Secondary Drying 
Scanning Electron Microscopy  
T 
Tc 
Temperature 
Collapse Temperature 
Tcc Condenser Chamber Temperature 
TE Eutectic Temperature 
Tg’ Glass Transition Temperature of the Maximally Freeze-Concentrated 
Amorphous Phase 
TF Freezing Point 
TN Nucleation Temperature 
Tp Product Temperature 
Ts Shelf Temperature 
TGA Thermogravimetric analysis  
XRPD X-Ray Powder Diaffractometry 
  
 
 
 
1 
 
1 Introduction and Goal 
Patients much prefer the oral medication, offering an ease of use of the medication and a non-
invasive treatment unlike parenteral injectable for instance. Indeed, the oral solid dosage form 
represents ca. 60 % of the market (Wright, 2015). Nevertheless, conventional tablets or 
capsules are raising an important problem among patients: difficulty of swallowing. That is 
why the development of orally disintegrating tablets (ODTs) continuously increased the past 
decade (Lipp, 2013; Pfister and Ghosh, 2010a). 
ODTs are described as oral solid dosage form that disintegrates within a few seconds in the 
oral cavity without taking water or without chewing. The disintegrated drug forms a 
suspension or solution in the mouth which is easy to swallow, providing to the patient an easier 
drug administration. ODTs are therefore offering patients a more convenient treatment than 
conventional tablets or capsules, especially when patients present swallowing problems, such 
as pediatric, geriatric and psychiatric patients (Amar et al., 2015; Pfister and Ghosh, 2010a; 
Seager, 1998). ODTs do not only offer advantages to the patient’s comfort and compliance. In 
some cases, they also help the drug to act more quickly by delivering the active pharmaceutical 
ingredient (API) directly in the oral cavity i.e. Seligiline Zydis® (Seager, 1998). In contrary 
to conventional tablets or capsules, the API in the ODT case is already released from its 
excipients in the mouth and a fraction of API may be absorbed in the pre-gastric tract, 
accelerating its onset of action (Seager, 1998). Many different manufacturing techniques of 
ODTs exist, such as direct compression, molding, melt granulation or freeze-drying 
(McLaughlin et al., 2009). The work presented in this thesis involved the ODTs manufactured 
by freeze-drying technology. There are three main technologies using freeze-drying 
(McLaughlin et al., 2009): Zydis® (Catalent), Lyoc® (TEVA) and Quicksolv® (Janssen). The 
Lyoc® technology will be deeply studied in this thesis. This technology involves the 
lyophilisation of an aqueous highly concentrated suspension containing different excipients 
and at least one API, dispensed in preformed blister cavities.  
The aim of this thesis was the formulation and process development of freeze-dried tablets on 
the basis of the developed Lyoc® technology, in order to enhance the scientific database 
related to this technology. Indeed, there is only little literature related to the formulation and 
process development of Lyocs® available. For this purpose, an excipient screening on possible 
diluents and binders was firstly investigated in order to select the excipients usable in the 
Lyoc® technology. The influence of the API nature on Lyocs® was also studied, in order to 
gather more information of the use of water-soluble/less-water soluble APIs in the Lyoc® 
technology. For this purpose, the Lyoc® quality and the Lyoc® morphology using 
paracetamol, and sildenafil citrate as less-water soluble APIs, and metoclopramide HCl and 
metamizol sodium as water-soluble APIs were investigated. Finally, paracetamol was used as 
model drug in order to study the effect of the diluent nature on the API release and the content 
of uniformity of the Lyocs®. As a suspension is produced and frozen, the risk of sedimentation 
during the freezing step is high, resulting in a bad product quality. The Lyocs® were 
manufactured in a GMP-environment, and characterized according to the European 
Pharmacopeia (Ph. Eur.).    
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2 Theory and Scientific Knowledge 
2.1 Orally Disintegrating Tablets  
Pharmaceutical companies are increasingly adapting their products to the patients’ needs and 
expectations in order to improve their compliance and adherence to the treatment. Between all 
the existing ways of drug administration in the body such as oral, parenteral, transdermal or 
pulmonary, the most preferred and common used is the oral one (Felton, 2013; Lipp, 2013). 
Indeed, in comparison to the other routes of drug administration, the oral one is easier to use, 
non-invasive and considered as accurate in dosing (Felton, 2013; Lipp, 2013). Nevertheless, it 
was reported in a survey conducted by Hermes Pharma, that 55% of the population may have 
difficulties in swallowing capsules or tablets primarily due to their large size (HermesPharma, 
2014). To overcome these swallowing issues, some patients are breaking the tablets (32% of 
the people surveyed), chewing the tablets (9% of the people surveyed) or crushing the tablets 
(17% of the people surveyed) before administration, which could lead to a modification of API 
release profile and have an impact on the treatment efficiency. Finally, 8% of the patients 
surveyed simply stop taking their medication (HermesPharma, 2014). This swallowing issue 
is also affecting the increasing elderly population, which is often administered multiple 
medications several times per day. These conventional oral dosage forms can become 
disturbing for older people, which could have an impact on their compliance and on the 
treatment acceptance. As shown in the Figure 2-1, the elderly population is globally increasing 
and is supposed to continue on this rate of extension until 2050 (UnitedNations, 2015). 
 
Figure 2-1: Global population by broad age group, 1950-2050 (UnitedNations, 2015). 
That is why novel oral drugs have been developed such as ODTs, Orally Disintegrating 
Granules, or Orally Disintegrating Films, offering to the patients a more convenient therapy 
and consequently a better adherence to the treatment. In this thesis, only the ODTs will be 
discussed. 
2.1.1 Definition, Advantages and Drawbacks of ODTs 
United States Food and Drug Administration defined ODTs as “a solid dosage form containing 
medicinal substances which disintegrates rapidly, usually within a matter of seconds, when 
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placed upon the tongue” (CDER, 2008). The Ph. Eur. defines ODTs as “tablets intended to be 
placed in the mouth where it disperses rapidly before swallowing within 3 minutes” (EDQM, 
2014e).  
This pharmaceutical dosage form offers plenty of advantages for the patient in comparison to 
the conventional oral forms (Kumare, 2008; Parkash et al., 2011), such as: 
- Simplicity of administration (no need of water for this form), 
- Does not leave any residue in the mouth after administration, 
- Form adapted for patients who have swallowing difficulties (paediatric, geriatric, and 
patients suffering from dysphagia), 
- Form adapted for psychiatric use, 
- Form adapted to patients who do not have an immediate access to water (bedridden, 
travelling or busy patients), 
- Discreet treatment (Kumare, 2008; Parkash et al., 2011). 
All these advantages lead to an improvement of the patient’s observance and compliance, 
helping them to better respect the posology and to take their medication correctly (Parkash et 
al., 2011).  
ODTs also give a marketing strength to the pharmaceutical companies, enabling them to 
extend their patent protection and their product line by offering an added product value (Pfister 
and Ghosh, 2010a). Indeed, when a drug patent is about to expire, pharmaceutical companies 
often improve their dosage form to meet the patients expectations. This marketing launch 
strategy decreases the costs of research and development in comparison to the one of a novel 
chemical entity and improves its revenue by extending their portfolio and gaining the 
customers’ loyalty through the provision of a more convenient treatment (Srivastava et al., 
2014). The number of commercial ODTs launched on the combined US, EU and Japanese 
market was estimated to grow from over 200 products in 2006 (TechnologyCatalysts, 2008) 
to 450 products in 2009 (TechnologyCatalysts, 2010). This global ODT development growth 
trend doubled the global revenue of ODT market from 2006 with $3.8 billion 
(TechnologyCatalysts, 2008) to 2009 with $6.4 billion (TechnologyCatalysts, 2010), and was 
expected to exceed $13 billion by 2015 (TechnologyCatalysts, 2010).  
Despite all those advantages brought by ODTs, some challenges and limitations of this dosage 
form also have to be highlighted. As a matter of fact, ODTs are very friable and hard to handle. 
Therefore, ODTs require a special unit of blister packaging, which can increase the 
manufacturing costs. ODTs are also often hygroscopic, which forces the manufacturer to work 
in a special environment condition with low relative humidity. Moreover, as the ODT 
disintegrates in the mouth, the API will be tasted by the patient. In the case of bitter APIs, a 
taste masking technique will have to be developed in order to improve the mouth feeling. The 
excipients will also have to be carefully chosen in order to prevent a gritty feeling in the mouth. 
Finally, due to the tablet size limitation and the taste masking techniques that may be used in 
the formulation, the dose in ODT is often limited in comparison to conventional tablets 
(Parkash et al., 2011; Pfister and Ghosh, 2010a; Srivastava et al., 2014). As the dosage form 
is disintegrating in the mouth, its mode of action should be discussed. Do the ODTs act like a 
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conventional tablet or capsule, or is the API’s bioavailability improved thanks to a pre-gastric 
absorption? This issue will be discussed in detail in the following section. 
2.1.2 System of Action of ODTs 
One of the most important characteristics of a drug is its pharmacokinetics, i.e. the fate of the 
drug in the body. The latter is described through the LADME model (Liberation, Absorption, 
Distribution, Metabolism, and Excretion). Pharmacokinetics of a drug not only depends on the 
physicochemical properties of the API (e.g. solubility, permeability, crystallinity, pH, particle 
size), but also on the pharmaceutical form, on the administration route of a drug and on some 
patient-related factors such as age, gender, corpulence (Le, 2014d). The ADME model is 
summarized in Figure 2-2 and will be described in this chapter: 
 
Figure 2-2: Schema of the fate of drugs in the body after oral administration occurring after the liberation of the API 
(Faqi, 2013). 
2.1.2.1 Absorption 
Once a drug is administered to a patient, the API has to be released from its pharmaceutical 
form in order to be dissolved in the biological fluids (Le, 2014a). In our case, the ODT 
disintegrates instantly in contact with saliva, releasing the API from its matrix in the oral cavity 
of the patient, i.e. liberation step (Seager, 1998).  
The absorption step represents the movement of the API from the site of administration to the 
blood circulation (Le, 2014a; Sakai, 2008). Two scenarios are possible in our case: the API 
can either be completely or partly absorbed in the mouth during the tablet disintegration, or it 
can be absorbed along the gastro-intestinal tract (GIT), like a conventional oral dosage form 
(Pfister and Ghosh, 2010b; Seager, 1998). The estimated surface areas available for drug 
absorption in intraoral and GIT, the local pH, the enzymatic activity and the drug absorption 
capacity are summarized in Table 2-1. 
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Table 2-1: Characteristics of the Oral Cavity and GIT (Pfister and Ghosh, 2010a). 
Absorptive 
Site 
Estimated 
Surface Area 
Local 
pH 
Relative Enzymatic 
Activity 
Relative Drug 
Absorption Capacity 
Oral cavity 100 cm² 5,8 to 
7,6 
Moderate High 
Esophagus - 6 to 7 Low Low 
Stomach 0,1 to 0,2 m²  1 to 3 High High 
Small 
intestine 
100 m² 3 to 4 High High 
Large 
intestine 
0,5 to 1 m² 4 to 6 Moderate Low 
Rectum 200 to 400 cm² 5 to 6 Low Low 
 
Despite the small surface area of the oral cavity (100 cm²), the oral mucosa tissue and its rich 
vascularity gives to the API a high capacity to be absorbed (Pfister and Ghosh, 2010a). When 
oral absorption occurs, the API goes directly in the systemic circulation, avoiding a hepatic 
first pass metabolism. Unfortunately, this scenario is pretty rare for ODTs, as the contact of 
the API with the oral cavity is too short (Le, 2014a). It could nevertheless be observed for the 
Selegiline Zydis® formulation for example, where the area under curve measured was eight 
times higher than the one of a conventional tablet, as shown in Figure 2-3 (Seager, 1998).  
 
Figure 2-3: Selegiline concentration in plasma following oral administration of tablet ( , 10 mg); Zydis® ( , 10 
mg) (Seager, 1998). 
This phenomenon could also be observed for other APIs such as apomorphine, buspirone, 
midazolam or timolol (Kearney, 2002). It was thus concluded that buccal absorption was 
observed for APIs having (Kearney, 2002): 
- Molecular weight < 500 Da 
- High aqueous solubility 
- log P at pH 6-7 > 1 
- Dose less than 20 mg. 
Indeed, it was noticed that for doses smaller than 20 mg, a greater amount of the dissolved 
drug is retained on the surface of the oral mucosa and can easily be absorbed. On the contrary, 
larger doses of API will form a mass in the mouth, which will be directly swallowed to go to 
the stomach (Kearney, 2002).  
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When any oral absorption is observed, the API will be absorbed like a conventional dosage 
form, i.e. dissolved in the gastric fluid, spread in the small intestine and absorbed through the 
intestinal epithelia. Most drug absorption occurs in the small intestine because of its large 
surface area and of the higher permeable nature of its membrane in comparision to the ones of 
the stomach (Le, 2014a).  
During the passage through the GIT, the API will be exposed to different pH environments as 
described in the Table 2.1. It will thus have an impact on the API solubility and stability. 
Moreover, the permeability of the API through the biological membranes also defines the 
ability of the API to reach the bloodstream. That is why API solubility and permeability both 
have an impact on absorption (Le, 2014a).     
2.1.2.2 Distribution 
Distribution is the next step after absorption in the LADME model, determining the transport 
of the absorbed drug to the body’s tissues. Once the API enters the systemic circulation, it is 
transported in the blood either free (unbound) or bound to plasma proteins (such as albumin 
or globulin).  
As shown in the Figure 2-4, the API molecules will have to diffuse from the blood to the 
extravascular environment in order to reach the body’s tissue (Le, 2014b; Umasankar, 2014). 
The diffusion process will depend on the size of the API molecule: 
- The drug molecules smaller than 50 Da pass directly between the cell membranes, also 
called the paracellular route. 
- The lipophilic molecules cross the cell membranes through passive diffusion,  
- The polar or ionized molecules will be actively transported thanks to a carrier. 
 
Figure 2-4: Plasma membrane barrier and drug diffusion (ECF = Extra Cellular Fluid) (Umasankar, 2014). 
The bound API molecules are too large to diffuse from the blood to the extravascular 
environment (Umasankar, 2014). That is why only the free API molecules will have a 
pharmacological activity (Le, 2014b; Umasankar, 2014). Distribution of a drug is not uniform 
because of the different blood flow rate, permeability and diffusion across the cell membrane. 
That is why well-perfused organs (i.e. liver, kidney, brain) initially receive more API than the 
less-perfused ones (i.e. muscle, fat).  
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2.1.2.3 Metabolism 
As soon as the API is ingested and distributed, it will be considered as a foreign substance by 
the body. Thus, the body will rapidly fight against it to reject it (Pelkonen and Ahokas, 2009). 
That is why distribution, metabolism and excretion occur quite simultaneously. When the 
parent drug reaches the liver or the kidneys, the API is biotransformed into metabolites, which 
can be either less or more toxic molecules. This biotransformation can happen in two kinds of 
reactions:  
- Phase I: The API becomes more polar through reactions of oxidation, reduction or 
hydrolysis, using metabolic enzymes like cytochrome P450 in order to catalyze the reaction 
(Pelkonen and Ahokas, 2009; Sakai, 2008). 
- Phase II: Reactions of conjugation between the API and another substance like glucuronic 
acid or sulfuric acid occur, increasing the API solubility and consequently making it more 
easily excreted by the kidneys (Pelkonen and Ahokas, 2009; Sakai, 2008). 
2.1.2.4 Excretion 
When a drug is distributed in the organism, the drug and its metabolites have to be removed 
otherwise the drug concentration will continue to increase after the administration of each 
successive dose. The organs involved in this step are the kidneys, the biliary system, the lungs, 
the intestine walls, the salivary glands, the sweat glands and the mammary glands (Sunu, 
2013). The kidneys are the principal organs of water-soluble API excretion (Le, 2014c). 
Indeed, the kidneys are filtering the blood and are creating urine to remove the wastes 
contained in the blood (Pelkonen and Ahokas, 2009). The limited water-soluble APIs will be 
reabsorbed in the bloodstream at the end of the filtration, and will recirculate in the whole 
body again (Sakai, 2008). Biliary system also plays a role in the excretion of large molecules 
or of lipophilic APIs for example, which are excreted through feces (Pelkonen and Ahokas, 
2009). The other excretion ways only play a minimal role in the excretion step. 
2.1.3 Manufacturing Technologies of ODTs  
The orally disintegrating property of an ODT is not only linked to the judicious selection of 
highly water-soluble diluents, but also to the highly porous structure present in the tablet. The 
pores enable the saliva to quickly get inside the tablet, leading to the disintegration of the 
matrix and the release of the API as a suspension or a solution in the mouth that will be further 
swallowed. Several ODTs manufacturing techniques have been developed lately and patented 
and are summarized in Table 2-2.  
Table 2-2: ODTs patented technologies, describing their principle, advantages and disadvantages (Amar et al., 2015; 
Sharma et al., 2010; Srivastava et al., 2014). 
Technology Principle Advantages (++) / 
Drawbacks (--) 
Freeze-drying 
ZYDIS®, LYOC®, 
QUICKSOLV® Technologies 
A suspension composed of 
water, of different excipients 
and of at least one API is 
++ very fast disintegration 
time. 
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As underlined by Table 2-2, direct compression is the easier and cheaper technique to 
manufacture ODTs.  
Despite the complexity of lyophilization (formulation development and process parameters) 
and its expensive cost (energy and time costly, low productivity in comparison to tablet press), 
this process is increasingly used in the pharmaceutical industry because of the different 
advantages that this technique offers (Siow et al., 2016): 
-  Preserved API characteristics (minimum physical and chemical changes during the 
process), 
- Highly porous structure obtained through sublimation of ice crystals, 
- Faster product dissolution in mouth in comparison to conventional ODTs (Catalent, 
2013), 
- Better mouth feeling (less sandy than conventional ODTs (Catalent, 2013), 
lyophilized. The porous 
structure is given by the 
sublimated water. 
--bad mechanical strength 
needing appropriated 
packaging (peel-off blister), 
costly manufacturing 
processes, moisture 
sensitive products requiring 
low relative humidity 
manufacturing rooms.  
Direct compression 
WOWTAB® Technology 
The API is mixed with a 
poor compressible 
saccharide and granulated 
with a good compressible 
saccharide. The granulate is 
then directly compressed. 
++ good mechanical 
strength, low production 
costs 
-- moisture sensitive APIs 
cannot be used, gritty 
feeling 
Floss-based technology 
COTTON CANDY®, 
SHEARFORM®, FLASHDOSE® 
Technologies 
Saccharides or 
polysaccharides are 
simultaneously flash melted 
and centrifuged to form the 
matrix. It is then partially 
recrystallized to improve the 
flowability and 
compressability. The matrix 
is then milled, mixed to the 
API and further compressed. 
++ good mechanical 
strength, large drug loading 
-- high temperature process 
temperature sensitive 
APIs cannot be used 
Effervescent with taste 
masked API 
ORASOLV®, ORAQUICK® 
Technologies 
The taste of the API is 
masked using a coating 
technique. The coated API 
is then mixed to an 
effervescent couple 
composed of a dry acid and 
a dry base that speeds up the 
tablet disintegration. The 
mixture is then directly 
compressed.  
++ bad tastes are covered 
up. 
-- low mechanical strength,  
moisture sensitive products 
(due to the effervescent 
couple) requiring low 
relative humidity 
manufacturing rooms.    
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- Precise dosage through a fully automated pipette. 
The manufacture of ODTs by means of lyophilization is unfortunately poorly documented in 
terms of formulation and of process development. The existing patented freeze-drying 
techniques will be further discussed in this section. 
2.1.3.1 Zydis® Technology 
Zydis®, developed by R.P. Scherer, was the first marketed fast-dissolving technology of solid 
oral dosage forms (Kearney, 2002). Those lyophilized products disintegrate in the mouth 
within a few seconds (3-6 sec), due to the highly porous structure (Pfister and Ghosh, 2010a).  
13 Zydis® products are currently globally marketed, as mentioned in Table 2-3. 
Table 2-3: Zydis® products present on the global market (Kearney, 2002). 
Product API Company First launch 
Temesta Lorazepam Wyeth 1986 
Seresta Oxazepam Wyeth 1986 
Feldene Piroxicam Pfizer 1992 
Imodium Loperamide Janssen 1993 
Pepcid Famotidine Merck 1993 
Claritin Loratadine Schering Plough 1997 
Innovace Enalapril Merck 1998 
Maxalt Rizatriptan Merck 1998 
Zelapar Selegiline Elan 1998 
Zofran Ondansetron Glaxo Wellcome 1999 
Motilium Domperidone Janssen 1999 
Zyprexa Olanzapine Eli Lilly 2000 
Semper Scopolamine/chlorpheniramine Taisho 2000 
 
Almost all of these products are bio-equivalent to their conventional dosage forms, and are 
developed as product line extensions, with the aim of improving the patient’s compliance. 
Nevertheless, it was demonstrated for some products like Zelapar for instance, that the 
bioavailability of the Selegiline was way better than the conventional tablet, due to a pre-
gastric absorption. These kinds of products need then a new clinical study in order to determine 
the toxicity risks and to adapt the dosage (Kearney, 2002; Seager, 1998). 
In this technology, the API is suspended in an aqueous solution composed of a water-soluble 
polymer (mostly gelatin) and a crystalline sugar alcohol (mostly mannitol). The water-soluble 
polymer provides the strength and resilience of the tablet, whereas the sugar alcohol provides 
hardness and an elegant structure to the product (Seager, 1998). As shown in Figure 2-5, this 
solution will be pumped and dosed by weight into preformed blisters with an automated 
dispensing system to ensure the homogeneity of the samples. The product is frozen within a 
few minutes through a liquid nitrogen freezing tunnel. This flash freezing set the homogeneity 
of the substances and creates ice crystal lattice within the product (Kearney, 2002). The blisters 
will be progressively stored in a refrigerated chamber, to keep the product frozen during the 
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entire dispensing step. The trays are loaded onto temperature-controlled shelves of the freeze-
dryer and the ice crystals will be removed through sublimation, giving this porous structure to 
the tablet. The gap between the shelves is minimal (see Figure 2-6), in order to maximize the 
batch size and minimize the drying time, through a higher heat transfer. The typical drying 
process lasts about 5 hours, allowing the product to reach a final residual moisture of 2% 
(Kearney, 2002). Once dried, the blisters are directly sealed with an aluminum foil in order to 
prevent moisture to be reabsorbed into the product (Kearney, 2002; Travers and Grother, 
2013).  
 
 
Figure 2-5: Schema of the Zydis® manufacturing 
process (Kearney, 2002). 
 
 
 
Three main drawbacks can be underlined in this technique. The first one is the use of gelatin, 
an animal-derived excipient, in the formulation. Indeed, drugs containing gelatin can lead to a 
non-adherence to the treatment due to religious beliefs (Sattar et al., 2004) or 
dietary/vegetarian reasons (Vissamsetti et al., 2012).     
The second disadvantage of this technique is the limited drug loading of water soluble APIs, 
set at 60 mg / dose in comparison to 400 mg / dose for non-water soluble APIs (Seager, 1998). 
This phenomenon can be explained through the fact that water soluble APIs may build up an 
amorphous structure inside the tablet during the freezing process, leading to collapse of the 
structure during the primary drying step (Seager, 1998).  
The last disadvantage is the very fragile character of the Zydis® products, due to the use a 
low-concentration matrix in the formulation. Indeed, the more excipients, the less porous 
structure, and the longer the disintegration of the freeze-dried tablet (Fu et al., 2004; Kearney, 
2002). That is why the packaging has to be adapted in order not to break the tablets, by using 
peel-off blister packaging for instance, which add an extra cost to the Zydis® technique.  
2.1.3.2 Lyoc® Technology 
The Lyoc® technology was developed by the Lafon Group and differs from the Zydis® 
technology in several points. Firstly, the Lyoc® formulation is a viscous aqueous matrix 
mainly composed of a mixture of an undissolved crystalline filler (mannitol or lactose) and a 
water soluble polymer (dextran). As the Lyoc® technique requires a high-concentrated matrix, 
the porosity of Lyoc® products is lower than the Zydis® ones, having an impact on its 
Figure 2-6: Bespoke Zydis® freeze-drier, loaded with  
blister units (Travers and Grother, 2013). 
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disintegration time (< 10 sec) and on its hardness. Lyoc® products are denser and more robust 
than the Zydis® ones (Fu et al., 2004; Kearney, 2002; Pfister and Ghosh, 2010a). 
The Lyoc® production process also differs from the Zydis® one. The suspension is dosed by 
weight with an automated dispensing system in blisters and progressively stored in a freezing 
chamber at -40°C as shown in Figure 2-7 (Fulzele et al., 2012). The product is frozen within 
one hour, giving the frozen product larger ice crystals than the Zydis® ones due to the slower 
freezing rate (Pikal, 2010). The trays are loaded onto the shelves of the freeze-dryer, where 
the temperature sensors will be connected in order to keep an eye on the product temperature 
evolution during the drying process. As shown in Figure 2-8, the Lyoc® freeze-dryer 
configuration is also different than the Zydis® one, as 3 blister tracks are superposed one over 
the other in order to maximize the batch size and to maximize the production yield. The inter-
shelf space is hence bigger in the case of the Lyoc® technology. For more productivity and 
efficiency, the production team works in three shift work, imposing the whole process to last 
8 hours (from the mixing step until the end of drying). The product reaches a final residual 
moisture of 3% (Kearney, 2002). Once dried, the blisters are directly sealed with an aluminum 
foil in order to avoid the moisture to be reabsorbed into the product (Kearney, 2002; Travers 
and Grother, 2013). As the Lyoc® products are robust, they can be packaged in a push-through 
blister packaging, reducing the packaging costs in comparison to the Zydis® technology 
(Kearney, 2002).  
 
 
Figure 2-7: Schema of the Lyoc® manufacturing 
process (Fulzele et al., 2012). 
 
 
7 Lyoc® products, summarized in Table 2-4, are currently on the market. 
Table 2-4: Lyoc® products present on the market (Doctissimo, 2015). 
Product API Company 
Loperamide Lyoc® Loperamide Teva Sante 
Paralyoc® (250 and 500 mg) Paracetamol Teva Sante 
Spasfon Lyoc® (80 and 160 mg) Phloroglucinol Teva Sante 
Vogalene Lyoc® Metopimazine Teva Sante 
Vogalib® Metopimazine Teva Sante 
 
Figure 2-8: Lyoc® freeze-drier, loaded with  
blister units (Fulzele et al., 2012). 
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2.1.3.3 QuickSolv® Technology 
The QuickSolv® technology was developed by the company Janssen Pharmaceutica (Jeong et 
al., 2010). The principle of this technique is based on removing a solid frozen solvent from a 
frozen matrix mixture and is described in the U.S. patent 5,215,756 (Gole et al., 1993). A 
mixture of a matrix agent, API, secondary components (i.e. sweeting agents, surfactant and 
flavor agents) and a first solvent (mostly water) is distributed in blisters. The preparation is 
frozen through a liquid nitrogen freezing tunnel and is then immersed into a second solvent 
(mostly ethanol) at a temperature below the melting point of the first solvent. The solidified 
first solvent will thus dissolve into the second solvent and be removed from the tablet. The 
residual first solvent can be removed using a vacuum chamber under reduced pressure. If the 
API is soluble in the second solvent, it can dissolve during the immersion step. In this case, a 
placebo mixture has to be frozen, and the API will be dispersed in a carrier solvent immiscible 
with the placebo mixture and loaded on the matrix after the immersion step. The QuickSolv® 
technique is not so used compared to the Zydis® and the Lyoc® one. 2 examples of 
QuickSolv® products are mentioned in Table 2-5. 
Table 2-5: Example of QuickSolv® products present on the market (McLaughlin et al., 2009). 
Product API 
Propulsid QuickSolv® Cisapride 
Risperdal Risperidon 
2.1.3.4 Zydis® vs. Lyoc® 
The two most well-known lyophilization techniques for the manufacture of ODTs are Zydis® 
and Lyoc®. Table 2-6 summarizes the differences between those two techniques. 
Table 2-6: Review of Zydis® vs. Lyoc®. 
Zydis® Lyoc® 
  
Lyocs® are much bigger tablets than the Zydis® one, allowing larger drug load. 
Disintegration time 3-6 sec  Disintegration time < 10 sec 
Freezing-step through a nitrogen tunnel  
quick freezing step. 
Freezing-step in a freezing room  slower 
freezing step than Zydis®, leading to larger 
ice crystals than in Zydis® products. 
1 track per shelve, reducing the efficiency. 3 tracks per shelve  bigger productivity 
than Zydis®. 
Product extremely crumbly  peel-off 
blister 
Product quite resilient  normal blister 
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Hygroscopic product  manufacture in a 
dry air environment 
Hygroscopic product  manufacture in a dry 
air environment 
2.2 Freeze-drying in ODTs 
2.2.1 Generalities (Jennings, 2008d) 
Lyophilization is a very gentle stabilizing drying process, where the solvent, in our case water, 
is removed through sublimation from a frozen liquid sample to provide a dried product. It 
allows the preservation of the physical and biological characteristics of some heat sensitive 
products, such as proteins, vaccines or microorganisms. The water removal during the 
lyophilization process indeed limits the degradation reactions of the product. As the solvent 
used in the Lyoc® technology is water, the use of the water phase diagram is necessary to 
understand the sublimation process. Figure 2-9 shows a triple point (Pressure p=6,11mbar and 
Temperature T=0,01°C). At this triple point, the three water phases, i.e. solid, liquid and gas, 
are simultaneously coexisting. Below this point (at p = 0,37 mbar for example), the ice is 
directly converted from a solid form to a gaseous form by increasing the temperature up to -
30 °C. If p is higher than 6,11mbar, water passes through all phases by increasing T: solid  
liquid  gas. That is why in the lyophilization process, when the freezing step is over, p has 
to decrease below the triple point before starting the primary drying step in order to preserve 
the product quality (Jennings, 2008a). 
 
Figure 2-9: Water phase diagram (ChristMartin, 2015), describing the matter change of state: A= from solid to 
liquid (melting) and from liquid to gas (evaporation), B= from solid to gas (sublimation). 
2.2.2 Lyophilization Cycle 
The lyophilization cycle is composed of three steps: 
1) The freezing step consists in freezing the water which is present in the sample, by 
cooling down the product to a low temperature at atmospheric pressure,  
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2) The primary drying step consists in removing the frozen free water by sublimation 
under vacuum, 
3) The secondary drying step consists in removing the bound water remaining in the 
sample by desorption. 
 
 
 
 
 
 
 
 
Figure 2-10: Example of a lyophilization cycle. (p: red; T: blue), representing the freezing step (      ), the primary 
drying step (      ) and the secondary drying step (      ) 
2.2.2.1 Freezing step 
2.2.2.1.1 Structure of Ice 
As the product is initially in the liquid state, the product needs firstly to be frozen before 
sublimation occurs. During this step, the water molecules will build up a particular ice 
structure within the product.   
Ice exists in different crystalline forms, also called polymorphs (Jennings, 2008b). The 
molecular arrangement differs from one polymorph to the other, having an impact on the free 
energy of each polymorph and consequently on their thermodynamically stability (Jennings, 
2008b). Indeed, the polymorphic structure of lower free energy is thermodynamically more 
stable (Ronis, 2001). Ordinary ice exists in two different crystal structures: Ih (hexagonal 
structure), and Ic (cubic structure) (Dutch, 2001; Jennings, 2008b). The Ic structure only exists 
at Patm at T lower than -100 °C and transforms into the Ih structure when warmed over -80°C 
(Dutch, 2001; Jennings, 2008b). As shown on Figure 2-11, ice presents many polymorphs. 
The transition from Ice I to a higher form (II to VII, described in Table 2-7) is only possible at 
high pressure (over 2 kbar) (Dutch, 2001). As the freezing step of the lyophilization process 
takes place at Patm and T above -80°C, the ice will form the Ih structure.  
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Figure 2-11: Phase diagram of water at high pressure (Dutch, 2001). 
 
Table 2-7: Polymorphic forms of ice (Dutch, 2001). 
 Type Crystal structure 
Ordinary Ice Ih Hexagonal 
Ic Cubic 
High-Pressure Ice II Rhombohedral 
III Tetragonal 
V Monoclinic 
VI Tetragonal 
VII Cubic 
 
Figure 2-12 represents the lattice hexagonal structure of the Ih form. The red atoms represent 
oxygen atoms, whereas the solid lines represent hydrogen bonds. The hydrogen atoms are not 
represented here. As it can be seen in Figure 2-12, each oxygen atom is surrounded by 4 other 
oxygen atoms, forming a tetrahedral structure. The oxygen-oxygen distance is 2,75 Å and the 
hydrogen-oxygen distance in the water molecule is 0,99 Å (Jennings, 2008b), which sets the 
hydrogen-oxygen distance in the hydrogen bond at 1,75 Å. During the freezing step, ice is 
forming the Ih structure. As the free space between the ice crystals is small, most solutes cannot 
pass in this crystalline structure, forcing the substances to concentrate in the interstitial region 
of ice crystal (Jennings, 2008b). However, a separation of solvent-solutes occurs, giving the 
freeze-dried tablets this porous structure after sublimation.    
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Figure 2-12: Crystalline structure of ice Ih   (Hidehisa, 2013). 
2.2.2.1.2 Crystal Growth 
During the freezing step, crystal nuclei of ice are formed in the sample (nucleation). Those 
nuclei are the initiator of ice crystals formation (see Figure 2-13). Indeed, crystal growth will 
occur step by step, until grains are formed (Jennings, 2008a). This nucleation can either be 
homogenous or heterogeneous (Daniels, 2014). In the first case, the ice nucleation occurs 
spontaneously involving only the aggregation of pure water molecules (Pikal and Nail, 2014). 
In the second case, impurity comes into play (such as dirt, sensor, container wall), helping the 
orientation of molecules to form a stable nucleus (Pikal and Nail, 2014). 
 
Figure 2-13: Ice nucleation transforming nuclei in crystals through crystal growth (Daniels, 2014). 
As explained above, the formation of ice crystal is not spontaneous but it occurs step by step. 
Firstly, the nuclei are formed at the nucleation temperature (TN on Figure 2-14), followed by 
the crystal growth. Nucleation rarely occurs at the thermodynamic solution freezing point (TF 
on Figure 2-14), but it often occurs 10-20°C below because of supercooling (Nail et al., 2002; 
Shon and Mather, 2012). A difference between the nucleation temperature and the freezing 
point can be observed on Figure 2-14, which is called the degree of supercooling. The increase 
of temperature from TN to TF is due to the heat caused by the sudden ice crystallization (Pikal, 
2010). After TF, the product cools down, converting continuously water into ice.  
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Figure 2-14: Evolution of the product temperature during the freezing step, designating the nucleation temperature 
(TN) and the thermodynamic freezing point (TF) (Pikal and Nail, 2014) . 
The supercooling is especially dependent on the cooling rate and on the freezing methods used 
(see Figure 2-15) (Jennings, 2008a; Tang and Pikal, 2004) and will also have an impact on the 
ice crystal structure and size. As shown on Figure 2-15: high degree of supercooling will occur 
in case of slow freezing (Awotwe-Otoo and Khan, 2015), resulting in the formation of small 
ice crystals and so giving small pores to the product during sublimation (Shon and Mather, 
2012; Tang and Pikal, 2004) . The small pores will impose a bigger resistance to the mass 
transfer of water vapour during the primary drying, making the sublimation difficult and 
increasing the primary drying duration (Awotwe-Otoo and Khan, 2015; Shon and Mather, 
2012). In the contrary, low degree of supercooling will result in the formation of bigger ice 
crystals, resulting in bigger pores within the product during sublimation (Shon and Mather, 
2012; Tang and Pikal, 2004). The freezing step has hence an impact on the morphological 
characteristics of the product.   
 
Figure 2-15: Representation of fast and slow freezing (Hidehisa, 2013). 
During the ice crystals formation, the solutes (such as the API and the excipients) are forced 
to be detained in the interstitial region, i.e. between the ice crystals (Jennings, 2008c), and are 
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concentrating until they also build up either crystallize or a solid amorphous system, according 
to their freezing behaviour (Milton, 2010). Two phases thus exist in the product, which are ice 
and freeze-concentrated solution (Daniels, 2014). The physical behaviour of the solutes during 
the freezing step is summarized below, on the Figure 2-16: 
 
Figure 2-16: Physical behavior of the sample during the freezing step (Daniels, 2014). 
2.2.2.1.3 Eutectic System 
An eutectic system is defined from the FDA as “a point of a phase diagram where all phases 
are present and the temperature and composition of the liquid phase cannot be altered without 
one of the phases disappearing” (FDA, 2014). To describe this system, the phase diagram of 
Sodium Chloride/Water (see Figure 2-14) in combination with the Gibb’s phase rule can be 
used:  
f=C-P+2 
where f=number of degrees of freedom (i.e. number of variables that must be fixed to define 
the system), C=number of components and P=number of phases. The number 2 indicates that 
T and p can vary. 
Yes No 
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Figure 2-17: Phase diagram of Sodium Chloride/Water (Daniels, 2014). 
On Figure 2-17, 2 typical curves can be observed: 
- The “liquidus” red line representing the freezing-point depression of water  (Phase 
Diagram Crystallization, 2010) . The addition of a solute in a solvent will result in a 
decrease of the vapor pressure of water, leading to a freezing point lower than the one 
of water pure (Jennings, 2008h). The freezing-point depression is hence proportional 
to the amount of the solute present in the solution (Jennings, 2008h).  
- The “solidus” blue line is the separation between the systems Solid and Solution+Solid 
or Solid and Solution for the point E (Phase Diagram Crystallization, 2010). 
Let us consider a NaCl solution with an initially concentration x1. During the freezing step, 
the T decreases until reaching x2, where the crystallization of pure water molecules begins. At 
x2, two phases are at the equilibrium, i.e. Solution and Ice. As the temperature keeps 
decreasing, the water concentration within the sample will decrease, consequently the 
concentration of NaCl increases in the interstitial region (Jennings, 2008h). That is why the 
system will follow the red curve x2E on the Figure 2-17 until reaching the point E. At the 
equilibrium point E, all the four phases coexist (Jennings, 2008h), i.e. Solution, Ice, NaCl and 
Eutectic mixture. Therefore at E, C=2, P=4 and so f=0 which means that a change in 
temperature or in the composition of the solution can only be possible when the number of 
present phases changes so that f≠0 (Jennings, 2008h). This means that at the eutectic 
temperature (TE) the NaCl ions crystallize next to water (Labconco, 2010). Below TE, the 
system is separating itself in ice crystals, NaCl crystals and eutectic mixture and the whole 
system is completely frozen (Labconco, 2010). Above TE, the system will melt and the system 
will come back in the Solution state (MillrockTechnology, 2009). 
During the primary drying phase, when the product temperature (Tp) exceeds TE the first few 
hours, the cake structure will be destroyed due to solutes melting and the visual aspect of the 
product will not be acceptable (Labconco, 2010). TE is thus the critical temperature of the 
process. That is why the product has to be frozen at least 10°C below TE to give a sufficient 
energy by rising up the temperature so that the maximum sublimation can occurs before 
reaching TE preventing destroying the cake structure (Tang and Pikal, 2004). 
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2.2.2.1.4 Amorphous System 
Lots of sugar and polymer solutions do not crystallize as expected at the eutectic point but 
solidify like an amorphous glass. Indeed, the solution near the ice crystals is supersaturated. 
This phenomenon is represented on Figure 2-18: 
 
Figure 2-18: Phase diagramm of a Sucrose/Water solution (Tang and Pikal, 2004). 
The sucrose solution of concentration x1 is frozen with the same mechanism explained 
previously. When Tp goes below TE, the solution will increasingly concentrate in sucrose. The 
solute solution will hence become more and more viscous until the glass transition temperature 
of the maximally freeze-concentrated amorphous phase (Tg’) is reached. When Tp goes below 
Tg’, the crystallization speed is so slow that the system will solidify like a glass, without any 
complete phase separation (Daniels, 2014; Hatley et al., 1996). The interstitial glassy solute 
phase contains thus a quantity of non-crystalline water, also called non-frozen water (Daniels, 
2014).  
During the primary drying step, when Tg’ is exceeded the viscosity of the amorphous phase 
will decrease, destroying the porous structure of the cake. This phenomenon is named collapse 
and occurs at the collapse temperature (Tc), only a few degrees higher than Tg’ (Jennings, 
2008e; Pikal, 2010). Tg’ is hence the critical temperature of the process. 
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2.2.2.1.5 In Practice 
At the end of the freezing step, all the amount of liquid has to be frozen and Tp needs to be at 
least at 10°C below TE (for crystalline solid) or Tg’ (for amorphous solid) of the matrix builder 
temperature to ensure the complete solidification of the product (Tang and Pikal, 2004). For 
an optimum process time, the freezing speed rate should be between 0,2 °C/min to 10°C/min 
(Daniels, 2014). The product is cooled until Tp reaches the shelf temperature (Ts), set up 10°C 
below the eutectic temperature of the mixture filler/water. This step is made under atmospheric 
pressure. The freezing duration depends on the thickness of the product pipetted volume. If 
the volume thickness is less than 1 cm, the freezing step will last one hour. If the volume 
thickness is bigger than 1 cm, the freezing step will last at least two hours (Tang and Pikal, 
2004). As the Lyoc® thickness is around 0,5 cm, the freezing step lasts up to one hour in 
production. 
2.2.2.2 Primary Drying (P.D) 
2.2.2.2.1 Energy Transfer 
During this step, the frozen water will sublimate, transforming itself directly into water vapour 
(step B on Figure 2-9). The porous nature of the Lyoc® products comes from the place formed 
by the ice water sublimation (see Figure 2-19).  
 
Figure 2-19: Origin of the porous nature of Lyoc® (Schubert, 2014). 
The water vapour released by the product will condense and freeze at the surface of the 
condenser, which is the colder site of the freeze-dryer (between -80 and -90 °C). Sublimation, 
which is an endothermic phenomenon, requires high amounts of energy (ca. 3800 kJ/kg ice 
(Daniels, 2014)). This energy will be thermally brought to the product by the increase of Ts 
(Nail et al., 2002). A difference can nevertheless be observed between the Zydis® technology 
and the Lyoc® technology. In the Lyoc® technology, the blisters are not in direct contact with 
the shelves, but positioned on trays. Thermal conduction thus does not happen to a great extent 
in the Lyoc® technology, reducing considerably the energy input in comparison to other 
lyophilization techniques. On the same way, convection is also almost irrelevant in our case 
(Nail et al., 2002), as the distance between the shelves and the blister is too large (ca. 1,5 cm). 
That is why the heat transfer taking place in the case of the Lyoc® technology is almost 
exclusively due to radiation from the shelves and from the walls of the chamber (see Figure 
2-20). It can be seen on Figure 2-20 that sublimation within the Lyoc® products is 
heterogeneous (Tang and Pikal, 2004). Indeed, the water vapour will begin to evaporate out of 
the blister from the top surface of the Lyoc® to the bottom of the blister, until the free frozen 
water is completely removed. This sublimation evolution is called “sublimation front”. 
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Figure 2-20: Types of heat transfer present in the Lyoc® technology (Daniels, 2014). 
2.2.2.2.2 Mass Transfer 
As explained in the previous Section, the system needs an energy input in order to sublimate. 
This energy is given by heat, and can be mathematically expressed as (Tang and Pikal, 2004): 
𝑑𝑄
𝑑𝑡
= ∆𝐻𝑆.
𝑑𝑚
𝑑𝑡
 
where 
𝑑𝑄
𝑑𝑡
 represents the heat transfer rate, ΔHs the heat of ice sublimation and 
𝑑𝑚
𝑑𝑡
 is the ice 
sublimation rate. After thermal energy has been applied to the system, the ice will transform 
in vapour, transferring the vapour out of the product through the pores of the Lyocs®. Once 
the vapour molecules are in the chamber, they will transfer out of the chamber, following a 
pressure gradient, in order to be trapped in a frozen state on the condenser that has the colder 
temperature Tcc (Condenser Chamber Temperature) of the system. This mass transfer is 
possible and accentuated through the use of vacuum (Nail et al., 2002; Tang and Pikal, 2004). 
Indeed, as expressed in the following equation proposed by Pikal (Pikal and Nail, 2014), the 
mass transfer depends on the difference between the pressure in the chamber (Pc) and the 
vapour pressure of ice (P0) and on the resistance to sublimation of the dry layer (Rc):   
𝑑𝑚
𝑑𝑡
=
𝑃0 − 𝑃𝐶
𝑅𝐶
 
The difference between Pc and P0 is obviously the driving force of sublimation (Tang and 
Pikal, 2004). This means that Pc has to be much lower than P0 in order to allow a high 
sublimation rate (mass of ice sublimate per unit of time) and thus to accelerate the P.D step. 
Nevertheless, too low Pc could lead to large heterogeneity in heat transfer (Tang and Pikal, 
2004) and as a consequence cause heterogeneity in Tp within the Lyocs® (Tang and Pikal, 
2004). That is why a study on the influence of this ΔP on the sublimation speed was made and 
summarized by Le Floch (Le Floch, 2008). It was identified that the maximal sublimation 
speed was observed at 𝑃𝐶 =
𝑃0
2
. The resistance of the dry layer is also an important factor that 
must be taken into consideration (Tang and Pikal, 2004). Indeed, as mentioned in Section 
2.2.3.2.1, the sublimation is heterogeneous, going from the top of the product to the bottom. 
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Through sublimation, the top of the product is then transformed into a dry layer, which forces 
the vapour of the bottom layer to sublimate. Therefore, the larger the product layer, the more 
difficult it is to sublimate the bottom of the product. 
To summarize, sublimation results from: 
- a higher shelf temperature 
- a low pressure (below the triple point) correlated to the TCC to increase the diffusion 
speed rate. 
The factors which influence the primary drying speed are: 
- The morphology of the frozen suspension: the smaller the pore size is, the more 
difficult for the vapour water will be able to escape (Pikal, 2010). 
- The heating energy brought to the product. 
- The vacuum (the deeper down the vacuum goes, the faster the sublimation). 
- The transport path to the condenser. 
As explained in Section 2.2.3.1, the product can either form an eutectic or an amorphous 
system. The sublimation mechanism of water can thus differ, according to the system built up 
during the freezing step. As shown in Figure 2-21, 4 mechanisms are possible: 
- When an eutectic system is built up (A), the ice crystals form canals (Jennings, 2008a), 
allowing the water vapour to diffuse out of the matrix. Those free canals are thus the 
origin of the porous structure formed in Lyocs®.  
- When TP is higher than TE and when too many ice crystals are still present in the 
Lyoc®, the eutectic mixture melt (Tang and Pikal, 2004), as explained in Section 
2.2.3.1.1. This phenomenon is called collapse (B). During collapse, the product softens 
in the surface area and can no longer support its own structure (ChristMartin, 2015). 
That is why the collapse temperature needs to be known, in order not to exceed it during 
the beginning of primary drying (Tang and Pikal, 2004). It is usually measured by 
means of DSC (Jennings, 2008g). 
- When an amorphous system is built up (C), ice crystals are immersed in glassy 
interstitial material (Jennings, 2008a), hampering the flow out of the Lyoc® of water 
vapour. Indeed, water vapour has first to diffuse through the amorphous matrix. 
Eutectic mixtures are for this reason easier to sublimate than amorphous systems.  
- When the resistance of steam diffusion through the amorphous material is too high, 
cracks from which the steam will be released appear in the amorphous structure (D).  
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Figure 2-21: Mechanisms of sublimation during P.D of lyophilization. A=Direct sublimation, B=Collapse, C=Diffusion 
through the matrix, D=Escape through cracking (Daniels, 2014). 
2.2.2.1.3 Annealing 
As detailed in the previous paragraphs, two main parameters are essential on the P.D step, 
namely the physical behaviour of the frozen solute (eutectic systems possess higher critical 
temperature than amorphous systems and thus higher temperature can be applied to the product 
during the P.D step which reduce the P.D duration) and the size of ice crystals (bigger ice 
crystals lead to a faster sublimation). The crystallization of an amorphous solute can thus be 
induced by means of a thermal treatment between the end of the freezing step and the 
beginning of the P.D step (Abdul-Fattah and Truong, 2010; Wang and Pikal, 2012). This 
thermal treatment, also called annealing, consists in warming up the product at a temperature 
above its Tg’ without reaching Tc in order to prevent collapse (Barley, 2016; Wang and Pikal, 
2012). This temperature is then held during a few hours before being brought again to a lower 
temperature (Wang and Pikal, 2012). Above Tg’, the mobility of the molecules increases 
(Wang and Pikal, 2012), allowing crystals to grow through the Ostwald ripening mechanism 
(Wang and Pikal, 2012). The small crystals will indeed migrate around the bigger ones, 
offering to the product a good homogeneity and a good visual aspect (Chang and Patro, 2004). 
This phenomenon will thus lead to the creation of larger ice crystals (Wang and Pikal, 2012), 
and so reduce the resistance to water vapour during the P.D step due to bigger pores (Chang 
and Patro, 2004), accelerating the sublimation step. In the case of glycine and mannitol, a 
conversion of the amorphous proportion into crystalline state could be observed after 
annealing, increasing the critical temperature of the formulation (see Figure 2-18). The P.D 
step can thus be performed at higher temperature, decreasing its duration. In our case, 
annealing is not considered to be an appropriate measure, as it would take too much time in 
the production step, reducing the productivity. That is why annealing will not be studied 
further. 
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2.2.2.2.4 In Practice 
In order to avoid reaching the triple point (see Figure 2-9), the pressure in the chamber is firstly 
decreased under the vapour pressure of ice at Tp, and Ts is then increased by heating the thermal 
fluid present in the shelves. Tp has to remain 5 to 10°C below the collapse temperature of the 
product at the beginning of the primary drying to prevent the deformation of the product by 
collapse. Then, Ts is surprisingly set up around 50°C in order to reduce the cycle time by 
increasing the energy transfer. This high Ts is specific to the Lyoc® technology, as radiation 
is the main energy transfer occurring during the P.D step.  This step finishes when Tp reaches 
Ts (Pikal, 2010). In production, this step can last up to 4 hours. All the evolutions of Tp, Ts and 
Pc are monitored by the use of sensors and can thus be observed in real time. The delimitation 
between Primary Drying and Secondary Drying can also be done by means of other methods 
such as: 
- Pressure rise test (as shown on figure 2-22) the valve present between the condenser 
and the chamber is closed during a short time in order to isolate the product, and Pc is 
observed, in order to check if a rise in pressure can be observed. If the pressure rises, 
this means that sublimated water vapour accumulates in the chamber and thus the 
product is not completely dried. That is why the valve is reopened and the primary 
drying step is prolonged  (Fissore et al., 2011). The slower the pressure rises, the drier 
the product (Reihbandt, 2016). 
 
Figure 2-22: Principle of Pressure Rise Test (ChristMartin, 2015). 
- Comparative pressure measurement (Pirani vs. Capacitive manometer: Pc is controlled 
with a capacitive manometer, whereas the Pirani gauge measures the thermal 
conductivity of the water vapour in the chamber. As soon as the Pirani pressure 
decreases, the gas composition of the chamber is changing from water vapor to 
nitrogen, meaning that the sublimation is completed (Bhambere et al., 2015),    
- Decrease of sample weight (by using a microbalance (ChristMartin, 2015))  
- Determination of the water vapour in the chamber by means of moisture sensors (the 
moisture sensor measures the dew point i.e. it can determine the presence of ice or 
liquid in the sample. The dew point starts decreasing as soon as the sublimation is 
completed (Reihbandt, 2016)). 
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The combination between Tp and Pressure rise test is used in this thesis in order to ensure the 
end of the Primary Drying step. 
2.2.2.3 Secondary Drying (S.D) 
At the end of the Primary Drying, the entire free water is removed from the product and only 
bound water (between 10-30% of the total water content (Sadikoglu et al., 2006)) is present in 
the freeze-dried product (Bhambere et al., 2015). In the case of Lyocs®, the content of 
remaining water should not exceed 3 %. The nature of bound water present in the product 
depends on the matrix physical state (Daniels, 2014). In crystalline matrices, the bound water 
is either adsorbed on the surface of the matrix crystals or is present as water of hydration within 
the matrix (Daniels, 2014). In amorphous matrices, the bound water is absorbed within the 
matrix (Daniels, 2014). That is why the rate of water extraction is limited by desorption and 
evaporation at the surface of the sample in the case of crystalline matrix, whereas it is limited 
by diffusion of water molecule from the inside of the amorphous matrix through the pore 
structure (Daniels, 2014; Pikal, 2010). In practice, higher temperature than during Primary 
Drying is applied to the product at low chamber pressure (down to 1 µbar) (Bhambere et al., 
2015). Bound water requires more energy to be removed than free water, as bound water 
formed physicochemical interactions with the dried matrix (Galan, 2010). A further study was 
made by Pikal on the Secondary Drying step regarding the influence of the solid state of the 
matrix, T and Pc on the rate of Secondary Drying (Pikal, 2010; Pikal and Nail, 2014) and is 
explained in the following sections.  
2.2.2.3.1 Influence of the Matrix Solid State on Secondary Drying 
The kinetics of S.D of three different systems (see Figure 2-23), namely Mannitol (crystalline) 
(Pikal, 2010), Povidone (amorphous) (Pikal, 2010) and Moxalactam di-sodium (amorphous) 
(Pikal, 2010) were firstly studied. Bound water is therefore being extracted from a crystalline 
or an amorphous matrix. F represents the fractional attainment of equilibrium (i.e. near zero 
water) (Pikal, 2010). That is why 1-F represents the normalized water content. It can be noticed 
on Figure 2-23 that the first hour, the three products lost the maximum amount of water 
(around 0,2 % for Mannitol, 2 % for Povidone and 4 % for  Moxalactam di-sodium), followed 
by a lower drying rate and finally a plateau at the end of the S.D (around 0,1 % for Mannitol, 
1 % for Povidone and 3 % for  Moxalactam di-sodium) (Pikal, 2010). The lower plateau 
observed in the case of Mannitol in comparison to Povidone or Moxalactam di-sodium can be 
explained by the faster extraction of water in a crystalline matrix than in an amorphous matrix, 
possibly due to the fact that trapped water in amorphous matrix has to diffuse from the inside 
of the sample through the pores whereas adsorbed water has to desorb and to evaporate from 
the surface of the Lyoc® (Pikal, 2010). 
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Figure 2-23: Kinetics of S.D of Mannitol (triangles), Povidone (squares), and Moxalactam di-sodium (circles). Sample 
preparation: 5 % aqueous solution, 1 cm fill depth, hydration to a uniform moisture of 7 %. S.D conditions: Tp = 18 
°C, PC = 267 mbar (Pikal, 2010).  
2.2.2.3.2 Influence of Temperature on Secondary Drying 
S.D was performed on the Moxalactam di-sodium solution of Chapter 2.2.2.3.1 (Pikal and 
Nail, 2014) with different drying T (see Figure 2-24). It is obviously seen that the drying T has 
a great influence on the content of water. Indeed, the greater the drying T, the quicker the water 
is removed and the lower the plateau. This is due to the extra thermal energy brought to the 
system and helping the trapped water to diffuse more easily through amorphous the matrix. 
 
Figure 2-24: Kinetics of S.D of Moxalactam with a drying T of 36 °C (triangles), 18 °C (squares), and 2 °C (circles). 
Sample preparation: 5 % aqueous solution, 1 cm fill depth, hydration to an uniform moisture of 7 %. S.D conditions:  
PC = 267 mbar (Pikal and Nail, 2014). 
2.2.2.3.3 Influence of Pressure on Secondary Drying 
S.D was performed on the Moxalactam di-sodium and the Povidone solutions of Chapter 
2.2.2.3.1 (Pikal and Nail, 2014) with different drying T (see Figure 2-25). Unlike for P.D, Pc 
does not show any influence on the S.D rate. It can indeed be observed in Figure 2-25, that 
whatever Pc, the amount of water in the sample is unaltered, meaning that the removal of water 
in amorphous matrix is limited by the transport, i.e. diffusion in the solid.   
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Figure 2-25: Kinetics of S.D of Moxalactam (squares), and of Povidone (triangles) with different PC: blue = 0,2 Torr 
(i.e. 267 mbar) and green = 0,05 Torr (i.e. 67 mbar). Sample preparation: 5 % aqueous solution, 1 cm fill depth, 
hydration to a uniform moisture of 7 % (Pikal and Nail, 2014). 
2.2.3 Equipment Presentation (AzbilTelstar, 2015; Jennings, 2008c)  
 
Figure 2-26: Schematic drawing of a freeze-dryer (Jennings, 2008c). A=Drying Chamber, B=Usable shelves, 
C=Unusable shelf, D=Condenser chamber, E=condenser surfaces, F=Vacuum pump. 
2.2.3.1 Drying Chamber 
The drying chamber (A on Figure 2-26), which is generally constructed from stainless steel, 
resists the necessary temperatures and pressures required to the production process. The 
chamber is closed to the external environment thanks to an acrylic glass or metal door. A 
gasket is also present in order to allow the vacuum to be correctly set in the chamber. The 
whole chamber needs to be correctly thermally sealed to prevent thermal conductivity from 
the environment to the chamber. 
The chamber is composed of usable (B on Figure 2-26) and unusable stainless steel shelves (C 
on Figure 2-26). In the case of the Lyoc® technology, the product is loaded on trays on these 
usable shelves (see Figure 2-8). The unusable shelf, which is situated at the top of the chamber, 
helps to protect the products placed on the upper usable shelf from radiation of the drying 
chamber upper wall. All the usable shelves are bypassed by a heat-transfer fluid (usually 
silicon oil), which has a double action: 
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- It removes energy from the product during the freezing step by quickly cooling down 
the shelves, 
- It supplies the product with energy by heating up the shelves for the primary and 
secondary drying.  
Ts can go from -50°C to 80°C, according to the nature of the heat-transfer fluid.   
2.2.3.2 Condenser Chamber 
The condenser chamber (D on Figure 2-26) contains condenser surfaces (E on Figure 2-26) 
that capture the water vapour removed from the Lyoc® in the drying chamber. The cooling 
coils are cooled down to approx. -80°C through refrigerant fluid. The condenser system needs 
to be efficient, in order to avoid a Tcc increase, which could lead to sending back water 
molecules towards the shelves and compromise the product quality. The condenser chamber 
is either in the same chamber as the drying chamber, or in a separate one. In the second case, 
the two chambers are connected by means of a large tube to allow the migration of water 
molecules. The two chambers are then separated by a valve which allows them to be isolated 
from each other in order to perform a pressure rise test (mentioned in Section 2.2.2.2.4). 
2.2.3.3 Vacuum Pump 
The vacuum pumping system (F on Figure 2-26) regulates the vacuum level during the primary 
and secondary drying steps. Its role is to decrease the partial pressure of non-condensable gas 
in order to evacuate the water vapour out of the chamber (ChristMartin, 2015). It has to be 
able to lower the pressure down to 1 µbar.  
2.2.3.4 Sensors 
The freeze-dryer also contains different types of sensors to control the evolution of 
temperature, pressure and the amount of water in the sample during the experiment: 
- Temperature sensors (usually PT100 sensors) measure Tp, Ts and Tcc, 
- Vacuum gauge measures the pressure in the chamber (Pirani and capacitive vacuum 
gauge, as explained in section 2.2.2.2.4), 
- LyoRx sensor measures the electrical resistance present in the product, allowing the 
identification of the solidification and the defrost points. 
2.2.4 Product Formulation 
Formulation of freeze-dried tablets requires the use of several excipients bringing different 
properties and characteristics to the product. Indeed, the tablet needs to be hard enough to 
allow the handling by the patient without breaking, but need also to disintegrate as fast as 
possible and to have a satisfactory appearance. The viscosity of the suspension needs to be as 
low as possible in order to be pumped through the long automated dispensing system, but 
sedimentation has also to be avoided which means that viscosity must not be too low. The 
physical characteristics of the suspension needed to produce Lyocs® such as viscosity, degree 
of sedimentation, excipient particle size, API solubility, are thus very important. Excipients 
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are thus used in order to solve all those challenges, and to give to the product an acceptable 
visual aspect. The different types and several examples of excipients used in the Lyoc® 
formulations are listed in Table 2-8. 
Table 2-8: Roles of excipients used in Lyocs® (Cephalon, 2009). 
Class Role Example 
Bulking agent / 
Filler 
Component in large amount in the 
formulation, providing product elegance 
(Pikal, 2010). Support the cryoprotectant. 
Mannitol, Sorbitol, 
Lactose, Glycine.   
Hardness 
builder / 
Binding agent 
Provides the sufficient hardness to the 
Lyocs® in order to be pushed out of the 
blisters without being broken. 
Dextran, Hypromellose, 
Copovidone 
Viscosity control Prevents the suspension to sediment too 
quickly. Reduce the sedimentation 
velocity of the suspension. 
Xanthan gum 
Dispersing agent Helps the dispersion and the 
homogenization of the powder in water. 
Gives a smooth taste in mouth thanks to its 
surfactant action. 
Improves the appearance of the Lyocs® 
surface. 
Polysorbate 80,  
Poloxamer 188,  
Castor oil, 
Macrogol 15 
hydroxystearate,  
Docusate natrium. 
Sweetening and 
flavouring 
agents 
Gives flavour and a pleasant taste in 
mouth. 
Sucralose, Aspartame, 
Acesulfam K, Flavours. 
pH buffer Improves the chemical stability of an API. 
Plays a role on the API solubility. 
Optimize the extent of API ionization.  
Citric acid, sodium 
hydroxide.  
Solvent Solvent used to produce the suspension. It 
will be removed during the lyophilisation 
process and will give to the freeze-dried 
tablet a porous nature. 
Water. 
 
A closer look will be made on the formulation development, and more specifically on the API, 
filler and binder requirements.  
2.2.4.1 Formulation Development 
2.2.4.1.1 API requirements 
H. Seager stated in an article (Seager, 1998) that the solubility of the API had a big influence 
on the freeze-dried product. It was indeed assumed that a non-soluble water APIs build up a 
crystalline structure during the freezing process (Seager, 1998), whereas water soluble APIs 
build up an amorphous structure (Seager, 1998). The creation of amorphous structure is 
leading to difficulties in the drying process due to smaller critical temperature, and is thus 
more prone to collapse and softening of the structure. H. Seager set limits to the use of non-
water soluble APIs at 400 mg / dose in order to keep the desired porous characteristics, and 60 
mg / dose for water soluble APIs in order to keep a good cake structure (Seager, 1998). The 
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use of crystal forming excipients or ion-exchange resins can reduce the solubility of the water 
soluble API or protect it from collapse (Seager, 1998). Nevertheless, those techniques are 
bulky for the formulation and lead thus to the manufacture of bigger tablets. H. Seager also 
proposed another technique in the case of water-soluble APIs (Seager, 1998), which is 
producing a placebo matrix and spray the mixture API/organic solvent on it. The solvent will 
then evaporate and the API will be trapped in the pores of the matrix (Seager, 1998). However, 
this method imposes an additional step and additional costs to the process, which could be 
inconvenient for the manufacturing of this dosage form already long and expensive. Another 
characteristic is required on the non-soluble water API particle size in order to prevent 
sedimentation in the suspension during the process and to avoid a gritty feeling in the mouth 
during the uptake in mouth of the drug from the patient. For those purposes, the API particle 
size should not exceed 50 µm (Seager, 1998).  
2.2.4.1.2 Filler 
Lyoc® suspension is a saturated suspension mainly composed of filler. This dense suspension 
will give to the final product an elegant visual aspect. As explained in section 2.2.3.1, 
substances that build up a crystalline structure during the freezing step are preferred. They 
allow the P.D to be done at higher temperature rates, as those substances have higher critical 
temperatures than amorphous substances, and also give an elegant aspect to the product 
(Seager, 1998). Typical fillers used in freeze-dried tablets are Mannitol, Glycine, Sorbitol, 
Lactose or Maltose (Jennings, 2008f; Seager, 1998) (collapse temperature of Mannitol: -28 
°C, Lactose: -28 °C, Sorbitol: -46 °C (Pikal, 2010)). Mannitol is an excipient widely used in 
the ODTs formulation because of its pleasant taste and its cooling effect in the mouth 
(Roquette, 2006). Mannitol also confers the specificity of collapse protective agent (Pikal, 
2010; Seager, 1998), as it crystallizes during the freeze-drying process, making it the most 
commonly used filler in freeze-drying applications (Pikal, 2010). Glycine also crystallizes 
during freeze-drying (Pikal, 2010). It is nevertheless rather used for freeze-dried injectable 
formulations (Rowe et al., 2009).  
2.2.4.1.3 Binding Agent 
Binding agents are typically water soluble polymers, that are forming glassy amorphous 
structures necessary for the strength and the resilience of freeze-dried tablets (Seager, 1998). 
The entire amount of binding agent is completely dissolved in the solvent, unlike the filler. 
Those substances are prone to protect the API during the lyophilization and especially during 
the freezing step, playing the role of cryoprotectant. Povidone and dextran were indeed used 
as cryoprotectants of living cells (Jennings, 2008f) during the freezing step. The most 
commonly binders used are gelatin, dextran, povidone, alginates (Pikal, 2010; Seager, 1998). 
Those polymers also allow increasing the collapse temperature of the formulation due to their 
high Tg’ (dextran: -10 °C, povidone: -20 °C, gelatin: -9 °C (Pikal, 2010)). The low Tc of the 
filler will thus be increased, making the lyophilization cycle more efficient.  
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2.2.4.2 Suspension 
In the Lyoc® technology viscosity plays a fundamental role. In order to develop a viscosity 
measurement method, each step of the production process has to be considered. The aim of 
this study is to allow in future a scale-up of the formulation from the laboratory scale to the 
production scale. In production, the suspension will indeed be pumped from the mixing 
container until the filling-nozzles through horizontal pipes. Nevertheless, sedimentation has to 
be prevented for a good quality of the Lyocs®. That is why the suspension has to have an 
adequate viscosity and consistency in order to flow correctly through the pipes and not to 
sediment. The flow in the pipes can be roughly described by the Hagen/Poisseuille equation 
(Mezger, 2012), where the maximum shear rate γw is located at the smallest diameter of the 
whole process, i.e. at the filling nozzle.  
γw =
4V
Πr3
 where r= filling nozzle -radius [m] und V=volume flow rate [m3/s] 
After taking the parameters and characteristics of the installation used in production into 
consideration, the shear rate should be as follows 0 s-1 < γw < 170 s
-1 because of the production 
parameters summarized in Table 2-9. 
Table 2-9: Production scale parameters of the dispensing step. 
Production parameters Value 
r [mm] 2,5 mm 
Filling time [s] [0,5 ; 0,65]  
V [mL] [1 ; 1,25]  
 
The mixing step also has to be taken into consideration which is defined to be up to 500 s-1 
according to the literature (Triantafillopoulos, 1988). The warming up of the suspension in the 
production scale is not feasible with the equipment present on the site (too long dispensing 
pipes). That is why the influence of the temperature on the viscosity is not studied. 
As previously explained, the viscosity of the suspension needs to be as low as possible to allow 
the suspension to be pumped, avoiding at the same time sedimentation to occur. Sedimentation 
and viscosity of a system is however strongly depending on the particle size of the material 
and the concentration of the suspension. Sedimentation is firstly studied with the help of the 
Stokes law (Pavlik, 2011). Considering an arbitrary spherical particle in the suspension, this 
later is subject to three main forces, namely the weight force Fw due to gravity (Pavlik, 2011), 
the buoyancy force Fb of the immersed particle (Pavlik, 2011) and the drag force Fd 
corresponding to the resistance of the viscous fluid on the particle (Pavlik, 2011) (see Figure 
2-27), with:  
𝐹𝑤 = 
4
3
 𝜋𝑟3 𝜌𝑝𝑔 
𝐹𝑏 = −
4
3
 𝜋𝑟3 𝜌𝑓𝑔 
𝐹𝑑 = −6 𝜋𝜂𝑟𝑣 
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where ρp represents the mass density of the particles, ρf  represents the mass density of the 
fluid, g represents the gravitational acceleration, r represents the radius of the particle, η 
represents the viscosity of the medium and v represents the velocity of the spherical particle 
(Pavlik, 2011).  
 
Figure 2-27: Representation of the forces (Fb, Fd, Fw) acting on a spherical particle moving in a fluid at a velocity v 
(Pavlik, 2011). 
At equilibrium, Fw + Fd + Fb=0, which lead to the expression of the velocity of the sphere 
𝑣 =
2(𝜌𝑝 − 𝜌𝑓)
9η
𝑔𝑟² 
showing that the velocity of a spherical particle falling in a fluid, i.e. the settling velocity,  
increases with the square of the radius of the particle. 
Regarding the viscosity, it depends not only on the loading concentration, but also on the 
particle size of the suspended material (Remmler, 2015). Indeed, the Einstein equation 
developed for low concentrated suspensions (Remmler, 2015) states that    
𝜂 = 𝜂0(1 + 2,5 𝜙) 
where η is the viscosity of the suspension, η0 is the viscosity of the medium, 𝜙 is the volume 
fraction of solid in the suspension. According to the Einstein equation, it can be seen that the 
viscosity is increasing with the concentration of particles in the medium. This relation is valid 
for 0 % < 𝜙 < 10 % (Remmler, 2015), as Einstein did not take into consideration the interaction 
between the particles (Remmler, 2015). That is why Krieger-Dougherty developed a model 
describing the interaction between particle and fluid according to the concentration of particles 
suspended (Remmler, 2015). In the case of Lyocs® formulation, the system is loaded up to 65 
% of particles, inviting us to take into consideration the following Krieger-Dougherty equation 
(Remmler, 2015). 
𝜂 = 𝜂0 (1 −
𝜙
𝜙𝑚
)
−[𝜂]𝜙𝑚
 
where 𝜙𝑚represents the maximum volume fraction of solids in suspension and [η] represents 
the intrinsic viscosity (=2,5 for spheres (Remmler, 2015)). This equation reflects the fact that 
the viscosity is highly dependent on the concentration of particles in the medium as shown on 
Figure 2-28. At the lower volume fraction of particles (red curve), the system is nearly 
Newtonian (η is independent on the shear stress and shear rate). By increasing the volume 
fraction of particles in the medium (blue and green curves), the system becomes shear-thinning 
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(η decreases as shear rate increases). The increase of particles in the suspension leads to a 
higher interaction between the particles, leading to an increase in viscosity (Remmler, 2015).  
 
Figure 2-28: Impact of solid loading on viscosity. Red=45 % of particles, Blue=55 % of particles, Green=61 % of 
particles (Remmler, 2015). 
The Krieger-Dougherty equation can also explains the influence of the particle size 
distribution on the viscosity. The input of different particle size distribution is shown in Figure 
2-29. A monodisperse distribution will have a lower 𝜙𝑚 than a polydisperse distribution, 
because of the particle packing (Remmler, 2015). Indeed, a monodisperse distribution will 
only have one particle size, or rather a uniform particle size, which will give a bigger empty 
space between the particles in that case. Contrariwise, a polydisperse distribution will contain 
not only big particles, but also smaller which are able to fill out the empty space between the 
bigger particles, increasing the ability to load more particles in the medium (Remmler, 2015). 
Those small particles will play the role of internal lubricant (Remmler, 2015), causing a 
decrease in the viscosity, as shown in Figure 2-29. 
 
Figure 2-29: Influence of the particle distribution on the viscosity (Remmler, 2015). 
  
The influence of the particle size is also playing an important role on the viscosity (Pahl et al., 
1991). Indeed, for a given 𝜙, a smaller particle size will increase the number of particles in the 
medium (Pahl et al., 1991), increasing the interaction between the particles and thus increasing 
the viscosity (Pahl et al., 1991).   
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3   Materials and Methods 
3.1 Materials 
 
3.1.1 Fillers Used 
Table 3-1: Fillers used. 
Trade Name Chemical Name, Ph. Eur. Producer 
Lactose Monohydrate O-β-D-Galactopyranosyl-
(14)-α-D-glucopyranose 
monohydrate 
Alpavit 
Maltose Monohydrate 4-O-α-D-Glucopyranosyl-β-D-
glucopyranose monohydrate 
Merck 
Neosorb 70/02 liquid 
sorbitol 
D-Glucitol 
ROQUETTE 
Neosorb P100T sorbitol 
Parteck SI 150 Merck 
Pearlitol® 25 C mannitol D-Mannitol 
ROQUETTE 
Pearlitol® 50 C mannitol 
Pearlitol® 110 C mannitol 
Pearlitol® 160 C mannitol 
Pearlitol® 400 DC mannitol 
Pearlitol® 100 SD mannitol 
SweetPearl P90 maltitol 4-O-α-D-Glucopyranosyl-D-
glucitol 
Merck 
Xylisorb 90 xylitol xylo-Pentane-1,2,3,4,5-pentol ROQUETTE 
 
3.1.2 Hardness Builders 
Table 3-2: Hardness Builders used. 
Trade Name Chemical Name, Ph. Eur. Producer 
Copovidone Kollidon VA 64 Poly(1-vinylpyrrolidone-co-
vinyl acetate) 
BASF 
Dextran 70 Dextran Pharmacosmos A/S 
EMDEX Dextrates  JRS PHARMA GMBH 
& CO.KG 
Hypromellose 2910, 6 mPa.s Methyl Hydroxypropyl 
Cellulose  
Samsung Fine Chemicals 
Co., Ltd. 
Lycatab DSH Maltodextrin Roquette 
Polyvinyl Alcohol Ethenol, homopolymer Japan VAM & Poval Co., 
LTD 
Povidone K25 1-Ethenyl-2-pyrrolidinone 
homopolymer 
Ashland Industries 
Deutschland GmbH 
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3.1.3 APIs 
Table 3-3: APIs used. 
Substance Producer 
Metamizol Sodium Sanofi-Aventis 
Metoclopramide 
Hydrochlorid Monohydrate 
AMSA SpA IT-COMO 
Sildenafil Citrate ASSIA CHEMICAL 
INDUSTRIES LTD 
Paracetamol Aptalis Pharma S.r.l. 
Phloroglucinol Anhydrous DSM Pharma Chemicals 
 
3.1.4 Other Excipients 
Table 3-4: Other excipients used 
Substance Role 
Purified Water Solvent  
3.2 Equipments and Software 
Table 3-5: Equipments and Software used. 
Process step Devices used Producer 
Weighting step  PG5002-S DeltaRange® Mettler Toledo 
Suspension production Beaker (400 mL) Duran Group 
Stirrer RW20 IKA 
Dispersion impeller - 
In Process Control (IPC) 
on the suspension 
DSC822e 
Software: STARe SW 12.00 
Mettler Toledo 
Rheometer MCR 301 
Plan-Plan Geometry 
Software: Rheoplus/32 V3.40 
Anton Paar 
Graduated cylinder (25 mL) Duran Group 
Blister molding IN-PACK Blister machine Omar 
PVC Foil (250 µm) - 
Aluminum Foil (20 µm) - 
Freeze-dryer (FD) Multipette M4 Eppendorf 
Freeze-dryer Epsilon 2-6D 
Software: Martin Christ LPC-32 
Christ 
IPC on the Lyocs® MultiCheck ERWEKA 
ZT72 ERWEKA 
Drying oven Heratherm Oven 
OMH60 
Thermo Scientific 
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D8 Advance powder X-ray 
diffractometer 
Software: Bruker AXS 
Bruker AXS 
SEM Zeiss DSM 940 A 
Software: Orion Vers. 5.25 
Carl Zeiss 
Sputter coater BioRad E 5100 BioRad 
Raman microscope alpha 500 WITec GmbH 
AccuPyc 1330 Micromeritics Instrument 
Corporation 
DSC822e 
Software: STARe SW 12.00 
Mettler Toledo 
TGA/DSC1 
Software: STARe WF DB1 
Mettler Toledo 
API release Fully Automated AT70 Smart 
(UV-Vis spectrophotometer) 
Software: WinSotax 
Dissolution System 6.2.3 
SOTAX 
Basketstation BS60 SOTAX 
Glass fibre filter GF 1 µm Gelman 
PE-Lambda 35 Perkin Elmer 
Fraction collector C613/15 SOTAX 
pH-meter  Metrohm 
0,1 cm quartz cell HELLMA® 
Content of uniformity Photometer Agilent HP 8453 
Software: UV-Visible 
ChemStation 
Agilent 
Peristaltic pump - 
0,01 cm quartz cell HELLMA® 
Statistical study DoE Software JMP 11 
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3.2.1 Manufacturing Process Flow Chart 
 
Figure 3-1: Schematic representation of the manufacturing process flow chart. 
3.2.2 Manufacture of the Suspension 
Figure 3-1 summarizes the entire manufacturing process, from powder mixture to IPC of the 
Lyocs®. In order to obtain good Lyocs® quality, suspensions containing 50% to 60% of solids 
(w/w) are freeze-dried. For the development step, 120 Lyocs® of 1 mL are produced per batch. 
Therefore the batch size of dried substances is set at 150 g. Initially, water is weighed in a 400 
mL beaker. If an API is present in the formulation, it is dispersed in water until visual 
homogeneity is noticed. Filler and binder are then mixed together before being added to the 
water. A dispersion impeller is used in order to disperse homogenously the suspended solids 
in water. The suspension is mixed at 400 rpm for 30 minutes in order to have a homogeneous 
mixture. PVC blisters (15 mm diameter and 8 mm depth) are molded by using a blistering 
machine. The suspension is pipetted by means of a Multipette and blisters are filled with 1 mL 
of suspension.  
Powder
Mixture
•Batch size = 150 g. 
•Filler is sieved through a 800 µm sieve in order to break the possible agglomerates.
•Filler and binder are manually mixed together.
•API is weight separately.
Suspen-
sion
•400 mL Beaker, where water is weight in. API is firstly dispersed during ca. 5min, to be sure that it correctly disperses in the water.
•Slowly incorporation of the powder mixture in the water, using a dispersion mixer.
•Mixing time = 30min, to ensure the homogenity of the suspension, speed mixture = up to 400 rpm.
IPC
•Viscosity measurement (Plate Plate  system).
•Degree of sedimentation measurement.
•Measurments performed after 30 min of mixing time.
Suspension 
distribution
•PVC blisters are filled using a Multipette.
•The filling volume is dosed by weight. 
•After the distribution, the blisters are laid on trays and are afterwards directly introduced into the FD in order to avoid sedimentation.
Freezing 
step
•The product is frozen in the FD down to -30°C to -40°C.
Freeze-
drying
•Primary drying.
•Secondary drying.
Sealing
•Aluminium foils are used to seal the blisters.
IPC
•The quality of the product is controlled (Hardness, disintegration time, visual aspect).
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3.2.3 IPC on the Suspension 
3.2.3.1 Determination of the Critical Temperature  
3.2.3.1.1 Differential Scanning Calorimetry (DSC) 
The critical temperature of the suspension was firstly measured using a DSC DSC822e from 
Mettler Toledo. This step is primordial in order to optimize the lyophilization process. 10 mg 
of the suspension are filled into an aluminum crucible and the crucible is then sealed with a 
perforated aluminum seal. The crucible is then cooled down to -60 °C with a cooling rate of -
5 K/min. The sample is held at -60 °C during 10 minutes and is then warmed up to 20 °C with 
a heating rate of 1 K/min in order to obtain sharp peaks and thus to obtain accurate results. 
Only the warming-up curve is analyzed.  
3.2.3.1.2 Freeze-Dryer For Freezing-Heating Cycle 
1 mL of the suspension is filled into a blister cavity and placed in the freeze-dryer using the 
same freezing conditions as those during the Lyocs® production. The samples are then 
exposed to the conditions mentioned in Table 3-6: 
Table 3-6: Method developed to measure the critical temperature of the suspensions formulated using a FD. 
Step Temperature Pressure 
Pre-cooling of shelves -40°C 1000 mbar 
Freezing of the suspension -40°C 1000 mbar 
FD chamber put under pressure -40°C 0,1 mbar 
Warming up From -40°C to 20°C with a 
heating rate of 2 K/min 
0,1 mbar 
The critical temperature is determined at the temperature at which the Lyocs® present air 
bubbles on their surface.  
3.2.3.2 Viscosity Measurement 
Based on Section 2.2.4.2, the suspension viscosity measurement is carried out in the rotational 
mode for 2 s-1 < γ  < 500 s-1. As the suspension contains large particles, a parallel plate 
measuring system is used. Otherwise, with a cone plate system, the particles could agglomerate 
at the tip of the cone (AntonPaar). A wet cloth is also set all around the measurement geometry 
to prevent the suspension from drying out on the edge during the measurement. The 
measurement method is summarized in Table 3-7:  
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Table 3-7: Viscosity measurement method. 
Measurement time 30 sec 1 min 30 points every 20 sec 
Temperature of the 
bottom plate 
20°C 20°C 20°C 
Rotation, 𝛄  γ = 5 s-1  γ = 0 s-1 γ = 2-500 s-1 
Explanation These 2 steps are to unify the sample and 
to remove its history (due to stress caused 
on the sample during mixing and 
pipetting). 
Measurement of the 
suspension viscosity. 
 
The viscosity of the suspension is evaluated at γw, i.e. at the filling nozzle where the maximum 
shear rate is located.  
3.2.3.3 Degree of Sedimentation 
Sedimentation occurs in a liquid dosage form when the particles are settling under gravitational 
force. This phenomenon should be avoided during the production of Lyocs®. If it happens, it 
could indeed impact the quality of the product and on the API repartition within the Lyocs®.  
The degree of sedimentation is measured using a 25 mL graduated cylinder: 
𝐹 =
𝑉at t=60 min
𝑉at t=0 min
 (Swarbrick et al., 2014). 
where Vat t=60 min represents the equilibrium volume of the sediment after 60 min of standing 
time in mL and Vat t=0 min represents the total volume of the suspension in mL. 
The larger F, the better the suspendability.  
The sedimentation of the suspension in the FD will then be visually observed and associated 
to the F value and to the viscosity value. 
3.2.4 Lyocs® Manufacture 
The Lyocs® are produced the same way as in the production site. On each shelf three racks 
are superposed on each other. On each rack, two blister foils (20 Lyocs® per blister foil) are 
placed. The production efficiency is then 120 Lyocs® per shelf. Figure 3-2 represents the FD 
used during the whole experiments of this dissertation.  
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Figure 3-2: Filled FD Epsilon 2-6D (3 shelves with 3 racks per shelf) 
1 mL of suspension is pipetted in each blister cavity, which corresponds to a product height of 
ca. 5 mm. The lyophilization process is summarized in Table 3-8: 
Table 3-8: Lyophilization manufacturing process of Lyocs®. 
Step Time [hh:mm] T [°C] Vacuum [mbar] T ramp [°C/min] 
Loading 00:00 -40 1000 - 
Freezing 02:15 -40 1000 - 
Primary Drying 00:35 -40 0,2 - 
01:35 45 0,2 0,90 
06:00 45 0,2 - 
Secondary Drying 04:00 45 0,2 - 
00:30 25 0,2 0,67 
00:30 25 0,2 - 
Total duration 15:25    
 
During the process, four temperature sensors (PT 100) control the product temperature. The 
LyoRx sensor monitors the electrical resistance of the product during the whole process. This 
sensor cannot only determine the freezing point but it can also emit a warning in case of 
collapse during the primary drying step. In Figure 3-3, an example of a lyophilization cycle is 
represented, showing both set parameters (such as shelf temperature, set vacuum), and the 
experiment values obtained during lyophilization (such as product temperature, vacuum in the 
chamber).  
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Figure 3-3: Freeze-drying process: Temperature and Pressure evolution as function of time, white=loading step, 
green=freezing step, red=P.D, blue=S.D. Curves legend is summarized on the top of the graph. 
3.2.5 In Process Control on Lyocs® 
3.2.5.1 Visual Aspect 
The Lyocs® are firstly visually examined at the end of lyophilization cycle. The Lyocs® 
quality is also observed after unpacking (powdery, presence of cracks or bumps on the surface 
of the Lyocs®), in order to check if the freeze-dried tablets are resilient enough to de-blistering 
activities and if the Lyocs® keep a good consistency.  
3.2.5.2 Weight, Dimension and Resistance to Crushing (Hardness) 
20 Lyocs® (n=20) are randomly collected from the whole batch and checked using a 
MultiCheck apparatus from ERWEKA. The average of the Lyocs® weight, hardness, diameter 
and height are measured according to the paragraph 2.9.8 of the Ph. Eur. (EDQM, 2014d). 
3.2.5.3 Disintegration Time 
As the Lyocs® are supposed to disintegrate within 30 seconds in the mouth, the disintegration 
time is a crucial parameter. In this thesis, the disintegration time is determined according to 
the paragraph 2.9.1 of the Ph. Eur. (EDQM, 2014a), using an automated disintegration 
apparatus ZT72 from ERWEKA. The disintegration time (D.T) of 6 Lyocs® (n=6) is measured 
in 700 mL of purified water warmed up at 37°C. 
3.2.5.4 Moisture Content 
The moisture content contained in Lyocs® is measured using a loss on drying (LoD) method 
according to the chapter 2.2.32 of the Ph. Eur. (EDQM, 2014b). 10 Lyocs® are carefully 
milled and 1 g of sample is collected in a glass bottle previously dried. The bottle is placed in 
an oven at 105°C for 4 hours and cooled down afterwards in a desiccator during 2 hours. The 
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bottle is then weighed again in order to determine the LoD. Each measurement is made in 
duplicate (n=2).   
3.2.5.5 Scanning Electron Microscopy (SEM) 
The determination of the morphology of the Lyocs® is made through SEM. The Lyocs® are 
broken into two pieces (1st step on Figure 3-4), and one piece is glued on the aluminum sample 
carrier with a conductive paste. The sample is then coated with a thin gold layer under pressure 
(ca. 0,04 mbar) by means of a sputter coater Biorad E 5100. This sputter coating process is 
made 4 times during 60 s, with a current of 20 mA and an acceleration voltage of 2,1 kV. The 
sample is then analyzed with a Zeiss DSM 940 A SEM, applying an acceleration voltage of 
5000 V. A general view of the whole Lyoc®, a zoomed view of the upper surface of the Lyoc® 
and a zoomed view of the middle of the Lyoc® are photographed, as shown on Figure 3-4. 
 
1st step: sample preparation 
 
General view of the entire Lyoc® 
 
Zoomed view of the upper surface 
 
Zoomed view of the middle 
Figure 3-4: Sample preparation and picture sampling point. 
3.2.5.6 Solid State Determination 
To determine the solid state of the different materials present in the formulation before and 
after lyophilization, three different techniques were used (namely DSC, Thermogravimetric 
analysis TGA and X-ray diffraction). 
3.2.5.6.1 DSC  
5 mg of the powder is filled into an aluminum crucible and the crucible is then sealed with a 
perforated aluminum seal. The crucible is then warmed up to from room temperature to 300 
°C with a heating rate of 10 K/min, using a DSC822e from Mettler Toledo. 
3.2.5.6.2 TGA  
5 mg of the powder is filled into an aluminum crucible. The crucible is then warmed up to 
from room temperature to 300 °C with a heating rate of 10 K/min, using a TGA/DSC1 from 
Mettler Toledo. 
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3.2.5.6.3 X-Ray Diffraction 
The X-ray diffraction of the different raw materials, placebo Lyocs® and drug loaded Lyocs® 
are conducted with a D8 Advance powder X-ray diffractometer from Bruker AXS. The 
conditions of the measurement are summarized in Table 3-9: 
Table 3-9: Conditions of the X-ray powder diffractometry (XRPD) measurements. 
Diffractometer geometry Reflection mode (Bragg-Brentano geometry) 
Radiation Cu Kα1/α2 
Source 34 kV / 40 mA 
Detector Vantec-1 (electronic window: 3°) 
Kβ filter Ni (diffracted beam) 
Measuring circle diameter 435 mm 
Detector window slit 12 mm 
Anti-scatter slit (diffracted beam) 8 mm 
Divergence slit v6.00 (variable) 
Soller slit (incident /diffracted beam) 2.5° 
2θ range  2° ≤ 2θ ≤ 55° 
Step size  0.016 
Step time  0.2 s 
 
3.2.5.7 Raman Microscopy 
Raman microscopy is used in order to evaluate the API spatial distribution within the Lyocs® 
and to determine if the lyophilized API exists in a crystalline state, an amorphous state or in a 
solid solution with a molecularly dispersed API as represented in Figure 3-5. Indeed, during 
lyophilization, the API could solidify in interaction with one of the excipients by H-bounding 
for instance (Gryczke, 2012), leading to a solid solution state. 
 
Figure 3-5: Schematic representation of an API in crystalline, amorphous or molecularly dispersed state (Gryczke, 
2012) 
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Figure 3-6: Illustration of the spatial mapping (Lunter, 2016). 
The XY and XZ orientations (see Figure 3-6) are scanned with the Raman microscope alpha 
500, WITec GmbH, using a laser of 532 nm with a power of 20 mW and a radiation time of 
0,08 sec.  
On the XY plane, two scans are taken with different objective sizes: 
- a 500x500 µm area is scanned with a 10x0,25 Numerical Aperture NA objective 
(Resolution ca. 1,3 µm) 
- a 100x100 µm area is scanned with a 40x0,6 NA objective (Resolution ca. 0,8 µm). 
On the XZ plane, a 50x25 µm area is scanned with a 40x0,6 NA objective (Resolution ca. 0,8 
µm). 
Raman Imaging is then conducted by adding a filter to the measured scans. Indeed, a spatial 
mapping is achievable by adjusting the following equation to each spectrum of the scanned 
section 
𝑆 = ∑ 𝑎𝑘?⃗⃗?𝑘
𝑁
𝑘=1
 
where ?⃗⃗?𝑘represents the Raman spectrum of the substance k, N represents the number of 
compounds present in the sample, 𝑎𝑘 represents the adjustment factor of the substance 
proportional to the percentage of substance present in the sample and 𝑆 is the superposition of 
each spectrum. 
Intensity images are calculated for each compound by means of the 𝑎𝑘 factor, giving a specific 
color to each substance.  
3.2.5.8 Porosity  
The density ρ of Lyocs® is measured by means of a gas pycnometer (AccuPyc 1330, 
Micromeritics), in order to determine the free volume within the Lyocs® and thus evaluate the 
porosity of the manufactured products. The porosity of ODTs is indeed an important 
parameter, allowing the estimation of water penetration into the sample (Ölmez and Vural, 
2009).  
The sample is firstly purged with helium 10 times with a purge pressure of 134 kPa in order 
to remove the last molecule of water that could be present in the sample. The sample density 
is then measured 5 times with a helium equilibration rate of 34 Pa/min. This method is applied 
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on 5 Lyocs®. After that, the porosity is calculated with the following equations (Ölmez and 
Vural, 2009): 
  
𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 [%] = [1 − (
𝑚
𝜌. 𝑉
 )] . 100 
The experimental values are compared to the calculated ones, resulting from the following 
equation established in the U.S. patent 20100080829 A1 (Dulieu et al., 2010): 
  
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 [%] =
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 𝑝𝑒𝑟 𝐿𝑦𝑜𝑐®
𝑉𝑜𝑙𝑢𝑚𝑒 𝑝𝑖𝑝𝑒𝑡𝑡𝑒𝑑 
. 100 
3.2.5.9 API Release – Paracetamol Lyocs® 
The equipment used to measure the in-vitro API release is constituted of a UV-vis 
spectrophotometer (SOTAX Fully Automated AT70 Smart) composed of a paddle stirrer 
apparatus (SOTAX Basketstation BS60), in an initial volume of 900 mL of phosphate buffer 
(pH 5,8) at a temperature of 37 ± 0,5 °C with a stirring speed of 50 rpm. The sampling is 
automatically performed at 5, 10, 15, 20, 30, 45 and 60 min after providing the Lyoc® to the 
system. The sample is filtered on a 1 µm glass filter (GF) before reaching the 0,1 cm quartz 
cell. The API concentration is then determined at a wavelength of 243 nm (see Annex 6.3). 
The measurement is performed on 6 Lyocs®.   
3.2.5.10 Uniformity of Dosage Form – Paracetamol Lyocs® 
3.2.5.10.1 Uniformity of Dosage Form on Entire Lyoc® 
The uniformity of dosage form of each batch is measured, in order to check the homogeneity 
of API within the tablets. This test is performed based on the Ph. Eur., paragraph 2.9.40 
(EDQM, 2014f). 10 tablets are randomly picked up in the whole batch and each tablet is 
separately dissolved in 100 mL of solvent. The content of uniformity is measured by means of 
UV-VIS spectroscopy with a wavelength λ range between 200 and 500 nm (λmax of 
paracetamol = 249 nm according to the Ph. Eur. (EDQM, 2014c)) with a 0,1 mm quartz 
cuvette. The solvent used to dissolve the tablets is [1 mL 85% H3PO4 in 1 L H2O : MeOH 
(9:1)].  
3.2.5.10.2 Uniformity of Dosage Form on Half Lyoc® 
API sedimentation within Lyocs® is studied by cutting the Lyoc® in the half horizontal plane 
and by measuring the API content in each half of Lyoc®. Each half Lyoc® is weighed and 
dissolved in 50 mL of solvent in order to keep the same measurement parameters as in the 
chapter 3.2.5.10.1. An absorption measurement is then performed on each sample. The API 
content per half Lyoc® is calculated by means of the following equation: 
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𝐴𝑃𝐼 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 [𝑚𝑔/𝑔] =
𝐴𝑇𝑠𝑡 𝐶𝑅𝑒𝑓 𝑉𝑇𝑠𝑡 ?̅?
𝐴𝑅𝑒𝑓 𝑚𝑇𝑠𝑡
 
ATst = Absorption of the test solution  
CRef = Concentration [mg/mL] of the reference substance in the reference solution 
VTst = Volume [mL] of the test solution 
?̅? = Average mass [g] 
ARef = Absorption of the reference 
mTst = Initial weight [mg] of the test substance 
 
As represented on Figure 3-7:  
- the top of the Lyoc® represents the part of the Lyoc® in contact with the Aluminum 
foil, 
- the bottom of the Lyoc® represents the part of the Lyoc® in contact with the bottom 
of the PVC foil.    
 
 
Figure 3-7: Representation "Top / Bottom" of the Lyoc®.            
3.2.5.11 Statistical Analysis 
The statistical software JMP® is used in the frame of the formulation development, in order 
to work on formulation optimization of Lyocs®.  
The “Custom Design Tool” was chosen in the JMP Software, since this tool takes into 
consideration the different responses, factors and constraints of the system and builds up the 
associated “Design of Experiment” adapted to the given issue. The factors were defined to be 
the compounds concentrations (i.e. water, binder, filler) whereas the responses were defined 
to be the resulting quality attributes (i.e. viscosity, degree of sedimentation, hardness and 
disintegration time).  
The “Factors and Responses” limits were defined and entered in the JMP Software before 
creating computer-assisted the experimental design of 12 runs with one center point and a 2nd 
term interactions. Those 12 formulations allow evaluating all responses by varying each factor 
in the determined range. Each formulation was prepared at a batch size of 120 Lyocs®. 
After inserting the experimental response data, each response was analyzed individually in 
order to determine how well the statistical model fits the response data. To achieve this, the 
statistical adjustment of each response to the model was checked with the tool “Fit Model”. 
This tool analyses the possible interactions and the quadratic effects between the factors, and 
therefore rebuild a better adjusted model if necessary. The model was considered as fitted 
when the R² and R²Adj values of the “Actual by predicted Plot” were > 0.990. A fitted least 
Top 
Bottom
m 
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squares model was then used to determine the effect of each factor on each response. In a 
second step, an analysis on the “Sorted Parameter Estimated” table was carried out in order to 
determine the statistical significant factors and interactions present for each response. Factors 
with t-values < 0,05 were considered as significant, meaning that those factors have an 
influence on the studied response.   
Finally, the determination of the optimized formulation was performed by means of the 
optimizer tool “Prediction Profiler” available in the JMP Software, by maximizing the 
desirability function of each response. Once the optimized formulation was estimated, it was 
experimentally tested in order to measure the responses obtained and to check if the predicted 
values fitted with the experimental responses.  
Statistical difference was evaluated by means of the t-value calculated with the equation 
(ResearchMethodsKnowledgeBase, 2006): 
𝑡 =
|?̅?1 − ?̅?2|
√𝑠1²
𝑛 +
𝑠2²
𝑛
 
Statistical analysis on the API dissolution profile was performed by means of the evaluation 
of both difference factor (f1) and similarity factor (f2), given by (CDER, 1997; EMEA, 2010):  
𝑓1 =
∑[𝑅(𝑡) − 𝑇(𝑡)]
∑[𝑅(𝑡)]
 
𝑓2 = 50𝑥𝑙𝑜𝑔
[
 
 
 
 
 
100
√1 +
∑[𝑅(𝑡) − 𝑇(𝑡)]
2
𝑛 ]
 
 
 
 
 
  
With n = number of sampling points, R(t) = mean percentage of dissolved API for reference 
product at time t and T(t) = mean percentage of dissolved API for tested product at time t. 
Two dissolution profiles are deemed to be similar or equivalent when f1 < 15 and f2 > 50 
(CDER, 1997; EMEA, 2010).   
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4 Results and Discussion 
4.1 Excipient Screening 
An excipient screening was carried out, in order to determine which excipients could be used 
in the Lyoc® technology. In the currently marketed formulations, only two types of matrix 
builder are used, namely mannitol and lactose, and only dextran is used as hardness builder. 
This gives the formulator too few choices for the formulation development of a drug. This 
study was conducted on placebos. 
4.1.1 Study on Diluents 
Diluent is the main compound present in the Lyocs®. Not only does it give the tablet a 
homogenous structure, but it also protects and should not interact with the API. As the Lyocs® 
are disintegrating in the mouth, their organoleptic properties should be pleasant to ensure the 
patient compliance. Therefore only sweet soluble diluents were taken into consideration. 
Those six substances listed in Table 4-1 were deeper examined in more details. 
Table 4-1: List of investigated diluents and their relative sweetness (Roquette, 2012; Rowe et al., 2009). 
Diluent Sweetness relative to sucrose  
Lactose monohydrate (present in marketed products) 0,2  
Maltitol  0,9 
Maltose monohydrate   0,3  
Mannitol (present in marketed products) 0,4 
Sorbitol  0,6 
Xylitol  ca. 1 
 
4.1.1.1 Substance Description 
Lactose monohydrate (Rowe et al., 2009): 
Lactose is a disaccharide composed of galactose and glucose units (Figure 4-1). Lactose is a 
white crystalline powder. A Maillard-reaction can occur between lactose and substances 
having a primary or secondary amine group, leading to a brown coloration of the finish 
product. This could impede the visual aspect of the product, leading to possible complaints 
from the client. Its melting range lies between 201 and 202°C.   
 
 
 
C12H22O11 
 
 
M=360,31 g/mol 
Figure 4-1: Structural formula of lactose monohydrate. 
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Maltitol (Rowe et al., 2009): 
Maltitol is a disaccharide composed of one glucose unit linked with a sorbitol unit (Figure 4-
2). Maltitol is a white crystalline powder, having a sweet taste. It is also a non-hygroscopic 
substance (maximum 1,0 % water), which is an advantage for the Lyoc® technology. Its 
melting range lies between 148 and 151°C.  
 
 
 
C12H24O11 
 
 
M=344,32 g/mol 
Figure 4-2: Structural formula of maltitol. 
 
Maltose monohydrate (Rowe et al., 2009): 
Maltose is a disaccharide of two glucose units (Figure 4-3). Maltose is a white crystalline 
powder, having a sweet taste. A Maillard-reaction can occur between maltose and substances 
having a primary amine group, leading to a brown coloration of the product. This could impede 
the visual aspect of the product, leading to possible complaints from the client. Its melting 
range lies between 120 and 125°C.  
 
 
 
C6H14O11 + H2O 
 
 
M=360,31 g/mol 
Figure 4-3: Structural formula of maltose monohydrate. 
 
Mannitol (Rowe et al., 2009): 
Mannitol is an acyclic sugar alcohol, containing six alcohol groups (Figure 4-4). Mannitol is 
a white crystalline powder, having a sweet taste and a cooling effect in the mouth. Mannitol is 
also a non-hygroscopic substance (maximum 0,5 % water), which is an advantage for the 
Lyoc® technology. Mannitol possesses three polymorphic modifications, namely α, β and δ. 
The melting range of mannitol lies between 166 and 168°C. 
 
 
 
C6H14O6 
 
 
M=182,17 g/mol 
Figure 4-4: Structural formula of mannitol. 
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Sorbitol (Rowe et al., 2009): 
Sorbitol is an isomer of mannitol (Figure 4-5). Sorbitol is a white hygroscopic crystalline 
powder, having a sweet taste. Sorbitol possesses four crystalline polymorphs and one 
amorphous form, which leads to different melting points between 93 and 112°C.  
 
 
 
C6H14O6 
 
 
M=182,17 g/mol 
Figure 4-5: Structural formula of sorbitol. 
 
Xylitol (Rowe et al., 2009): 
Xylitol is an acyclic sugar alcohol, containing five alcohol groups (Figure 4-6). Xylitol is a 
white crystalline hygroscopic powder, having a sweet taste and a cooling effect in the mouth. 
Its melting range lies between 92 and 96°C.  
 
 
 
C5H12O5 
 
 
M=152,15 g/mol 
Figure 4-6: Structural formula of xylitol. 
4.1.1.2 Suspension Characterization 
Lyocs® are produced from a viscous suspension. Indeed, the suspension is saturated in diluent. 
The diluent is thus not completely dissolved in water, which gives the final product a consistent 
structure. As explained in the section 2.2.5, the diluent should be a crystallizing excipient due 
to its higher critical temperature (Tc) in comparison to an amorphous compound (Te > Tg’). 
The use of a crystalline filler will have a huge impact on the process time (since a higher Tc 
allows faster increase of T and/or higher Ts settings during the sublimation phase) and will 
also protect the API during the lyophilization cycle. The solid state and the critical temperature 
of the Diluent/Water suspensions were firstly determined through DSC (see Annex 6.1.1). 
The DSC thermograms of lactose, maltose and mannitol suspensions present a sharp 
exothermic peak, proving that these substances build up a crystalline structure during 
lyophilization. Moreover, they have a higher Tc than the other substances. The DSC 
thermograms of sorbitol presented a glass transition (broader peak than the crystalline one) 
meaning that this substance builds up an amorphous structure with a quite low Tc. Maltitol and 
xylitol build up both a crystalline and an amorphous structure with a low Tc. Considering the 
solid state of the maltitol, sorbitol and xylitol suspensions, can those substances be used 
anyway within the framework of the Lyoc® technology? To answer this question, the FD was 
used. The suspensions analyzed through DSC were also analyzed with the FD method 
described in Chapter 3.2.3.1.2. The Tc results obtained with both methods are summarized in 
Table 4-2.  
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Table 4-2: Comparison of the different Diluent/Water suspensions Tc, measured by DSC (n=3) and with the freeze-
dryer (n=2). 
 Lactose 
 
(50% w/w) 
Maltitol 
 
(60% w/w) 
Maltose 
 
(50% w/w) 
Mannitol 
Pearlitol® 110 
C 
(50% w/w) 
Sorbitol 
Neosorb 
70/02 
(70% w/w) 
Xylitol 
 
(60% w/w) 
DSC 
measurement 
Tc [°C] 
0,49±0,26 -11,76±0,17 -2,45±0,93 -0,25±0,13 -32,90±0,23 -57,30±2,38 
Freeze-dryer 
measurement 
Tc [°C] 
None -14 -5 None Could not 
be frozen 
-17 
  
The lactose and mannitol suspensions do not reveal any air bubbles on the surface during the 
FD test. The frozen water is able to sublimate without causing collapse within the Lyocs®. 
The freezing temperature of the sorbitol suspension is too low to be reached in the FD, meaning 
that sorbitol cannot be used for the Lyoc® technology. The xylitol and maltitol suspensions 
have too low critical temperatures. These substances would need a much longer time to be 
freeze-dried and are therefore non-efficient from a production point of view. The maltose 
suspension has a higher critical temperature than maltitol, sorbitol and xylitol and could be 
considered as a new excipient usable in the Lyoc® technology.  
One advantage of the Tc measurement with the freeze-dryer is that the evolution of Tproduct can 
be followed in real time (see Figure 4-7). 
 
Figure 4-7: Evolution of Tproduct of the various diluents in function of time (n=2). 
Sublimation is an endothermic process, i.e. the product is absorbing heat energy from the 
shelves. As shown on Figure 4-7, two different Tproduct evolutions can be observed: the 
evolution of Tproduct of the lactose and mannitol suspensions is firstly decreasing before 
increasing again, whereas of the other Tproduct substances are increasing from the beginning. 
The fact that TP is decreasing is the sign of a beginning of evaporation within the product, 
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meaning that the product will be easily sublimated (Le Floch, 2008).  It could be explained by 
a faster onset of sublimation with lactose and mannitol than the other substances, leading to a 
higher water loss at the beginning of the drying process. During the first 10 min of sublimation, 
the frozen water may easily sublimate for mannitol and lactose, which could explain this 
evolution of temperature, unlike maltitol, xylitol and maltose. TP of maltitol, maltose and 
xylitol are increasing so fast that their Tc is reached too quickly, leading to the collapse of the 
Lyocs®. The lyophilization process of these latter three substances has to be prolonged to 
prevent a too fast temperature increase and they are therefore not potential diluents from a 
production point of view. Indeed, the manufacture of Lyocs® will not be productive enough 
by using excipients that need a long drying time.  
According to the Tc values and to the evolution of TP as well as considering the solid state of 
each diluent, mannitol and lactose are the most interesting substances. Nevertheless, lactose 
may cause an intolerance in some patients, which limits its use as excipient. Lactose is also 
subjected to the Maillard-reaction and is a hygroscopic substance (content of water ≈ 4,5-
5,5%). The Maillard-reaction could lead to a bad visual aspect of the product (due to brown 
coloration), whereas the hygroscopic criteria could lead to product absorbing too much water 
of the ambient air, impacting the quality of the final product by provoking a decrease of 
hardness for instance. The other negative point of lactose is that its taste is pretty flavorless 
unlike mannitol which has a cooling effect. As explained in the chapter 2.1.1, the taste of ODTs 
is an important criterion for patients. It is easier to mask the taste of an API with a sweet diluent 
having a cooling effect in mouth that with a tasteless diluent. Therefore, only mannitol will be 
studied in this thesis. 
4.1.2 Study on Binders 
Binders are used in Lyocs® formulation to give hardness and robustness to the freeze-dried 
tablets. This substance has to be a water-soluble polymer (Blonde, 1974). The choice of 
binders was made after a few investigations in patents (Blonde, 1974; Nguyen, 2011) and in 
the Handbook of Pharmaceutical Excipients (Rowe et al., 2009).  Table 4-3 shows a list of 
some typical binders with a summary of their main applications. 
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Table 4-3: List of investigated binders. 
Binder Main application 
Copovidone   Used as binder in direct compression and wet granulation or as 
film forming agent in coated solutions (Rowe et al., 2009). 
Dextran   Used as binder agent in lyophilization, as blood volume expander 
in intravenous solutions, or as lubricant in eye drops 
(Pharmacosmos, 2016).  
Dextrates   
 
Usually used as diluent in direct compression. Can also be used 
as binding agent by addition of water (Rowe et al., 2009).   
Hypromellose   Used as tablet binder, film forming agent in coated solutions or 
dissolution enhancer for example (Rowe et al., 2009).  
Maltodextrine   Used as binder and diluent in direct compression and wet 
granulation, such as viscosity increasing agent (Rowe et al., 
2009). 
Polyvinyl alcohol  Usually used in ophthalmic and topical products. Also used as 
stabilizing agents for emulsions (Rowe et al., 2009). 
Povidone   Used as binder in tableting and wet granulation or as dispersing 
agent (Rowe et al., 2009). 
 
4.1.2.1 Substance Description 
Copovidone (Rowe et al., 2009): 
Copovidone is a copolymer of 1-ethenyl-2-pyrrolidinone and ethenyl acetate (Figure 4-8). 
Copovidone is a white to yellow white amorphous, having a faint taste. It is a hygroscopic 
powder (less than povidone though). Its melting point stands at 140°C. 
 
 
 
(C6H9NO)n (C4H6O2)m       
 
 
M=111.1n + 86.1m g/mol 
Figure 4-8: Structural formula of copovidone. 
 
Dextran (Mogoşanu and Grumezescu, 2015): 
Dextran is a high molecular weight branched polysaccharide of D-glucose monomers (Figure 
4-9). It is a white tasteless powder.   
                                         (C6H10O5) n   
 
Figure 4-9: Structural formula of dextran. 
 
          
 
 
 
M is variable 
 
Dextrates (Rowe et al., 2009): 
Dextrates is a purified mixture of glucose monohydrate and different polysaccharides derived 
from starch. Dextrates is composed of 5% oligosaccharide and 95% glucose (w/w). Dextrates 
is a white sweet powder. It is slightly hygroscopic. Its melting point stands at 141°C. 
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Hypromellose (Rowe et al., 2009): 
Hypromellose is a mixture of methyl and hydroxypropyl ether of cellulose (Figure 4-10). It is 
a white tasteless hygroscopic powder. Hypromellose forms a viscous colloidal solution in 
water. It is available in several grades that vary in viscosity and substitution type. Its melting 
point range lies between 190 and 200°C.  
 
 
 
 
M is variable 
Figure 4-10: Structural formula of hypromellose. 
 
Maltodextrin (Rowe et al., 2009): 
Maltodextrin consists of D-glucose units with a dextrose equivalent (DE) less than 20 (Figure 
4-11). The DE value represents the hydrolysis of starch into glucose units. Maltodextrin is a 
nonsweet white powder. Its solubility and hygroscopicity increase as the DE increases.  
 
 
 
 
(C6H10O5)n      
 
 
 
M is variable 
Figure 4-11: Structural formula of maltodextrin. 
  
Polyvinyl alcohol (Rowe et al., 2009): 
As its name implies, the monomer of polyvinyl alcohol is vinyl alcohol (Figure 4-12). It is a 
white hygroscopic powder. Its melting point lies between 180 and 190°C. 
 
 
 
 
(C2H4O)n      
 
 
M is variable  
 
Figure 4-12: Structural formula of polyvinyl alcohol. 
 
Povidone (Rowe et al., 2009): 
Povidone has N-vinylpyrrolidone as monomer (Figure 4-13). It is a white hygroscopic 
amorphous powder. Its melting point stands at 150°C. 
 
 
 
(C6H6NO)n      
 
 
M is variable  
Figure 4-13: Structural formula of povidone. 
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4.1.2.2 Suspension Characterization 
As underlined in the U.S patent 3,855,712 (Blonde, 1974), binders are used in a proportion up 
to 10 % of the dried mass in lyophilized tablets. Above 10 % of binder, the resulting 
lyophilized tablet will be too hard because of the cohesion within the particles caused through 
its binding effect, leading to a disintegration time higher than 30 sec (Blonde, 1974). In order 
to see if binding agents have an impact on the Tc of mannitol, suspensions of Diluent/Binder 
(90 %/10 % w/w) were analyzed through DSC (see Annex 6.1.2). As shown in the Table 4-4, 
there were no significant changes on the Tc of mannitol, as the peaks of all binder types 
overlapped. This could be due to the too low concentration of binder in the suspension. Dextran 
seems to be the most appropriate binder, since Tc Diluent/Binder only differs from the Tc 
Diluent suspension from 0.02°C. Except for dextrates where the Tc was approx. 1 degree below 
the other binders, all other binders seem to be alternative binders for the Lyoc® technology.  
Table 4-4: Comparison of the different Diluent/Binder (90 %/10 % w/w) suspensions Tc with the 100 % Diluent 
suspension, measured by DSC (n=3). 
 90 %/10 % (w/w) 100 % diluent 
Copovidone   -0,44±0,12  
 
 
-0,25±0,13 
Dextran   -0,27±0,10 
Dextrates  -1,64±0,13 
Hypromellose   -0,72±1,05 
Maltodextrine   -0,69±0,08 
Polyvinyl alcohol  -0,64±0,17 
Povidone   -0,56±0,22 
 
4.1.3 Pre-formulation of Lyocs® 
The first challenge of the pre-formulation step was to define correctly the range of each 
compound present in the formulation. In fact: 
- the concentration of the binder should not exceed 10 %, otherwise as previously 
explained, the tablets might be too hard and might not disintegrate within 30 s (Dulieu 
et al., 2010), 
- the amount of diluent depends on the viscosity of the resulting suspension, 
- the amount of water present in the formulation is limited by the condenser capacity. In 
the production, three batches are continuously manufactured each day. After the third 
batch, the condenser is defrosted. 30 000 blisters of 8 or 10 Lyocs® are produced per 
batch. The condenser capacity is 600 kg. Considering that 90% of the condenser can 
efficiently entrap water, the maximal amount of water is established at 750 mg per 
Lyoc® (see Table 4-5). 
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Table 4-5: Calculation of the amount of water per Lyoc®. 
Blister per batch 30 000 
Lyocs® per blister 8 10 
Lyocs® per batch 240 000 300 000 
Total condenser capacity 600 kg 
90% of the condenser capacity 540 kg 
Condenser capacity per batch 180 kg 
Maximum amount of water per Lyoc® 750 mg 600 mg 
 
4.1.3.1 Test on Mannitol 
4.1.3.1.1 IPCs Range Determination 
IPCs are very important for the product quality determination. Lyocs® belong to the ODTs 
category, which means that they should disintegrate in the mouth within 30 sec. As the Lyocs® 
are packed in a PVC-blister foil sealed with a 25 µm aluminum foil, they have to be resilient 
enough to be pushed through this aluminum foil in order to resist the de-blistering step. 
Another alternative could be the use of peel-off blister. This option would unfortunately 
increase the production costs, which should be avoided as far as possible. Except the maximum 
disintegration time, there are no real range values of IPCs for the Lyoc® technology. That is 
why a pre-test was firstly performed to determine the different IPC ranges. Four marketed 
Lyocs® were studied in this section (see Table 4-6).  
Table 4-6: IPC results of manufactured products±SD. 
 Spasfon  
80 mg Lyoc® 
Spasfon  
160 mg Lyoc® 
Paralyoc  
500 mg Lyoc® 
Lopéramide  
2 mg Lyoc® 
η [mPa.s] 
Value read at 174 s-1 
239 241 Paracetamol micro-
encapsulated with 
cellulose to mask the 
taste   particle size 
=380 µm, too high 
for a viscosity 
measurement with 
the Plate-Plate 
geometry η 
measurement not 
relevant  
Lopéramide is an 
OEB 3 substance 
(substance too 
harmful to be 
handled by 
women). The 
suspension could 
not be 
reproduced and 
so the values of η 
and F could not 
be measured. 
F 
Measured with a 
graduated cylinder after 
letting the suspension 
stand 60 min 
0,98 0,99 1 
Hardness [N], 
n=20 
44±5 22±3 32±5 79±16 
D.T[s], n=6  4±1 71±35 150±30 89±28 
Visual aspect Lyocs® are visually 
good. Some are 
sticking to the 
aluminum foil. 
Lyocs® are not hard 
enough. 
They become broken 
when they are pushed 
through the blisters. 
Good quality: They 
do not stick to the 
blisters. 
Good quality: They 
do not stick to the 
blisters. 
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The disintegration time higher than 30 sec (see Table 4-6) is due to the unsuitable measurement 
method. The Lyocs® are sticking to the disks of the disintegration apparatus ZT72, distorting 
the results. The minimum hardness is defined to be between 22 N and 32 N (see Table 4-6). It 
could nevertheless not be precisely determined. That is why a second test was performed by 
producing placebos containing mannitol and different percentages of dextran (see Table 4-7). 
In the marketed formulations, the percentage of dextran is between 1,6 and 5,6 % of the total 
mass, the percentage of mannitol is between 22 and 55 % of the total mass and water is between 
43 and 57 % of the total mass. That is why the percentage of dextran was set under 1,7 % in 
order to determine the minimum hardness. 
Table 4-7: Placebo formulations with different percentages of dextran to determine the minimum hardness. 
%/dose 
 F1 F2 F3 
Batch Nr 140268 140269 140270 
Mannitol 55,60 55,03 54,46 
Dextran 0,57 1,14 1,71 
Water 43,83 43,83 43,83 
 
Table 4-8: IPCs results of the formulations F1-F3±SD. 
 F1 F2 F3 
Hardness [N], n=20 22±3 27±6 37±10 
D.T [s], n=6 4±1 5±1 4±2 
Visual aspect The Lyocs® are not 
hard enough: they 
become broken 
when they are 
pushed through the 
blister foils. They 
are powdery and 
leave a thin layer on 
the PVC foil. 
The Lyocs® are a bit 
powdery and leave a 
thin layer on the 
PVC foil. 
The Lyocs® leave a 
thin layer on the 
PVC foil. 
As shown in Table 4-8, F2 and F3 give good IPC results, unlike F1 where the Lyocs® were 
too soft. The minimum hardness (H) is therefore set at 27 N. 
Regarding the determination of degree sedimentation limits and the viscosity limits, different 
suspensions presenting different viscosities were produced and frozen in the freeze-dryer. It 
was noticed that: 
- for η < 50 mPa.s, the suspension settles during the freezing step, leading to powdery 
Lyocs®. 
- for η > 600 mPa.s, the suspension is too viscous and cannot be dispensed in the blister 
foils. 
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- for F < 0,85, the suspension settles during the freezing step, leading to powdery 
Lyocs®, which cannot be properly de-blistered without breaking. 
A summarized table of the IPC ranges is presented in Table 4.9: 
Table 4-9: Determination of IPC ranges of Lyocs®. 
 IPC range 
Viscosity  
Value read at 174 s-1 
50 < η < 600 mPa.s 
Degree of sedimentation  
Measured with a graduated cylinder after letting 
the suspension stand 60 min 
0,85 < F < 1 
Hardness   H > 27 N 
Time of disintegration   t < 30 sec 
4.1.3.1.2 Influence of Binders on Mannitol Lyocs®  
The binders mentioned in the section 4.1.2.1 were combined at different concentration to 
mannitol and the resulting Lyocs® quality was studied.  
The percentage of binder was increased progressively between 1,2 and 6,1 % of the wet mass 
(i.e. between 2 and 10 % of the dried mass, as mentioned in the U.S patent 3,855,712 (Blonde, 
1974)). As soon as the suspension was too viscous to be dispended in blisters or that the 
resulting D.T of the Lyocs® was too high, any further increase of the binder concentration was 
performed. The tested formulations are summarized in Tables 4-10 and 4-11. 
60 
 
Table 4-10: Formulations F1-F20 in %. 
% of substance 
 Copovidone Dextran Dextrates HPMC Malto- 
dextrin 
Polyvinyl 
alcohol 
Povidone 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 F18 F19 F20 
Mannitol 59,7 57,9 59,7 57,9 56,6 54,8 59,7 57,9 56,6 54,8 59,7 57,9 59,7 57,9 59,7 57,9 59,7 57,9 56,6 54,8 
Copovidone 1,2 3,0                   
Dextran   1,2 3,0 4,3 6,1               
Dextrates       1,2 3,0 4,3 6,1           
Hypromellose           1,2 3,0         
Maltodextrine             1,2 3,0       
Polyvinyl 
alcohol 
              1,2 3,0     
Povidone                 1,2 3,0 4,3 6,1 
Water 39,1 39,1 39,1 39,1 39,1 39,1 39,1 39,1 39,1 39,1 39,1 39,1 39,1 39,1 39,1 39,1 39,1 39,1 39,1 39,1 
 
Table 4-11: Formulations F1-F20 in mg/dose. 
mg / dose 
 Copovidone Dextran Dextrates HPMC Malto- 
dextrin 
Polyvinyl 
alcohol 
Povidone 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 F18 F19 F20 
Mannitol 686 665 686 665 651 630 686 665 651 630 686 665 686 665 686 665 686 665 651 630 
Copovidone 14 35                   
Dextran   14 35 49 70               
Dextrates       14 35 49 70           
Hypromellose           14 35         
Maltodextrine             14 35       
Polyvinyl 
alcohol 
              14 35     
Povidone                 14 35 49 70 
Water 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 
Total 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 
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IPCs are summarized in the table below (Table 4-12). 
Table 4-12: IPCs of formulations F1-F20. 
 Copovidone Dextran Dextrates HPMC Malto- 
dextrin 
Polyvinyl 
alcohol 
Povidone 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 F18 F19 F20 
H [N] 35 48 30 35 85 102 26 37 42 49 29 - 32 44 66 148 31 65 54 65 
D.T 
[s] 
10 12 12 11 11 18 12 7 3 4 29 - 12 9 13 105 5 9 10 20 
Visual 
aspect 
Do not stick 
to the 
blister. 
Smooth 
surface. 
Quick 
disintegrati
on in 
mouth. 
Bitter taste 
due to 
copovidone. 
Material 
sticks to 
the 
aluminum 
foil. Little 
bump on 
the 
surface. 
Powdery. 
Quick 
disintegra
tion in 
mouth. 
Not powdery. Do 
not stick to the 
blister. Little 
bump on the 
surface. Quick 
disintegration in 
mouth. 
Do not stick to the 
blister. Smooth 
surface. Quick 
disintegration in 
mouth. 
Do not stick 
to the blister. 
Smooth 
surface. Quick 
disintegration 
in mouth. 
F12 was too 
viscous and 
could not be 
pipetted. 
Material stays 
stuck to the 
aluminum 
foil. Smooth 
surface. Quick 
disintegration 
in mouth. 
F14 was hard 
to pipette. 
Do not stick 
to the 
blister. 
Smooth 
surface. 
Long DT for 
F16. 
Do not stick to the 
blister. Smooth 
surface. Quick 
disintegration in 
mouth. 
 
Based on the IPC results (H and D.T) and the visual aspect summarized in Table 4-12, dextran, dextrates and povidone are good binders. If an 
incompatibility can be observed between dextran and the API, dextrates or povidone both present a good alternative as binders. As copovidone 
gives a bitter taste to the tablets, it is not a suitable binder for the Lyoc® technology. The Lyocs® containing 5 % of polyvinyl alcohol disintegrated 
too slowly, which is the reason why it will not be further studied. HPMC and maltodextrin gave pipetting problems above 5 % (the resulting 
suspensions were too viscous). This could be linked to the fact that both substances also play the role of viscosity increasing agent (Rowe et al., 
2009).  
  
62 
 
4.1.3.2 Type of Mannitol 
Several types of mannitol exist, depending on its manufacturing process. Among each 
mannitol type, different grades of mannitol also exist, i.e. particle sizes with more or less fines. 
The particle size is also an important parameter to take into consideration in the ODTs 
formulation. Indeed, the larger the particle, the sandier the feeling in the mouth and the more 
unpleasant the tablet will taste. In our case, as mannitol is the main component in the 
formulation, its particle size can play also a role in sedimentation during the freezing step 
according to the Stokes’ law. The larger the particle size, the faster the sedimentation. That is 
why the mannitol type and its particle size are investigated in this section. 
4.1.3.2.1 Description of Mannitol Type 
Three kinds of mannitol are available in the Roquette® portfolio: Pearlitol® C, Pearlitol® DC 
and Pearlitol® SD (Roquette, 2016).  
Pearlitol® C refers to mannitol crystalline powder (Roquette, 2006). It is only composed of 
the β-modification of mannitol and is obtained by means of crystallization from water 
(Roquette, 2006). 4 grades are available: Pearlitol® 25 C (D50 = 25 µm), Pearlitol® 50 C (D50 
= 50 µm), Pearlitol® 110 C (D50 = 110 µm) and Pearlitol® 160 C (D50 = 160 µm) (Roquette, 
2016). The grade 110 C is a special grade manufactured for the Lyocs® production.  
Pearlitol® DC refers to mannitol used for direct compression (Roquette, 2006). It is only 
composed of the β-modification of mannitol and it is obtained through a thermal granulation 
process (Roquette, 2006). It is very condensed and is less porous than Pearlitol® C, which 
gives it a slow dissolution rate (Roquette, 2006). 3 grades are available: Pearlitol® 300 DC 
(D50 = 250 µm), Pearlitol® 400 DC (D50 = 360 µm) and Pearlitol® 500 DC (D50 = 520 µm) 
(Roquette, 2016). 
Pearlitol® SD refers to spray-dried mannitol (Roquette, 2006). It is mainly composed of the 
α-modification of mannitol (> 50%). The remaining fraction is the β-modification of mannitol 
(Roquette, 2006). 2 grades are available: Pearlitol® 100 SD (D50 = 100 µm) and Pearlitol® 
200 SD (D50 = 180 µm) (Roquette, 2016). 
In Figure 4-14, SEM images of the three types of mannitol are represented (Roquette, 2016). 
The differences previously described between the different mannitol qualities are distinctly 
observed: 
- The SEM image of Pearlitol® C shows an orthorhombic needles crystalline structure, 
- The SEM image of Pearlitol® DC shows granule particles having a porous structure, 
- The SEM image of Pearlitol® SD shows typical spray-dried particles. A porous 
structure is also visible. 
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Figure 4-14: SEM pictures of Pearlitol® C (left), Pearlitol® DC (middle) and Pearlitol® SD (right) (Roquette, 2016). 
4.1.3.2.2 Influence of Mannitol Type on IPC Results 
The aim of this study was to compare the IPC results according to the mannitol type. For this, 
the formulation of the model drug (Spasfon 80) was used to set the quantity of binder (i.e. 25 
mg/dose) and of diluent (i.e. 715 mg/dose). The quantity of water for each mannitol type 
formulation was then determined through viscosity measurements (see Figure 4-15). The 
purpose was to have similar formulations, i.e. same amount of binder, of water and of diluent, 
in order to have significant and representative IPC comparisons between the batches. The 
amount of water was thus adjusted in order to have a viscosity between 50 and 600 mPa.s (as 
explained in Chapter 4.1.3.1.1) to allow the pipetting step and to prevent suspension 
sedimentation.   
 
Figure 4-15: Viscosity measurement of suspensions of different mannitol type having different water contents (n=1). 
As shown in Figure 4-15, Spasfon 80 Lyoc® has a viscosity of 239 mPa.s.  
A manufacture problem was encountered with Pearlitol® 100 SD. The resulting suspension 
was too viscous, even with a water amount going up to 750 mg/dose (which is the maximum 
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amount of water, see Section 4.1.3), so that it was impossible to pipette this suspension and 
thus to measure its η. The Pearlitol® SD type is not usable at all for the Lyoc® technology, as 
the resulting suspension is too viscous to be pipetted. 
Pearlitol® 110 C and 160 C Lyoc® can be produced with a water amount up to 550 mg / dose, 
as their viscosities are beyond 50 mPa.s. For a water amount of 600 mg/dose, the suspensions 
of Pearlitol® 110 C and 160 C are too liquid (η < 50 mPa.s) and settle in the FD during the 
freezing step.  
Pearlitol® 400 DC suspension could only be produced from a water content of 550 mg/dose. 
For a lower water concentration, the suspension presented clusters and was thus not 
homogeneous.  
Pearlitol® 50 C suspension presented problems to be pipetted due to its lower particle size, 
corresponding to a higher impact on viscosity. Indeed, the formulation needed a water amount 
beyond 500 mg water/dose to be dispersible and to have an appropriate viscosity to be pipetted.  
Pearlitol® 25 C suspension also needed a water amount beyond 550 mg / dose. Using 
Pearlitol® 25 C with 600 mg water / dose would be better in term of viscosity, as η would be 
lower than 600 mPa.s. Nevertheless, for the other mannitol grades, water amount up to 550 
mg / dose resulted in suspensions that were too liquid and that settled in the FD. That is why 
the water amount was set up at 550 mg/dose for this test. The final formulation set for this test 
is summarized in Table 4-13. 
Table 4-13: Formulation determined for mannitol testing. 
Substance mg / dose 
Mannitol 715 
Dextran 25 
Water 550 
Total 1290 
 
4.1.3.2.3 Influence of Mannitol Type 
Lyocs® containing Pearlitol® 110 C and Pearlitol® 400 DC as diluents were produced as 
described in section 3.2 and their properties were compared. The formulations are summarized 
below, in Table 4-14. 
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Table 4-14: Formulations of Pearlitol® 110 C, 400 DC and 100 SD Lyocs® in mg/dose. 
Substance mg / dose 
 
Pearlitol® 110 C 
D50 = 110 µm 
SAP-Nr 245445 
Pearlitol® 400 DC 
D50 = 360 µm 
SAP-Nr 15534 
Batch Nr 160316 160047 
Mannitol 715 715 
Dextran 
SAP-Nr 236561 
25 25 
Water 
SAP-Nr 14022 
550 550 
Total 1290 1290 
 
IPCs are summarized in Table 4-15. 
Table 4-15: IPC results of the previous formulations ± SD. 
IPC results 
 Pearlitol® 110 C Pearlitol® 400 DC 
η [mPa.s] 78 107 
F 0,98 0,98 
Sedimentation in FD No No 
H [N] 53±8 51±17 
D.T [s] 5±1 5±3 
Results Quick disintegration in mouth, taste 
good. Good visual aspect. Do not 
break during unpacking. 
Quick disintegration in mouth, sandy 
feeling in the mouth. Lyocs® powdery 
on the surface. Do not break during 
unpacking. 
The D.T and H of both formulations were similar. The problem of the Pearlitol® DC type is 
its high mean particle size. The lowest particle size is 250 µm. Nevertheless, the sandy feeling 
in the mouth is already discernable from a particle size of 200 µm (Kimura et al., 2015). Since 
the lowest particle size of Pearlitol® DC is 250 µm, Pearlitol® DC could have been used in 
combination with Pearlitol® 100 C if it would have brought some formulation advantages. 
Nevertheless, H and D.T of the Pearlitol® DC formulation are similar to the one of the 
Pearlitol® C formulation. Moreover, the resulting Lyocs® containing Pearlitol® 400 DC have 
a powdery structure, which does not bring any advantages to use the DC mannitol type. 
Therefore only Pearlitol® C will be studied further. 
4.1.3.2.4 Influence of Mannitol Grade 
In the production, only the Pearlitol® 110 C grade is used for the manufacture of Lyocs®. In 
this section, all the 4 Pearlitol® C grades will be investigated (see Table 4-16). 
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Table 4-16: Formulations of Pearlitol® 25 C, 50 C, 110 C and 160 C Lyocs® in mg/dose. 
Substance mg / dose 
 
Pearlitol® 25 
C 
D50 = 25 µm 
SAP-Nr 129474 
Pearlitol® 50 C 
D50 = 50 µm 
SAP-Nr 261244 
Pearlitol® 110 
C 
D50 = 110 µm 
SAP-Nr 245445 
Pearlitol® 160 C 
D50 = 160 µm 
SAP-Nr 109613 
Batch Nr 160036 160037 160316 160317 
Mannitol 715 715 715 715 
Dextran 
SAP-Nr 236561 
25 25 25 25 
Water 
SAP-Nr 14022 
550 550 550 550 
Total 1290 1290 1290 1290 
 
Table 4-17: IPC results of the previous formulations. 
IPC results 
 Pearlitol® 25 C Pearlitol® 50 C Pearlitol® 110 
C 
Pearlitol® 160 
C 
η [mPa.s] 689 402 78 70 
F 1 1 0,98 0,96 
Sedimentation 
in FD 
No No No No 
H [N] 50±10 52±13 53±8 44±9 
D.T [s] 21±3 16±2 5±1 5±2 
Aspect Quick disintegration 
in mouth, taste very 
good (softer and 
cooler effect than 
Lyocs® using 
Pearlitol® 110C). 
Good visual aspect. 
Do not break during 
unpacking. 
Quick disintegration 
in mouth, taste very 
good (softer and 
cooler effect than 
Lyocs® using 
Pearlitol® 110C). 
Good visual aspect. 
Do not break during 
unpacking. 
Quick 
disintegration in 
mouth, taste good. 
Good visual 
aspect. Do not 
break during 
unpacking. 
Quick 
disintegration in 
mouth, sandy 
feeling in the 
mouth. Good 
visual aspect. Do 
not break during 
unpacking. 
According to the IPC results summarized in Table 4-17, Pearlitol® 25 C, 50 C and 110 C can 
be used for the production of Lyocs®. The advantages of both grades 25 C and 50 C is that 
they give an extra cooling effect in mouth and they present a smaller particle size, which will 
considerably reduce the risk of sedimentation during the Lyocs® manufacturing. Nevertheless, 
a higher amount of water is needed for both of those grades to avoid having a too viscous 
suspension (water amount from 450 mg/dose is usable for Pearlitol® 110 C and Pearlitol® 
160 C, as shown in Figure 4-15, vs. 550 mg of water/dose for Pearlitol® 25 C and Pearlitol® 
50 C). Indeed, for a constant mass of particles in a suspension, the smaller the particle size, 
the greater the number of particles is in the system and the more interactions between the 
particles (Fletcher and Hill). In addition, it can be noticed that the smaller the particle size, the 
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higher the disintegration time. This phenomenon could be due to the fact that those 2 grades 
create more cohesion within Lyocs® due to their small particle size. Particles may be able to 
stick really close together, giving a less porous structure to the Lyocs® unlike Pearlitol® 110 
C and Pearlitol® 160 C. Pearlitol® 160 C gave a sandy feeling in the mouth due to the larger 
particle size of this grade, which is a negative aspect for ODTs. That is why Pearlitol® 160 C 
is not recommended to be used alone. The best mannitol grade is Pearlitol® 110 C in term of 
viscosity, and Pearlitol® 25 C and 50 C have an interesting cooling effect in mouth but give 
the suspension a too high viscosity, which may cause pipetting problems. 
A mixture of mannitol grades (Pearlitol® 25 C and 160 C) could overcome both problems of 
high viscosity and sandy feeling in the mouth. Indeed, the extra cooling and smooth effect of 
Pearlitol® 25 C could bring an interesting plus in ODTs formulations. Moreover, the use of 
smaller grade could also overcome the possible API sedimentation due to its smaller particle 
size. Indeed, Pearlitol® 25 C will thicken the suspension, playing both roles of diluent and 
viscosity enhancer. That is why a further test was conducted by mixing both grades 25 C and 
160 C at different concentrations (see Table 4-18).  
Table 4-18: Formulations of Pearlitol® 25 C/160 C (1+1), 25 C/160 C (3+1) and 25 C/160 C (1+3) Lyocs® in mg/dose. 
Substance mg / dose 
 
Pearlitol® 25 C/160 C 
(3+1) 
Pearlitol® 25 C/160 C 
(1+1) 
Pearlitol® 25 C/160 C 
(1+3) 
Batch Nr 160296 160295 160297 
Pearlitol® 25 C 
SAP-Nr 129474 
476,7 357,5 238,3 
Pearlitol® 160C 
SAP-Nr 109613 
238,3 357,5 476,7 
Dextran 
SAP-Nr 236561 
25 25 25 
Water 
SAP-Nr 14022 
550 550 550 
Total 1190 1190 1190 
 
IPCs are summarized in Table 4-19. 
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Table 4-19: IPC results of the previous formulations ±SD. 
IPC results 
 
Pearlitol® 25 C/160 
C (3+1) 
Pearlitol® 25 C/160 
C (1+1) 
Pearlitol® 25 C/160 C 
(1+3) 
η [mPa.s] 331 183 143 
F 0,98 0,98 0,98 
Sedimentation in 
FD 
No No No 
H [N], n=20 56±13 39±12 70±15 
D.T [s], n=6 8±1 10±3 11±2 
Results Quick disintegration in 
mouth, taste good, not 
sandy, strong cooling 
effect in the mouth. Good 
visual aspect. Do not 
break during unpacking 
Quick disintegration in 
mouth, taste good, not 
sandy, strong cooling 
effect in the mouth. 
Good visual aspect. Do 
not break during 
unpacking 
Quick disintegration in 
mouth, taste good, not 
sandy, strong cooling 
effect in the mouth. Good 
visual aspect. Do not 
break during unpacking 
Table 4-19 clearly shows that η(1+3)< η(1+1)< η(3+1). This is coherent since the amount of 
Pearlitol® 25 C in the formulation is increasing as following: Pearlitol® 25 C amount (1+3) < 
Pearlitol® 25 C amount (1+1) < Pearlitol® 25 C amount (3+1). It could be expected that the 
more Pearlitol® 25 C, the longer D.T, and the harder the tablets, due to a higher amount of 
particles in the formulation. Nevertheless, this trend could not be observed. 
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Figure 4-16: Viscosity measurement of suspensions containing different grade of mannitol, with 550 mg water per 
Lyoc® (n=1). 
Figure 4-16 indicates the viscosity values of each Pearlitol® suspension. The combination of 
Pearlitol® 25 C/160 C gave a good viscosity profile to the suspension (143 mPa.s < η < 331 
mPa.s) and also better IPC results than the pure grades of Pearlitol® 25 C or Pearlitol® 160 
C. Indeed, the cooling effect of Pearlitol® 25 C was present in the 3 formulations presenting 
combination of 25 C and 160 C, unlike formulations using Pearlitol® 110 C or 160 C alone. 
The sandy effect of Pearlitol® 160 C disappeared in those formulations due to its reduced 
amount. D.T of combined Pearlitol® was lower of 10 seconds than the formulation containing 
Pearlitol® 25 C alone. This mixture of Pearlitol® 25 C and 160 C could then be a good 
alternative to the usual Pearlitol® 110 C used in marketed products, bringing an interesting 
cooling feeling in mouth to the ODT product. Between the three formulations composed of 
combined Pearlitol® grade, Pearlitol® 25 C/160 C (1+1) seems to be the favorite one, as its 
viscosity value is the nearest one to the one of the model drug (Spasfon 80 mg Lyoc®). 
Moreover, this formulation has the lower H, meaning that the resulting D.T in mouth should 
be the lower of the 3 formulations. 
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4.1.3.2.5 Microscopic Characteristics 
The morphology of the Lyocs® was studied through SEM. The manufactured sample Spasfon 
80mg Lyoc® collected from the production was used as model for the SEM analysis. Indeed, 
it is the earliest marketed formulation, composed of dextran, mannitol and phloroglucinol 
(API). Each sample was broken in two and three SEM-pictures were captured: a general view 
from the whole Lyoc®, a zoomed view of the upper surface of the Lyoc® and a zoomed view 
of the middle of the Lyoc®. The SEM pictures of Lyocs® were compared with one SEM 
picture of a Zydis® product found in the literature (Seager, 1998), in order to compare the two 
concurrent technologies. 
 
 
 
Figure 4-17: SEM pictures of a Zydis® matrix (x50 left, x150 right) (Seager, 1998). 
The highly porous structure of the Zydis® product shown in Figure 4-17 is due to the low 
excipients concentration, giving less dense products than with the Lyoc® technology. Vertical 
pores are visible in the Zydis® tablet, facilitating the saliva to go through the tablet.  
On the first picture of each Lyoc® sample (respectively Figure 4-18, 4-21, 4-24, 4-27, 4-30, 
4-33, 4-36, 4-39 and 4-42), their porosity structure is not so evident to be observed, unlike the 
Zydis® dosage forms. This is due to the high concentration of filler in the formulation of 
Lyocs®. Nevertheless, on the second picture of each sample (respectively Figure 4-19, 4-22, 
4-25, 4-28, 4-31, 4-34, 4-37, 4-40 and 4-43), when a finer zoom (either already visible with 
x100 in most cases or with x500) is used, the porous structure can be observed on the surface 
of the Lyocs®. Those pores allow the penetration of saliva in the whole tablet, resulting to the 
quick disintegration of the Lyoc® in the mouth. The third picture (respectively Figure 4-20, 
4-23, 4-26, 4-29, 4-32, 4-35, 4-38, 4-41 and 4-44) shows how porous the Lyocs® are. In 
general, an inhomogeneity within the tablets can be observed. This phenomenon may be due 
to the quick freezing rate during the lyophilization process. Indeed, mannitol is crystallizing 
during lyophilization. Slow freezing rates lead to large and homogenous crystals that have time 
to grow up, whereas fast freezing rates lead to an inhomogeneous structure of small ice crystals 
that have no time to be built up and to grow up (Daniels, 2014). As the freezing process for 
the Lyoc® technology is quite fast (T ramp = 0,90°C/min), mannitol crystals do not have time 
to grow up properly, giving this microscopic inhomogeneous structure. The needle crystalline 
structure of pure Pearlitol® C observed in its SEM picture (see Figure 4-14) is also 
recognizable in the Lyoc® structure. A finer structure and a better homogeneity is observed 
for Pearlitol® 25 C Lyocs® (see Figure 4-21) than Pearlitol® 50 C (see Figure 4-24), 110 C 
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(see Figure 4-27) and 160 C Lyocs® (see Figure 4-30). Nevertheless, Pearlitol® 110 C (see 
Figure 4-29) and 160 C Lyocs® (see Figure 4-32) present more space between the particles 
than Pearlitol® 25 C (see Figure 4-23) and 50 C Lyocs® (see Figure 4-26), which could 
explain the faster disintegration time of Pearlitol® 110 and 160 C Lyocs® (D.T respectively 
5 s for Pearlitol® 110 and 160 C Lyocs® vs. 21 s for Pearlitol® 25 C Lyocs® and 16 s for 50 
C Lyocs®). The space between the particles is indeed represented through the black areas 
visible between the particles. 
For Pearlitol® 400 DC Lyocs®, agglomerates can be observed on the top of Figure 4-33, 
representing the bottom of the blister cavity. This phenomenon was driven by the 
sedimentation of the large particle size of Pearlitol® 400 DC (D50 = 360 µm) during the 
freezing step.  
 
A further study was performed on the formulations containing a mixture of mannitol grades 
(25 C and 160 C). On the overall view of the Lyocs® (see Figures 4-36, 4-39 and 4-42), it can 
be observed that their structures are similar to the one of the Pearlitol® 110 C Lyocs® (see 
Figure 4-27) with additional coarse particles coming from the Pearlitol® 160 C. On the 
zoomed view of the Lyocs® (see Figures 4-38, 4-41 and 4-44), the space between the particles 
is also similar to the one of Pearlitol® 110 C Lyocs® (see Figure 4-29), which could explain 
their shorter D.T than the formulation containing pure Pearlitol® 25 C. 
   
The microscopic analysis carried out by means of SEM could thus identify the differences 
between the different mannitol types and grades used. It can be concluded that the formulations 
Pearlitol® 110 C, 25 C/160 C (1+1), 25 C/160 C (1+3), 25 C/160 C (3+1) Lyocs® are 
microscopically similar.  
In conclusion, even if Pearlitol® 110 C is widely used for the Lyocs® manufacture, a mixture 
of Pearlitol® 25 C and 160 C could be further investigated and used at larger scale, for its 
numerous benefits (such as its lower D.T, its innovative cooling taste, and its suitable 
viscosity). 
Combining both SEM and IPC results, the placebo matrix of the Pearlitol® 25/160 C (1+1) 
formulation seems to be the most appropriate since: 
- Its viscosity is high enough to avoid sedimentation of the API during freezing 
activities, 
- Its hardness is quite low, meaning that the D.T in mouth could be reduced in 
comparison to the remaining formulations.  
- Its microscopic structure is very similar to the one of Pearlitol® 110 C Lyocs®. 
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Figure 4-18: SEM picture of Spasfon Lyoc®  
(Entire structure), 14x magnification. 
 
Figure 4-19: SEM picture of Spasfon Lyoc® (Surface),  
100x magnification. 
 
Figure 4-20: SEM picture of Spasfon Lyoc® (Center),  
100x magnification. 
 
 
  
 
Figure 4-21: SEM picture of Pearlitol® 25 C Lyoc®  
(Entire structure), 14x magnification. 
 
Figure 4-22: SEM picture of Pearlitol® 25 C  
Lyoc® (Surface), 500x magnification. 
 
Figure 4-23: SEM picture of Pearlitol® 25 C  
Lyoc® (Center), 100x magnification. 
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Figure 4-24: SEM picture of Pearlitol® 50 C Lyoc®  
(Entire structure), 12x magnification. 
 
Figure 4-25: SEM picture of Pearlitol® 50 C  
Lyoc® (Surface), 100x magnification. 
 
Figure 4-26: SEM picture of Pearlitol® 50 C  
Lyoc® (Center), 100x magnification. 
 
 
  
 
Figure 4-27: SEM picture of Pearlitol® 110 C Lyoc®  
(Entire structure), 14x magnification. 
 
Figure 4-28: SEM picture of Pearlitol® 110 C  
Lyoc® (Surface), 500x magnification. 
 
Figure 4-29: SEM picture of Pearlitol® 110 C  
Lyoc® (Center), 100x magnification. 
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Figure 4-30: SEM picture of Pearlitol® 160 C Lyoc®  
(Entire structure), 12x magnification. 
 
Figure 4-31: SEM picture of Pearlitol® 160 C  
Lyoc® (Surface), 100x magnification. 
 
Figure 4-32: SEM picture of Pearlitol® 160 C  
Lyoc® (Center), 100x magnification. 
 
 
  
 
Figure 4-33: SEM picture of Pearlitol® 400 DC  
Lyoc® (Entire structure), 12x magnification. 
 
Figure 4-34: SEM picture of Pearlitol® 400 DC  
Lyoc® (Surface), 100x magnification. 
 
Figure 4-35: SEM picture of Pearlitol® 400 DC  
Lyoc® (Center), 100x magnification. 
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Figure 4-36: SEM picture of Pearlitol® 25/160 C  
(1+1) Lyoc® (Entire structure), 12x magnification. 
 
Figure 4-37: SEM picture of Pearlitol® 25/160 C  
(1+1) Lyoc® (Surface), 100x magnification. 
 
Figure 4-38: SEM picture of Pearlitol® 25/160 C  
(1+1) Lyoc® (Center), 100x magnification. 
 
 
  
 
Figure 4-39: SEM picture of Pearlitol® 25/160 C  
(1+3) Lyoc® (Entire structure), 12x magnification. 
 
Figure 4-40: SEM picture of Pearlitol® 25/160 C  
(1+3) Lyoc® (Surface), 100x magnification. 
 
Figure 4-41: SEM picture of Pearlitol® 25/160 C  
(1+3) Lyoc® (Center), 100x magnification. 
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Figure 4-42: SEM picture of Pearlitol® 25/160 C  
(3+1) Lyoc® (Entire structure), 12x magnification. 
 
Figure 4-43: SEM picture of Pearlitol® 25/160 C  
(3+1) Lyoc® (Surface), 100x magnification. 
 
Figure 4-44: SEM picture of Pearlitol® 25/160 C  
(3+1) Lyoc® (Center), 100x magnification. 
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4.1.3.2.6 Porosity of Lyocs® 
The porosity of the Lyocs® produced in the chapter 4.1.3.2.4 was measured as described in the 
Section 3.2.5.8 and calculated by means of the equation given in the U.S. patent 20100080829 
A1 (Dulieu et al., 2010), as explained in the Section 3.2.5.8: 
𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 [%] =
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 𝑝𝑒𝑟 𝐿𝑦𝑜𝑐®
𝑉𝑜𝑙𝑢𝑚𝑒 𝑝𝑖𝑝𝑒𝑡𝑡𝑒𝑑 
. 100 
Indeed, the porosity of the Lyoc® is resulting from the sublimated water, which corresponds to 
the percentage of water present in the dosage form before lyophilization. 
Table 4-20: Porosity measurements of the different Lyocs® (n=5) vs. porosity estimation. 
 Porosity measured [%] Porosity calculated [%] % error 
Spasfon 80 Lyoc® 52,1 53,5 2,7 
Pearlitol® 25 C 56,7 55,0  3,0 
Pearlitol® 50 C 53,6 55,0 2,6 
Pearlitol® 110 C 56,9 55,0 3,3 
Pearlitol® 160 C 58,9 55,0 6,6 
Pearlitol® 25/160 C (3+1) 58,8 55,0 6,5 
Pearlitol® 25/160 C (1+1) 58,4 55,0 5,8 
Pearlitol® 25/160 C (1+3) 58,6 55,0 6,1 
Table 4-20 summarizes the porosity results of the different Lyoc® formulations. The porosity 
values vary between 52 % and 59 %, compared to 80 % for the Zydis® technology (Kearney, 
2002). This huge difference is due to the structural aspect of the two different products: Zydis® 
products are composed of a low concentration of diluent, leading to a low intrinsic mechanical 
strength and a high porosity (Kearney, 2002), unlike Lyoc® products which are produced with 
a high diluent concentration.   
The % error between the measured porosity and the calculated one are lower than 5% for 
Pearlitol® 25 C Lyocs®, Pearlitol® 50 C Lyocs® and Pearlitol® 110 C Lyocs®.  
The % error of the formulations containing Pearlitol® 160 C is in fact higher than 5 %, but the 
measured porosity is still relatively close to the theoretical one. The formula used to calculate 
the porosity of Lyocs® seems thus suitable for the estimation of the product porosity once the 
formulation is determined.  
The higher measured porosity of formulations containing Pearlitol® 160 C could result to a 
lower D.T. Nevertheless, this trend could not be noticed in the D.T tests. This could be due to 
the fact that during the D.T, some Lyocs® are sticking to the disks, which hinders the Lyocs® 
to disintegrate properly.  
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4.1.4 Conclusion 
A first selection of excipients and a determination of their range of use could be set through this 
first study.  
It could be concluded that the favorite diluent regarding production efficiency and tolerance 
was mannitol. Among all the different types of mannitol available on the market (i.e. crystalline, 
spray-dried and thermal granulated), only the crystalline one is suitable to the Lyoc® 
technology, with a particle size lower than 160 µm in order to prevent a gritty sensation in 
mouth during Lyoc® administration. Mixtures of Pearlitol® C grades, and more precisely 
Pearlitol® 25 C and 160 C, could be successfully processed, bringing several advantages to the 
formulations:  
- it avoided the high viscosity problem encountered for the formulation containing Pearlitol® 
25 C alone,  
- it gave to the product an extra cooling and smooth effect due to Pearlitol® 25 C, 
- it prevented the sandy mouth feeling encountered for the formulation containing Pearlitol® 
160 C alone, 
- it gave to the resulting suspension a higher viscosity without using an extra viscosity enhancer,  
- does not require a special grade but can use two regular commercial grades. 
Regarding binders, diverse water-soluble polymers are appropriated for the Lyoc® technology, 
especially dextran, dextrates and povidone with a proportion Diluent/Binder up to 90 %/10 % 
w/w of the dried mass in lyophilized tablets. Over 10 %, the resulting lyophilized tablet will be 
too hard because of the cohesion built up by the binding agent, leading to a high disintegration 
time (Blonde, 1974). HPMC and maltodextrin can be used up to 5 % because of their viscosity 
enhancer properties (Rowe et al., 2009).  
4.2 Influence of Binder on Suspension and Lyoc® (DoE) 
DoE systems are increasingly used in pharmaceutical development, not only for formulation 
optimization, but also for process optimization, allowing development activities as cheapest as 
possible. Indeed, all responses are evaluated by varying each factor with as fewer experiments 
as possible. The goal of carrying out a DoE was to figure out if it is possible to determine an 
optimized formulation of Lyocs®. Indeed, the IPCs ranges are so broad that it might only be 
possible to find out the Design Space of a formulation without being able to optimize it. 
Moreover, the challenges present in formulation development of Lyocs® are very high, since 
Lyocs® have to be hard enough to be handled by the patient without breaking while at the same 
time the disintegration time should stay lower than 30 sec; the viscosity of the suspension has 
to be as low as possible in order to be able to be pumped while at the same time avoiding 
sedimentation. Two DoEs were performed using mannitol as diluent. In the first DoE, 
hypromellose was used as binder. Indeed, it was previously noticed that using a too high 
concentration of hypromellose could cause some pipetting problems because of the high 
viscosity of the resulting suspensions (see Section 4.1.3.1.2). The second DoE was made with 
dextran, which is used as binder in the marketed products. The JMP® Software was used to 
build up the DoEs and to analyze the resulting data. The “Custom Design” function in JMP® 
was used in order to get a tailor-made design meeting the specific requirements. 
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4.2.1 DoE Mannitol/Hypromellose 
4.2.1.1 Definition of Formulation Factors and Responses 
The three variables in the system were the concentration of Pearlitol® 110 C, hypromellose and 
water. Based on the previous pre-formulation tests (see Section 4.1.3.1.2), the ranges of the 
factors were firstly determined. The next step was to define which responses could be important 
and relevant to define and treat correctly this system. Viscosity η, degree of sedimentation F, 
hardness H and disintegration time D.T were determined as being the determining responses of 
the system. Table 4-21 summarizes the complete variables and responses of the studied system. 
Table 4-21: Definition of the factors and responses of the DoE system Mannitol / Hypromellose / Water. 
Factors 
Factors level  
Low High 
Mannitol 36 % 432 mg 61 %732 mg 
Hypromellose 0,5 %6 mg 3 %36 mg 
Water 36 %432 mg 61 %732 mg 
Responses Response Target Range 
Viscosity η [mPa.s] 50 < η < 600 mPa.s 
Degree of sedimentation F 0,85 < F < 1 
Hardness H [N] 27 < H < 80 N 
Disintegration time D.T [s] D.T < 30 s 
 
4.2.1.2 DoE Trial 
A total of 12 runs with one center point (F4) and a 2nd term interactions were generated and 
summarized on Figure 4-45 and 4-46: 
       
Figure 4-45: Ternary plot of the DoE  
Mannitol / Hypromellose / Water. 
  
Table 4-22 represents the 12 formulations of the DoE Mannitol / Hypromellose / Water in 
mg/dose. 
Figure 4-46: Zoom on Figure 4-45. 
80 
 
Table 4-22: DoE formulations. 
Substance 
mg / dose 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Batch Nr 150447 150448 150449 150450 150451 150452 150453 150454 150455 150456 150457 150458 
Mannitol 
SAP-Nr 245445 
582 454,8 470,4 591,6 723,6 732 732 723,6 432 724,8 470,4 432 
Hypromellose 
SAP-Nr 16458 
36 20,4 6 20,4 6 36 36 6 36 20,4 6 36 
Water 
SAP-Nr 14022 
582 724,8 723,6 588 470,4 432 432 470,4 732 454,8 432 660 
Total 1200 1200 1200 1200 1200 1200 1200 1200 1200 1200 908,4 1128 
 
Table 4-23: IPC results from F1-F12, ±SD. 
IPC results 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
η [mPa.s] 225 22 10 68 182 1770 1770 182 52 523 19 64 
F 0,96 0,72 0,5 0,94 0,9 1 1 0,92 0,84 0,98 0,86 0,96 
Sedimentation in 
FD 
No Yes Yes No No - - No Yes No Yes No 
H [N], n=20 43±11 22±3 10±4 38±6 10±10 - - 10±16 48±10 50±11 10±3 48±5 
D.T [s], n=6 16±8 5±6 5±3 16±5 9±2 - - 9±2 20±9 51±24 5±2 21±7 
 
120 Lyocs® were produced per batch. This is why the batch size of the dried substances was 
set up at 150g. The Lyocs® were manufactured and controlled like described in the section 3.2. 
IPCs are summarized in Table 4-23. 
 
A first approach could be performed before a statistical analysis of the data: 
- F6 and F7 were too viscous and could not be handled. It could be conclude that the ratio 
𝐻𝑦𝑝𝑟𝑜𝑚𝑒𝑙𝑙𝑜𝑠𝑒
𝑊𝑎𝑡𝑒𝑟
 has to stay below 8,3 % in order to have a suitable viscosity. Those two 
batches were excluded from the DoE as they could not give any experimental results. 
- Regarding H values, 6 mg per Lyoc® of hypromellose was defined to be too low to 
provide the Lyocs® a sufficient hardness.  
- When the amount of water is above 660 mg per Lyoc® (F2, F3 and F9), the suspension 
settles down in the freeze-dryer during the freezing step. It was noticed that when the 
suspension settles down in the freeze-dryer, the resulting Lyocs® are powdery after 
unpacking. As a consequence, the sedimentation of the suspension during the freezing 
step has to be controlled very carefully.  
- F2, F3, F9 and F11 gave powdery Lyocs® due to the sedimentation of the suspension 
in the freeze-dryer. A detailed statistical analysis need to be performed in order to define 
through which factor sedimentation occurs during the freezing step. 
- F1, F4, F5, F8, F10 and F12 had a very good visual aspect.   
4.2.1.3 Statistical Analysis  
Each response was analyzed individually in order to determine how well the statistical model 
fits the response data. The model was considered as fitted when the R² and R²Adj values were 
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near to 1. A fitted least squares model was then used to determine the effect of each factor on 
each response. Factors with t-values < 0,05 were considered as statistically significant.  
 
4.2.1.3.1 Study of the Viscosity Response 
The predicted plot of the viscosity (Figure 4-47) shows a very good fitting of the model, since 
R²=0,998.  
After analyzing the Sorted Parameter Estimates table, several statistically significant factors 
and interactions were observed for the viscosity. Hypromellose (t-value < 0,0001) and water (t-
value = 0,0005) both have a strong influence on the viscosity unlike mannitol (t-value = 0,7924). 
The Prediction Profiler plot also confirms this trend: the more hypromellose in the system, the 
more viscous the suspension is. The less water, the more viscous the suspension is. Those results 
are coherent since the higher the concentration of hypromellose in water, the more viscous the 
solution through the formation of a gel-structure. Mannitol does not seem to play an influence 
on the viscosity, as its plot in the Prediction Profiler shows a horizontal line tendency. 
Significant interactions between mannitol-water (t-value = 0,0002), mannitol-hypromellose (t-
value = 0,0022) and hypromellose-water (t-value = 0,0336) were also observed.  
The entire viscosity results meet the specifications for each factors within the ranges studied. 
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Figure 4-47: Viscosity response parameter estimates. 
 
4.2.1.3.2 Study of the F Response 
The predicted plot of F (Figure 4-48) shows a proper fitting of the model since R²=0.956. An 
adjustment of the model through JMP® was still performed (new R²=0,998).  
After analyzing the Sorted Parameter Estimates table, several statistically significant factors 
and interactions were observed for F. Hypromellose (t-value = 0,0053) and water (t-value = 
0,0067) seem to have a strong influence on F unlike mannitol (t-value = 0,5602). A significant 
interaction between hypromellose-water (t-value = 0,0143) was also observed. Quadratic 
effects of water (t-value = 0,0143) and hypromellose (t-value = 0,0225) on F were also noticed. 
These results are coherent, since hypromellose builds up a gel structure in water, decreasing the 
risks of sedimentation. These results are also obviously linked to the one of the viscosity. 
According to the Prediction Profiler, hypromellose has to stay above 0,6% and water has to stay 
below 55% in order to stay within the IPCs specifications defined in section 4.2.1.1.  
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Predicted plot of the response F before                  Predicted plot of the response F after 
 fitting the model                          fitting the model 
 
Figure 4-48: F response parameter estimates. 
 
4.2.1.3.3 Study of the Hardness Response 
The predicted plot of Hardness (Figure 4-49) shows a correct fitting of the model (R²=0.903). 
An adjustment of the model through JMP® was possible (new R²=0,898 and R²Adj improved).  
After analyzing the Sorted Parameter Estimates table, only hypromellose (t-value = 0,0004) 
seemed to be statistically significant for the hardness. On the Prediction Profiler plot, it can be 
detected that the more binder in the formulation, the harder the Lyocs®; and the less water in 
the formulation, the harder the Lyocs®. Once again, these results are coherent since the less 
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water in the formulation the less porous are the Lyocs® and the more resilient are the Lyocs®. 
According to the Prediction Profiler, hypromellose has to stay above 1% in order to have 
Lyocs® hard enough. 
                          
  Predicted plot of the response H before                    Predicted plot of the response H after 
  fitting the model                             fitting the model 
 
Figure 4-49: H response parameter estimates. 
 
4.2.1.3.4 Study of the Disintegration Time Response  
The predicted plot of disintegration time (Figure 4-50) shows a bad fitting of the model 
(R²=0.849). An adjustment of the model through JMP® was possible (new R²=0,847 and R²Adj 
improved).  
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After analyzing the Sorted Parameter Estimates table, hypromellose (t-value = 0,0058) is 
significant for the disintegration time. As it is supported in the literature, the Prediction Profiler 
plot shows that the more binder in the formulation, the slower the disintegration time. Indeed, 
the binder is bringing cohesion between the particles within the Lyocs®, reinforcing the 
structure of the Lyocs® and so, increasing the D.T. Mannitol showed to have a quadratic effect 
(t-value = 0,0214) and mannitol proportion should stay below 58 % in order to have a D.T < 30 
sec. An interaction between mannitol-hypromellose (t-value = 0,0226) was also observed. The 
problem of the technique used for the measurement of the D.T is that the Lyocs® stick 
sometimes on the disk, which may skew the results. Another quantifying method more 
appropriate for the ODTs, such as Texture Analyzer, should be used.  
 
                            
Predicted plot of the response D.T before                  Predicted plot of the response D.T after 
 fitting the model                            fitting the model 
 
Figure 4-50: D.T response parameter estimates. 
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After having analyzed the entire statistical results, the Design Space of DoE 
Mannitol/Hypromellose could be adjusted at: [36 %<Mannitol<58 %], [1 %<HPMC<3 %],  
[36 %<H2O<55 %] 
4.2.1.3.5 Optimized Formulation 
After adjusting individually the model of each response, the tool “Prediction Profiler” of JMP® 
could calculate the optimized formulation. Figure 4-51 summarizes the prediction values of 
each response for the optimized formulation, by maximizing the desirability function of each 
response.  
Table 4-24: Optimized formulation 
converted in mg/dose. 
 
Figure 4-51: Optimized formulation of the DoE Mannitol / Hypromellose / Water in %. 
Lyocs® composed with optimized formulation summarized in Table 4-24 were produced to 
check if the predicted values fitted with the experimental responses. Table 4-25 summarizes the 
IPC results of the predicted and the actual parameter values. 
Table 4-25: IPC results of the optimized formulations, and difference calculated between the experiment results and 
the predicted results (Δ) ± SD. 
 
 
 
The differences between the predicted responses and the experimental responses calculated in 
Table 4-25 are not significant since they are very low, meaning that the model fits very well.  
This DoE not only allowed to determine a Design Space of the different factors of the 
formulation (especially the min and max values of hypromellose and the maximum ratio of  
Optimized Formulation 
[mg / dose] 
Batch Nr 160027 
Mannitol 
SAP-Nr 245445 
612 
Hypromellose 
SAP-Nr 16458 
24 
Water 
SAP-Nr 14022 
564 
Total 1200 
IPC results Predicted Measured Difference Δ 
Viscosity [mPa.s], n=1 211 209 Δη = 2 mPa.s 
F, n=1 0,98 0,96 ΔF = 0,02 
Hardness [N], n=20 45 51±10 ΔH = 6 N 
D.T [s], n=6 20 25±10 Δt = 5 s 
87 
 
𝐻𝑦𝑝𝑟𝑜𝑚𝑒𝑙𝑙𝑜𝑠𝑒
𝑊𝑎𝑡𝑒𝑟
). It also allowed determining successfully its optimized formulation despite the 
broad ranges of IPCs. 
4.2.2 DoE Mannitol/Dextran 
An equivalent DoE study was performed with dextran as binder.  
4.2.2.1 Definition of Formulation Factors and Responses 
The three variables in the system were the concentration of Pearlitol® 110 C, dextran and water. 
Based on the previous pre-formulation tests (see section 4.1.3.1.2), the ranges of the factors 
were firstly set. As previously seen in the section 4.2.1.1, viscosity η, F, the hardness H and the 
disintegration time D.T were defined as responses. Table 4-26 summarizes the complete factors 
and responses of the studied system. 
Table 4-26: Definition of the factors and responses of the DoE system Mannitol / Dextran / Water. 
Factors 
Factors level [%] 
Low High 
Mannitol 40 % 480 mg 60 % 720 mg 
Dextran 1,5 % 18 mg 10 % 120 mg 
Water 30 % 360 mg 50 % 600 mg 
Responses Response Target Range 
Viscosity η [mPa.s] 50 < η < 600 mPa.s 
Degree of sedimentation F 0,85 < F < 1 
Hardness H [N] 27 < H < 80 N 
Disintegration time D.T [s] D.T < 30 s 
 
4.2.2.2 DoE Trial 
A total of 12 runs with one center point (F5) and a 2nd term interactions were generated (see 
Figure 4-52). 
 
Figure 4-52: Ternary plot of the DoE Mannitol/Dextran / Water and zoomed area. 
 
88 
 
Table 4-27 represents the 12 formulations of the DoE Mannitol / Dextran / Water in mg/dose. 
Table 4-27: DoE formulations. 
Substance mg / dose 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Batch Nr 160107 160108 160080 160109 160081 160084 160110 160082 160075 160083 160111 160085 
Mannitol 
SAP-Nr 245445 
480 720 720 539 629 493 600 720 720 720 582 619 
Dextran 
SAP-Nr 236561 
120 69 120 61 69 107 120 120 18 18 18 78 
Water 
SAP-Nr 14022 
600 411 360 600 502 600 480 360 462 462 600 503 
Total 1200 1200 1200 1200 1200 1200 1200 1200 1200 1200 1200 1200 
 
Table 4-28: IPC results from F1-F12, ±SD. 
IPC results 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
η [mPa.s] 100 1250 2130 56 248 93 594 - 94 226 27 272 
F 0,96 1 1 0,98 0,99 0,98 1 - 1 1 0,8 0,99 
Sedimentation 
in FD 
No No No No No No No - No No Yes No 
H [N], n=20, 136±52 96±14 179±27 73±30 87±20 64±19 130±27 - 45±8 70±13 38±7 120±25 
D.T [s], n=6 19±2 37±10 46±11 5±2 13±3 13±1 27±10 - 11±1 7±4 11±1 28±8 
120 Lyocs® were produced per batch. This is why the batch size of the dried substances was 
set up at 150g. The Lyocs® were manufactured and controlled like described in the section 3.2. 
IPC results are summarized in Table 4-28. 
A first approach could be performed before analyzing statistically the data: 
- The more dextran, the harder are the Lyocs® which is an advantage for the product 
handling by the patient, but the longer the disintegration time. 
-  F3 and F8 were too viscous. Lyocs® could barely be produced for F3 and could not be 
produced for F8. F8 was thus excluded from the DoE as it could not give any 
experimental results. 
- F11 gave powdery Lyocs® due to the sedimentation of the suspension during the 
freezing step. 
- F1, F2, F3, F4, F5, F6, F7, F9, F10 and F12 had a very good visual aspect.  
 
4.2.2.3 Statistical Analysis  
The same statistical analysis was carried on as in the section 4.2.1.3, i.e. a model adjustment 
before determining the optimized formulation. A fitted least squares model was then used to 
determine the effect of each factor on each response. Factors with t-values < 0,05 were 
considered as statistically significant.  
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4.2.2.3.1 Study of the Viscosity Response 
The predicted plot of the viscosity (Figure 4-53) shows a very good fitting of the model 
(R²=0,994).  
After analyzing the Sorted Parameter Estimates table, several statistically significant factors, 
quadratic effects and interactions were observed for the viscosity. Mannitol (t-value = 0,0175) 
and water (t-value = 0,0196) both have a strong influence on the viscosity unlike dextran (t-
value = 0,2514). In the DoE Mannitol/HPMC, the binder HPMC had a strong influence on the 
viscosity. In this case, dextran does not have a strong influence on the viscosity. This is 
coherent, since HPMC is a viscosity increasing agent unlike dextran. Quadratic effects of 
mannitol (t-value = 0,0177) and water (t-value = 0,0193) were also seemed to be statistically 
significant. This means that mannitol interacts with itself, such as water. Those quadratic effects 
of mannitol and water are detectable on the Prediction Profiler curves: 
Interpretation of the quadratic effect of mannitol: since the prediction profiler curve of mannitol 
is horizontal, mannitol does not have an influence on viscosity until 47.5 %. Beyond 47.5%, 
the more mannitol present in the formulation, the more viscous is the suspension.  This is 
coherent, since the viscosity is increasing with the concentration of particles in the medium. 
Significant interactions between mannitol-dextran (t-value = 0,0188) and dextran-water (t-
value = 0,0202) were also observed. 
The Prediction Profiler plot shows that an increase of mannitol in the suspension from 47.5% 
leads to an increase of the viscosity, and a decrease of water in the suspension below 48% also 
leads to an increase of the viscosity. Therefore, mannitol has to stay below 58% and water has 
to stay up to 38% in order to meet the viscosity range defined in the section 4.2.2.1. 
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Figure 4-53: Viscosity response parameter estimates.  
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4.2.2.3.2 Study of the F Response 
The predicted plot of F (Figure 4-54) shows a bad fitting of the model (R²=0.833). An 
adjustment of the model through JMP® was possible (new R²=0,890).  
After analyzing the Sorted Parameter Estimates table, mannitol (t-value < 0,0001) and water (t-
value = 0,0014) seem to have a strong influence on F unlike dextran (t-value = 0,1558). These 
results are coherent, since dextran does not play any influence on the viscosity of the 
suspension. The ratio mannitol/water plays here an important role on the viscosity and so on F. 
The more mannitol is present in the suspension the more viscous is the suspension and the less 
the suspension settles down. The less water is present in the formulation the more viscous is the 
suspension and the less the suspension settles down. This trend can also be observed on the 
Prediction Profiler plot. The results of F and of the viscosity are also linked and match perfectly 
with the theory. The entire F results met the specifications for each factor within the studied 
ranges. 
  
Predicted plot of the response F before                    Predicted plot of the response F after 
fitting the model                                       fitting the model  
 
Figure 4-54: F response parameter estimates. 
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4.2.2.3.3 Study of the Hardness Response 
The predicted plot of Hardness (Figure 4-55) shows a bad fitting of the model (R²=0.865). An 
adjustment of the model through JMP® was possible (new R²=0,851 and R²Adj improved).  
After analyzing the Sorted Parameter Estimates table, only dextran (t-value = 0,0009) and water 
(t-value = 0,0278) seemed to be statistically significant for the hardness. Once again, these 
results are coherent. The more binder in the formulation, the harder Lyocs® are. The less water 
in the formulation the less porous are the Lyocs® and the more resilient are the Lyocs®. This 
trend can also be seen on the Prediction Profiler plot. The entire hardness results meet the 
specifications for each factors within the ranges studied. 
 
  
Predicted plot of the response H before                    Predicted plot of the response H after 
 fitting the model                          fitting the model  
 
 
Figure 4-55: H response parameter estimates. 
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4.2.2.3.4 Study of the Disintegration Time Response 
The predicted plot of disintegration time (Figure 4-56) shows a bad fitting of the model 
(R²=0.892). An adjustment of the model through JMP® was possible (new R²=0,936 and R²Adj 
improved).  
After analyzing the Sorted Parameter Estimates table, any factors or interactions between 
factors seemed to be statistically significant for the disintegration time. All the t-values were 
greater than 0,05. Again, the problem of the disintegration time measurement is that the Lyocs® 
stick sometimes on the disk, which may skew the results. Another quantifying method more 
appropriate for the ODTs, such as Texture Analyzer, should be used. 
On the Prediction Profiler plot, it can be seen that the less water is present in the formulation, 
the higher the disintegration time. This again is linked to the porous structure left by the water 
in the Lyocs® after the drying step. The less water, the less porous Lyocs® are and the most 
difficult it is for the saliva to penetrate the pores and dissolve the tablet. The more binder and 
diluent, the slower the disintegration time. Nevertheless, the disintegration time stays within 
the IPC ranges for the mannitol and dextran studied ranges. Water has to be higher than 33% in 
order to give enough pores to the Lyocs® and to allow a fast disintegration.  
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Predicted plot of the response D.T before                Predicted plot of the response D.T after 
 fitting the model                          fitting the model  
 
Figure 4-56: D.T response parameter estimates. 
After having analyzed the entire statistical results, the Design Space of DoE Mannitol/Dextran 
could be adjusted at: [40 %<Mannitol<58 %], [1,5 %<Dextran<10 %], [38 %<H2O<50 %].  
4.2.2.3.5 Optimized Formulation 
After individually adjusting the model of each response, the tool “Prediction Profiler” of JMP® 
could calculate the optimized formulation. Figure 4-57 summarizes the prediction values of 
each response for the optimized formulation, by maximizing the desirability function of each 
response.  
 
 
95 
 
Table 4-29: Optimized formulation 
converted in mg/dose. 
 
Figure 4-57: Optimized formulation of the DoE Mannitol / Dextran / Water in %. 
Lyocs® composed with optimized formulation summarized in Table 4-29 were produced to 
check if the predicted values fitted with the experimental responses. Table 4-30 summarizes the 
IPC results of the predicted and the actual parameter values. 
Table 4-30: IPC results of the optimized formulations, and difference calculated between the experiment results and 
the predicted results (Δ), ±SD. 
 
 
 
The differences between the predicted responses and the experimental responses calculated in 
Table 4-30 are not significant since they are very low, which means that the model fits very 
well. A formulation optimization and a Design Space can also successfully be determined 
through DoE for the mixture Mannitol/Dextran/Water despite the broad ranges of IPCs. 
 
Optimized Formulation 
[mg/dose] 
Batch Nr 160282 
Mannitol 
SAP-Nr 245445 
720 
Dextran 
SAP-Nr 236561 
33 
Water 
SAP-Nr 14022 
447 
Total 1200 
IPC results Predicted Measured Difference Δ 
Viscosity [mPa.s], n=1 365 401 Δη = 36 mPa.s 
F, n=1 1,00 1,00 ΔF = 0 
H [N], n=20 79 85±24 ΔH = 6 N 
D.T [s], n=6 16 10±1 Δt = 6 s 
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4.3 Influence of water soluble and limited-water soluble APIs on 
Lyocs® 
A question which is raised in the literature is the maximum loading dose of water soluble API 
in freeze-dried tablets (limit of water-soluble API < 60 mg / dose (Seager, 1998)). It was indeed 
hypothesized that during the freezing or the drying step of the lyophilization process, water 
soluble API builds up an amorphous structure within the freeze-dried tablet, which can lead to 
a damage of the cake structure by collapsing (Seager, 1998). Two water soluble APIs and two 
limited-water soluble APIs were studied to check this hypothesis (see Table 4-31): 
Table 4-31: Water soluble and less-water soluble APIs studied with their respective solubility. 
API According to Ph. Eur. 
1.4 
Solubility [mg/mL] 
Metoclopramide HCl 
monohydrate 
SAP-Nr 15372 
Very soluble 67 (Selleckchem, 2013) 
Metamizol sodium 
SAP-Nr 17993  
Very soluble 500 (Caelo, 2015) 
Paracetamol 
SAP-Nr 251937   
Sparingly soluble 14 (TEVA-ratiopharm, 2010) 
Sildenafil Citrate   
SAP-Nr 115199 
Slightly soluble 3,5 (TEVA-ratiopharm, 2012) 
The problem encountered by using water-soluble API in the formulation is that from a specific 
amount of API, the Lyocs® are exploding in the freeze-dryer due to a loss of their structure. 
First of all, the limit dose of water-soluble API was figured out. The resulting Lyocs® having 
a good quality were then analyzed with X-ray powder diffraction with the method described in 
Section 3.2.5.6, to determine if the water soluble APIs build up an amorphous structure within 
Lyocs® during lyophilization.  
In this section, only the hardness and the disintegration time were measured for the IPC tests. 
The formulation of the model drug in terms of amount of excipients was used in this chapter. 
4.3.1 Study on Water-Soluble APIs 
4.3.1.1 Metoclopramide HCl Lyocs® 
The following formulations summarized in Table 4-32 were produced using metoclopramide 
HCl monohydrate as API, with a batch size of 150 g on dried substance. 
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Table 4-32: Composition of the tested formulations containing metoclopramide HCl. 
Substance mg / dose 
 Placebo F1 F2 F3 F4 F5 F6 
Batch Nr 150521 150534 150535 150488 150489 150490 150491 
Metoclopramide HCl  
SAP-Nr 15372 
0 50 100 110 120 130 140 
Mannitol 
SAP-Nr 245445 
715 665 615 605 595 585 575 
Dextran 
SAP-Nr 236561 
25 25 25 25 25 25 25 
Water 
SAP-Nr 14022 
550 550 550 550 550 550 550 
Total 1290 1290 1290 1290 1290 1290 1290 
For F1-F6, the API-water mixture was completely transparent, which means that the API was 
completely solved in water. The Metoclopramide HCl Lyocs® exploded beyond 140 mg API / 
dose. The maximal API load is thus evaluated at 18 % on the dried mass of Lyocs®. Table 4-
33 summarizes the H and D.T of the tested formulations.  
Table 4-33: IPC results of the tested formulations, ±SD. 
IPC results 
 Placebo F1 F2 F3 F4 F5 F6 
H [N], n=20 66±21 109±24 108±15 99±19 109±15 96±13 100±20 
D.T [s], n=6 15±2 4±2 7±6 5±1 3±0 4±2 5±0 
 
 
 
Figure 4-58: Hardness average with min and max values (n=20). 
No significant influence of the quantity of metoclopramide HCl in the formulation was noticed 
on the hardness of the resulting Lyocs® represented on Figure 4-58. This means that the 
Lyocs® are losing their structure from a certain amount of metoclopramide HCl within the 
Lyoc®, since a concentration beyond 140 mg of metoclopramide HCl led to a Lyoc® explosion 
during the sublimation step. The D.T of the Lyocs® is also decreasing as soon as API is present 
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in the formulation (see Table 4-33), meaning that the API is lowering the cohesion between the 
substances within the tablets, allowing the Lyocs® to disintegrate faster.  
Metoclopramide HCl 100 mg Lyoc® and the respective raw materials of its formulation were 
firstly analyzed by means of DSC in order to determine the solid state of metoclopramide HCl 
within Lyocs® after the lyophilization process. Figure 4-59 represents the crystalline structure 
of Pearlitol® 110 C through the presence of a sharp melting peak at 167,93 °C (n=3). Figure 4-
60 represents the crystalline structure of metoclopramide HCl through the presence of a sharp 
melting peak at 185,83 °C (n=3). The first 3-peak pattern (between ca. 60 °C and 115 °C) could 
be due to the loss of HCl gas or of water. A TGA analysis of metoclopramide HCl revealed that 
metoclopramide loses a half molecule of water per mol of metoclopramide (see Annex 6.2.1), 
meaning that metoclopramide HCl forms a hemihydrate after lyophilization.  
Figure 4-61 represents a superposition of the thermograms of Metoclopramide HCl 100 mg 
Lyoc® (black), mannitol (red), and metoclopramide HCl (green). The thermogram of the 
Metoclopramide HCl 100 mg Lyoc® only has a crystalline peak similar to the one of the 
mannitol pattern, with a slight shift probably due to a polymorphic change of mannitol 
transforming the β form to either α or δ after lyophilization, like already observed by Alexandre 
Kim (Kim et al., 1998). Indeed, Alexandra Kim brought to light the transformation of mannitol 
polymorphism as function of freezing rate (βα+β in the case of slow freezing and β δ for 
fast freezing). A melting peak of metoclopramide HCl is not notable on the black curve, which 
could be explained by the fact that metoclopramide HCl is getting amorphous during 
lyophilization. The solid state of metoclopramide HCl after lyophilization will be further study 
by XRPD.    
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Figure 4-59: DSC thermogram of mannitol. 
 
Figure 4-60: DSC thermogram of metoclopramide HCl. 
 
Figure 4-61: DSC thermogram of dextran (blue), mannitol (red), metoclopramide HCl (green) and Metoclopramide HCl 100 mg Lyoc® (black). 
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Metoclopramide HCl and the Lyocs® formulations (Placebo, F1, F2 and F4) were further 
analyzed through XRPD (see Figure 4-62) in order to deepen the previous DSC analysis. The 
freeze-dried tablets were carefully milled and the resulting powder was disposed on the sample 
carrier. 
 
Figure 4-62: X-ray powder diffractogram overlay of metoclopramide HCl and of the freeze-dried formulations. 
 
As shown in the figure 4-62, the diffractograms of Placebo, F1, F2 and F4 are identical 
regarding peak positions. All the reflexes from F1, F2 and F4 are thus related to the Placebo 
matrix. Due to the absence of reflexes related to metoclopramide HCl on the diffractograms F1, 
F2 and F4, metoclopramide HCl could be postulated to get amorphous through the 
lyophilization process.  
The Figure 4-63 shows the Raman spectra of each pure substance measured with the conditions 
described in the Section 3.2.5.7. Since the Raman spectra of each compound are very different 
from each other (see Figure 4-63), the API distribution within the Lyocs® should be easily 
detectable. 
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Figure 4-63: Raman spectra of mannitol (red), dextran (blue) and metoclopramide HCl (green). 
A horizontal and a vertical scan were conducted and the characteristic peaks of each substance 
were then registered in order to ascribe a color to each substance and to allow a color mapping 
representation of the Lyoc® surface. This analysis can thus detect at which position the 
substances can be localized. With this Raman analysis, it is also possible to determine if the 
substances solidify separately or together, by further studying the obtained mapping picture and 
the resulting Raman spectra. 
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Microscopic image of 
Metoclopramide HCl Lyoc®.  
The red square indicates the XY 
area where the scan was 
measured. 
 
Mapping image of the 
XY scan. 
Red: Mannitol. 
Green: Metoclopramide 
HCl. 
 
Mapping image of the XY 
scan. 
Red: Mannitol. 
Green: Metoclopramide 
HCl. 
 
Extract of Metoclopramide HCl 
spectrum. 
Green: API pure. 
Black: API in Lyoc®. 
  
Figure 4-64: Light microscopy picture, Raman mapping and spectra of Metoclopramide HCl Lyoc® in a large scan 
area, plane XY. 
Mannitol 
 
Dextran 
 
Metoclopramide HCl 
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Figure 4-64 represents the Raman mapping of a 500x500 µm area. The colored pictures were 
calculated with the spectra of mannitol and metoclopramide HCl. As dextran is present in a too 
low concentration in the Lyoc® formulation (i.e. 3,4 %) and due to its low Raman activity, it 
was not detectable. On the first mapping, the API is on the top, whereas on the second mapping, 
mannitol lies on the top. With those two mappings, it is thus possible to determine the areas 
where the API and mannitol solidified alone or in a close contact during the lyophilization 
process. The black areas present on the mapping is represented the porous structure of the 
Lyoc®. 
By scanning a position where the API is present in the Lyoc® and by comparing the resulting 
spectrum with the spectrum of pure API, a peak broadening could be observed in the spectrum 
extracted from the Lyoc® at ca. 1600 cm-1(see “Extract of Metoclopramide HCl spectrum” in 
Figure 4-64). The full width at half maximum was determined at 12 cm-1 for the API pure and 
19 cm-1 for the API in Lyoc®. This kind of phenomenon is a typical case of amorphization of 
the substance. This observation matches perfectly the results obtained with XRPD. Any peak 
broadening was detected for mannitol, meaning that mannitol is present in a crystalline state, 
disproving the statement that the API could exist in a solid solution state. Indeed, if this was the 
case, mannitol would also be present in an amorphous state.  
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Microscopic image of 
Metoclopramide HCl Lyoc®in 
the XY plane.  
The orange square indicates the 
XY area where the zoomed scan 
was measured. 
 
 
Mapping image of the 
XY scan. 
Red: Mannitol. 
Green: Metoclopramide 
HCl. 
The crosses indicate the 
position where the below 
spectra were extracted. 
 
 
Mapping image of the XY 
scan. 
Red: Mannitol. 
Green: Metoclopramide 
HCl. 
 
 
Extract of the XY mapping 
image. 
 
Pink: Position where 
mannitol and API were 
both detected. 
 
Blue: Position where only 
mannitol was detected. 
. 
Figure 4-65: Light microscopy picture, Raman mapping and spectra of Metoclopramide HCl Lyoc® in a zoomed scan 
area, plane XY. 
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Figure 4-65 shows the Raman mapping of a 100x100 µm area. Mapping images were again 
constructed, with API on the top for the first colored picture and mannitol on the top for the 
second picture. Those two mappings show that the API is only solidifying in a close contact 
with mannitol, whereas mannitol is also able to solidify alone. This hypothesis was proved by 
extracting two different spectra: one where API and mannitol are both present on the same 
position and another one were only mannitol was detected. For the pink pattern, both spectra of 
mannitol and metoclopramide HCl are visible, whereas the blue one only shows the intact 
spectrum of pure mannitol. This could be supported by two explanations:  
- Mannitol and metoclopramide HCl are either solidifying together, forming a mixed 
crystal, 
- or metoclopramide HCl is solidifying on or underneath mannitol, in a very close 
position.  
Depth profiling has to be performed in order to answer this question. 
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Microscopic image of 
Metoclopramide HCl Lyoc®.  
The orange square indicates the 
XY area where the zoomed scan 
was measured. The white line 
indicates the position of the XZ 
scan. The blue line indicates the 
position of the YZ scan. 
 
Mapping image of the 
XY scan 
Red: Mannitol 
Green: Metoclopramide 
HCl 
 
Mapping image of the XY 
scan 
Red: Mannitol 
Green: Metoclopramide 
HCl 
 
 
Mapping image of the XZ 
scan 
Red: Mannitol 
Green: Metoclopramide 
HCl 
 
Mapping image of the XZ 
scan 
Red: Mannitol 
Green: Metoclopramide 
HCl 
 
Extract of the YZ mapping 
image where mannitol and the 
API are both detectable on the 
same position. 
Green: API pure. 
Blue: Mannitol pure. 
Red: Spectrum of the position 
where mannitol and API are both 
detectable.  
 
Mapping image of the YZ 
scan 
Red: Mannitol 
Green: Metoclopramide 
HCl 
 
Mapping image of the YZ 
scan 
Red: Mannitol 
Green: Metoclopramide 
HCl 
Figure 4-66: Light microscopy picture, Raman mapping and spectra of Metoclopramide HCl Lyoc® in a depth profile 
area, planes XZ and YZ. 
Figure 4-66 is representing Raman mapping of depth profiles on the XY and YZ sections 
(50x25 µm area). Mapping images were again constructed, with API on the top for the first 
colored picture and mannitol on the top for the second picture. It could be clearly observed on 
both sections that the API is solidifying very close to mannitol. After extracting a spectrum on 
the YZ plan, where both mannitol and the API are detectable, the characteristic peak of 
metoclopramide HCl was shifted from ca. 1328 cm-1 for the pure API to 1320 cm-1 for the 
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lyophilized API. This shift could be explained by an existing interaction between the API and 
mannitol, which means that both substances are possibly interacting.  
According to the Raman results, it could be stated from the large scan area that metoclopramide 
HCl is getting amorphous during the lyophilization process, detectable through the broadening 
of the pattern peak of metoclopramide HCl at ca. 1600 cm-1. Moreover, the zoomed scan area 
could show that metoclopramide HCl may solidify really close to mannitol and that an 
interaction between mannitol and the API may exist.   
4.3.1.2 Metamizol Sodium Lyocs® 
The following formulations summarized in Table 4-34 were produced using metamizol Na as 
API, with a batch size of 150 g on dried substance. 
Table 4-34: Composition of the tested formulations containing metamizol sodium. 
Substance mg / dose 
 Placebo F1 F2 F3 F4 
Batch Nr 150521 150475 150476 150485 150486 
Metamizol sodium 
SAP-Nr 17993  
0 50 100 110 120 
Mannitol 
SAP-Nr 245445 
715 665 615 605 695 
Dextran 
SAP-Nr 236561 
25 25 25 25 25 
Water 
SAP-Nr 14022 
550 550 550 550 550 
Total 1290 1290 1290 1290 1290 
 
For F1-F4, the API-water mixture was completely transparent, meaning that the Metamizol Na 
was completely solved in water. The Metamizol Na Lyocs® exploded beyond 120 mg API. The 
maximal API load is thus evaluated at 15 % on the dried mass of Lyocs®. 
Table 4-35: IPC results of the tested formulations, ±SD. 
IPC results 
 Placebo F1 F2 F3 F4 
H [N], n=20 66±21 83±20 85±15 85±14 78±13 
D.T [s], n=6 15±2 14±3 11±5 8±4 5±5 
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Figure 4-67: Hardness average with min and max values (n=20). 
No significant influence of the quantity of metamizol Na in the formulation on the hardness of 
the resulting Lyocs® was noticed (see Figure 4-67). This means that the Lyocs® are losing 
their structure from a certain amount of metamizol Na (beyond 120 mg) within the Lyoc®, 
causing an explosion of the Lyoc® during the sublimation step. In the case of metamizol Na, 
the D.T is not suddenly decreasing (see Table 4-35), but it decreases step by step with increasing 
API in the formulation. This could mean that metamizol Na has more cohesion between the 
substances, maybe due to a partial amorphization of the API, unlike metoclopramide HCl where 
the amorphization was evaluated as fully.  
Metamizol Na 100 mg Lyoc® and the respective raw materials of its formulation were firstly 
analyzed by means of DSC in order to evaluate the solid state of metamizol Na after 
lyophilization. Figure 4-68 represents the crystalline structure of Pearlitol® 110 C through the 
presence of a sharp melting peak at 167,93 °C (n=3). Figure 4-69 shows a sharp endothermic-
exothermic peak 230 °C and 255 °C (n=3), which correspond to the deterioration of metamizol 
Na, probably by an oxidation-reduction reaction (Euro-OTC-Pharma, 2017; Fernandes et al., 
1999). The first bright peak (between ca. 90 °C and 155 °C) could be due to the loss of water, 
as the metamizol Na is used as the monohydrate. This theory was confirmed by a TGA analysis 
(see Annex 6.2.2) where the loss of weight of water was determined. Figure 4-70 represents a 
superposition of the thermograms of Metamizol Na 100 mg Lyoc® (black), mannitol (red), and 
metamizol Na (green). The thermogram of the Lyoc® shows a loss of water (first bright peak 
at ca. 135 °C), followed by a melting peak. This melting peak could represent a change in 
mannitol polymorphism after lyophilization (Kim et al., 1998) as already explained in 4.3.1.1. 
Moreover, the lack of the melting peak of metamizol Na on the thermogram of the Lyoc® could 
be due to the entire amorphization of the substance during lyophilization. Both of those theories 
will be further investigated by means of a XRPD study.  
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Figure 4-68: DSC thermogram of mannitol. 
 
Figure 4-69: DSC thermogram of metamizol Na. 
 
Figure 4-70: DSC thermogram of dextran (blue), mannitol (red), metamizol Na (green) and Metamizol Na 100 mg Lyoc® (black). 
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Metamizol Na and the Lyocs® formulations (placebo, F1, F2 and F4) were analyzed through 
XRPD (see Figure 4-71). The freeze-dried tablets were carefully milled and the resulting 
powder was disposed on the sample carrier. 
 
Figure 4-71: X-ray powder diffractogram overlay of metamizol sodium and of the freeze-dried formulations. 
As shown in Figure 4-71, the diffractograms of Placebo, F1 and F2 are identical regarding the 
peak positions. F1 and F2 do not have any characteristic reflexes of metamizol Na. F4 shows 
two additional peaks (at 3,4 and 15,7°2-Theta) which are not related to the ones of the placebo 
pattern. Those both additional peaks (at 3,4 and 15,7°2-Theta) are corresponding to the 
characteristic reflexes of metamizol Na. The API could be thus postulated to be partly 
amorphous. Indeed, the crystalline part present in F1 and F2 could be under the detection limit, 
which could explain the absence of the characteristic reflexes of metamizol sodium in F1 and 
F2.  
Figure 4-72 shows the Raman spectra of each pure substance measured with the conditions 
described in the Section 3.2.5.7. Since the Raman spectra of each compound are very different 
from each other (see Figure 4-72), the API distribution within the Lyocs® should be easily 
detectable.  
 
Figure 4-72: Raman spectra of mannitol, dextran and metamizol Na. 
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Dextran 
 
Metamizol Na 
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The same substances mapping analysis was performed as the one for Metoclopramide HCl 
Lyocs® through Raman microscopy. A horizontal and a vertical scan were conducted and the 
characteristic peaks of each substance were then registered and filtered in order to build up a 
color mapping representation of the Lyoc® surface. This analysis will thus determine at which 
position the substances can be observed and determine if the substances solidify alone or 
together, by further studying the obtained mapping picture. 
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Microscopic image of 
Matamizol Na Lyoc®.  
The red square indicates the 
XY area where the scan was 
measured. 
 
 
Mapping image of the 
XY scan. 
Red: Mannitol. 
Green: Metamizol Na. 
 
 
Mapping image of the XY 
scan. 
Red: Mannitol. 
Green: Metamizol Na. 
 
Metamizol Na Lyoc® spectra 
extracted at different positions 
(red scan and green scan). 
A difference in one of the API 
characteristic pattern can be 
observed (underlined in blue). 
 
Metamizol Na spectrum. 
The two crosses 
correspond to the 
extracted spectrum. 
 
The pattern difference can 
also be observed in the 
API pure. This can be due 
to a different 
polymorphism of the API 
or a different crystal 
position. 
Figure 4-73: Light microscopy picture, Raman mapping and spectra of metamizol Na Lyoc® in a large scan area, plane 
XY. 
Figure 4-73 represents the Raman mapping of a 500x500 µm area. The colored pictures were 
calculated with the spectra of mannitol and metamizol Na. As dextran is present in a too low 
concentration (3,4 %) and was actively low by Raman microscopy, it was not detectable. On 
the first mapping, the API lies on the top, whereas on the second mapping, mannitol lies on the 
top. With those two mappings, it is thus possible to determine the areas where the API and 
mannitol solidified alone or in a close contact during the lyophilization process. The black areas 
present on the mapping is represented the porous structure of the Lyoc®. 
By scanning a position where the API is present in the Lyoc®, any peak broadening could be 
observed, meaning that the API is also present in a crystalline state. The amorphous state could 
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not be detected by Raman, maybe because its pattern is too inactive in comparison to the 
crystalline one. Another phenomenon could nevertheless be observed: the pattern of lyophilized 
metamizol Na showed a different peak intensity on the triplet peak at ca. 1600 cm-1. After 
analyzing different positions of pure metamizol Na, this phenomenon could be also observed. 
The change of intensity within the peaks is not related to amorphization of metamizol Na during 
lyophilization, but is due to the orientation of the crystals within the sample. It could be 
concluded that for a same crystal having a different orientation, a different peak intensity is 
delivered.    
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Microscopic image of 
Metamizol Na Lyoc®in the 
XY plane.  
The orange square indicates 
the XY area where the 
zoomed scan was measured. 
 
Mapping image of the XY 
scan. 
Red: Mannitol. 
Green: Metamizol Na. 
 
 
 
Mapping image of the XY 
scan. 
Red: Mannitol. 
Green: Metamizol Na. 
Figure 4-74: Light microscopy picture and Raman mapping of Metamizol Na Lyoc® in a zoomed scan area, plane XY. 
 
The Figure 4-74 shows the Raman mapping of a 100x100 µm area. Mapping images were again 
constructed, with API on the top for the first colored picture and mannitol on the top for the 
second picture. Those two mappings show that the API is only solidifying in a close contact 
with mannitol, whereas mannitol is also able to solidify alone.   
- Mannitol and metamizol Na are either solidifying together, forming a mixed crystal, 
- or metamizol Na is solidifying on or underneath mannitol.  
Depth profiles were performed in order to answer this question. 
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Microscopic image of Metamizol 
Na Lyoc®.  
The orange square indicates the 
XY area where the zoomed scan 
was measured. The blue line 
indicates the position of the XZ 
scan. 
 
 
Mapping image of the XY 
scan. 
Red: Mannitol. 
Green: Metamizol Na. 
 
 
Mapping image of the XY 
scan. 
Red: Mannitol. 
Green: Metamizol Na. 
 
 
 
Mapping image of the XZ 
scan. 
Red: Mannitol. 
Green: Metamizol Na. 
 
 
Mapping image of the XZ 
scan. 
Red: Mannitol. 
Green: Metamizol Na. 
Figure 4-75: Light microscopy picture and Raman mapping of Metamizol Na Lyoc® in a depth profile area, plane XZ. 
Figure 4-75 is showing Raman mapping of depth profiles on the XY and YZ sections (50x25 
µm area). Mapping images were again constructed, with API on the top for the first colored 
picture and mannitol on the top for the second picture. It could be clearly observed on both 
sections that the API and mannitol are both solidifying alone.  
According to the Raman results, it could be stated that metamizol Na is also present in 
crystalline state after lyophilization, and that it solidifies separately from mannitol.  
The observation of crystalline API in the sample supports once again the results obtained by 
XRPD. Indeed, crystalline metamizol Na was also detectable at low intensity, meaning that the 
API is partly amorphous and crystalline. However, the amount of crystallized metamizole Na 
could not be exactly quantified in this complex mixture. 
4.3.2 Study on Less-Water Soluble APIs 
4.3.2.1 Paracetamol Lyocs® 
The following formulations summarized in Table 4-36 were produced using paracetamol as 
API, with a batch size of 150 g on dried substance. 
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Table 4-36: Composition of the tested formulations containing paracetamol. 
Substance mg / dose 
 Placebo F1 F2 F3 
Batch Nr 150521 160065 160066 160067 
Paracetamol 0 50 100 150 
Mannitol 715 665 615 565 
Dextran 25 25 25 25 
Water 550 550 550 550 
Total 1290 1290 1290 1290 
The 3 formulations gave Lyocs® of good quality (see IPC results in Table 4-37). It can be 
notice that the D.T stays quite constant for Placebo such as F1, F2, F3 (15 s < D.T < 17 s), 
showing that paracetamol does not play affect the Lyoc® morphology. 
Table 4-37: IPC results of the tested formulations, ±SD. 
IPC results 
 Placebo F1 F2 F3 
H [N], n=20 66±21 66±20 44±6 57±7 
D.T [s], n=6 15±2 15±2 17±2 16±2 
 
Paracetamol 100 mg Lyoc® and the raw materials contained in its formulation were firstly 
analyzed by means of DSC in order to determine the solid state of paracetamol after 
lyophilization. Figure 4-76 represents the crystalline structure of Pearlitol® 110 C through the 
presence of a sharp melting peak at 167,93 °C (n=3). Figure 4-77 represents the crystalline 
structure of paracetamol through the presence of a sharp melting peak at 171,04 °C (n=3). 
Figure 4-78 represents a superposition of the thermograms of Paracetamol 100 mg Lyoc® 
(black), mannitol (red), and paracetamol (green). The thermogram of the Lyoc® shows a single 
melting peak at 163,15 °C (n=3). This melting peak is shifted, as it corresponds neither to the 
one of mannitol nor paracetamol. This peak shift can be explained through two hypotheses: 
- either paracetamol is getting amorphous and mannitol polymorphism is changing after 
lyophilization, 
- or paracetamol is interacted with mannitol during lyophilization.  
These theories were further investigated by means of a XRPD measurement.  
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Figure 4-76: DSC thermogram of mannitol. 
 
Figure 4-77: DSC thermogram of paracetamol. 
  
Figure 4-78: DSC thermogram of dextran (blue), mannitol (red), paracetamol (green) and Paracetamol 100 mg Lyoc® (black). 
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Paracetamol and the formulations Placebo, F1, F2 and F3 were analyzed through XRPD (see 
Figure 4-79). The freeze-dried tablets were carefully milled and the resulting powder was 
disposed on the sample carrier. 
 
Figure 4-79: X-ray powder diffractogram overlay of paracetamol and of the freeze-dried formulations. 
As shown on Figure 4-79, F1, F2 and F3 have identical diffractograms regarding to the peak 
positions. They present characteristic reflexes of paracetamol. Moreover, the increasing peak 
intensity of the characteristic reflexes of pure crystalline paracetamol (at 12 and 15,5°2-Theta 
for instance) from F1 to F3 reinforce the fact that paracetamol stays in a crystalline state after 
lyophilization. Indeed, the fact that the peak intensity increases from F1 to F3 proves that the 
proportion of crystalline paracetamol after lyophilization increases with its concentration.  
4.3.2.2 Sildenafil Citrate Lyocs® 
The following formulations summarized in Table 4-38 were produced using sildenafil citrate 
as API, with a batch size of 150 g on dried substance. 
Table 4-38: Composition of the tested formulations containing sildenafil citrate. 
Substance mg / dose 
 Placebo F1 F2 F3 
Batch Nr 150521 150372 150373 150374 
Sildenafil Citrate   
SAP-Nr 115199 
0 50 100 150 
Mannitol 
SAP-Nr 245445 
715 665 615 565 
Dextran 
SAP-Nr 236561 
25 25 25 25 
Water 
SAP-Nr 14022 
550 550 550 550 
Total 1290 1290 1290 1290 
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Table 4-39: IPC results of the tested formulations ±SD. 
IPC results 
 Placebo F1 F2 F3 
H [N], n=20 66±21 65±11 61±8 62±8 
D.T [s], n=6 15±2 15±4 16±2 15±2 
 
The 3 formulations gave good Lyocs® quality (see IPC results in Table 4-39). The D.T of the 
placebo and the formulations containing API are similar, such as the H, meaning that the API 
does not have an influence on the Lyoc® quality/morphology. This could be due to the fact that 
the API may build up a crystalline structure, reinforcing the Lyoc® network in comparison to 
the Lyocs® of Section 4.3.1 containing water-soluble APIs.  
Sildenafil Citrate 100 mg Lyoc® and the respective raw materials of its formulation were firstly 
analyzed by means of DSC in order to check the solid state of sildenafil citrate after 
lyophilization. Figure 4-80 represents the crystalline structure of Pearlitol® 110 C through the 
presence of a sharp melting peak at 167,93 °C (n=3). Figure 4-81 shows a 3-peak pattern of 
sildenafil citrate between 190 °C and 220 °C (n=3), where the first peak represents the 
crystalline structure of sildenafil citrate, followed by its decomposition. Figure 4-82 represents 
a superposition of the thermograms of Sildenafil Citrate 100 mg Lyoc® (black), mannitol (red), 
and sildenafil citrate (green). The thermogram of the Lyoc® shows a double melting peak of 
mannitol, meaning that mannitol presents other polymorphs after lyophilization. The attenuated 
3-peak pattern of sildenafil citrate (due to the high concentration of mannitol in the formulation) 
is also present on the thermogram of the Lyoc® meaning that sildenafil stays crystalline after 
lyophilization. A double pic is observable at 168 °C (i.e the melting peak of mannitol), meaning 
that several polymorphic forms of mannitol are present in the Lyoc®, probably α and β (Kim 
et al., 1998) due to the slow freezing rate like explained in paragraph 4.3.1.1. 
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Figure 4-80: DSC thermogram of mannitol. 
 
Figure 4-81: DSC thermogram of sildenafil citrate. 
 
Figure 4-82: DSC thermogram of dextran (blue), mannitol (red), sildenafil citrate (green) and Sildenafil Citrate 100 mg Lyoc® (black). 
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Sildenafil citrate and the formulations Placebo, F1, F2 and F3 were analyzed through XRPD 
(see Figure 4-83). The freeze-dried tablets were carefully milled and the resulting powder was 
disposed on the sample carrier. 
 
Figure 4-83: X-ray powder diffractogram overlay of sildenafil citrate and of the freeze-dried formulations. 
As shown on Figure 4-83, F1, F2 and F3 have identical diffractograms regarding to the peak 
positions. They present characteristic reflexes of sildenafil citrate. Moreover, some 
concentration related differences could be detected in F1, F2 and F3 regarding the intensity of 
the characteristic reflexes of sildenafil citrate (at 7 and 14,5°2-Theta for instance). These signals 
are the proof of the presence of crystalline sildenafil citrate in those samples, meaning that 
sildenafil citrate stays in a crystalline state after lyophilization.  
4.3.3 Microscopic Characteristics 
The Lyocs® of both categories of API (i.e. water soluble and less-water soluble) were 
microscopically observed by means of SEM.   
Cracks could be observed on the surface of the Lyocs® (see respectively Figure 4-84, 4-87, 4-
90 and 4-93), which improve the penetration of saliva within the Lyocs®. Regarding the general 
morphology of the Lyocs®, a significant difference could be observed between water-soluble 
(see Figures 4-89 and 4-92) and less-water soluble APIs (see Figures 4-83 and 4-86). For 
Paracetamol 100 mg Lyoc® and Sildenafil 100 mg Lyocs® (i.e. less-water soluble APIs), a 
crystalline structure can be observed, unlike for Metamizol Na 100 mg Lyoc® and 
Metoclopramide HCl 100 mg Lyoc® (i.e. water soluble APIs), where the structure is more 
amorphous (the crystalline structure of mannitol is barely recognizable on Figures 4-91 and 4-
94). A sharp and arranged structure is observable in the case of Paracetamol 100 mg Lyoc® 
and Sildenafil 100 mg Lyocs® (limited-water soluble APIs), which is comparable to a 
crystalline structure. Whereas the structure of Metamizol Na 100 mg Lyoc® and 
Metoclopramide HCl 100 mg Lyoc® present more air between the particles (see the black areas 
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in Figures 4-89 and 4-92) with amorphous/melted particles. This larger pore structure may be 
responsible of the quicker D.T of Metamizol Na 100 mg Lyoc® (11 s) and Metoclopramide 
HCl 100 mg Lyoc® (7 s) in comparison to Paracetamol 100 mg Lyoc® (17 s) and Sildenafil 
100 mg Lyocs® (16 s), by allowing a higher penetration rate of saliva within the Lyocs®.  
These microscopic results are confirmed by the XRPD measurements, where the less-water 
soluble APIs remained crystalline after lyophilization unlike the water-soluble APIs which 
turned into an amorphous state. 
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Figure 4-84: SEM picture of Paracetamol 100 mg Lyoc® 
(Entire structure), 14x magnification. 
 
Figure 4-85: SEM picture of Paracetamol 100 mg Lyoc® 
(Surface), 500x magnification. 
 
Figure 4-86: SEM picture of Paracetamol 100 mg Lyoc® 
(Center), 100x magnification. 
 
 
  
 
Figure 4-87: SEM picture of Sildenafil 100 mg Lyoc® 
(Entire structure), 12x magnification. 
 
Figure 4-88: SEM picture of Sildenafil 100 mg Lyoc® 
(Surface), 100x magnification. 
 
Figure 4-89: SEM picture of Sildenafil 100 mg Lyoc® 
(Center), 100x magnification. 
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Figure 4-90: SEM picture of Metoclopramide HCl 100 mg 
Lyoc® (Entire structure), 12x magnification. 
 
Figure 4-91: SEM picture of Metoclopramide HCl 100 mg 
Lyoc® (Surface), 100x magnification. 
 
Figure 4-92: SEM picture of Metoclopramide HCl 100 mg 
Lyoc® (Center), 100x magnification. 
 
 
  
 
Figure 4-93: SEM picture of Metamizol Na 100 mg Lyoc® 
(Entire structure), 14x magnification. 
 
Figure 4-94: SEM picture of Metamizol Na 100 mg Lyoc® 
(Surface), 100x magnification. 
 
Figure 4-95: SEM picture of Metamizol Na 100 mg Lyoc® 
(Center), 100x magnification. 
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4.3.4 Conclusion 
The solubility characteristics of APIs used within Lyocs® was further investigated. In the 
frame of this study, two crystalline soluble APIs (metoclopramide HCl monohydrate and 
metamizol Na) and two crystalline less-soluble APIs (paracetamol and sildenafil citrate) were 
used in order to identify their solid state after lyophilization.  
For Lyocs® containing soluble APIs, XRPD and Raman mapping were conducted on the 
resulting Lyocs®, allowing the determination of the API solid state. Regarding the soluble 
APIs, they both get partially or completely amorphous during the lyophilization process. Due 
to this API amorphization, the cohesion within the Lyocs® was reduced, leading to an 
explosion of Lyocs® in the FD during the lyophilization. The loading limit of soluble API was 
estimated at 16 % of the total dried mass of the Lyoc®, meaning that above this percentage, 
no Lyocs® can be produced.  
Regarding the less-soluble APIs, XRPD study was the best method to prove that both APIs 
stay crystalline after lyophilization, giving elegance to the Lyoc® structure.  
4.4 Case Study: Development of Paracetamol 100 mg Lyocs® 
The development of Paracetamol 100 mg Lyocs® formulation was investigated in this chapter. 
Paracetamol was selected for this formulation development study, since it is sparingly soluble 
in water, which matches perfectly the class of API used in the Lyoc® technology (see Section 
4.3). Moreover, two doses of Paracetamol Lyocs® already exist on the market, namely 250 
mg and 500 mg doses. Both marketed formulations contain Pearlitol® 110 C and dextran as 
excipients. That is why any compatibility study between paracetamol and the two previously 
named excipients needed to be performed to ensure the stability of the API in the formulation. 
The influence of mannitol grade on the IPC results, on the API release and on the API 
sedimentation during lyophilization was especially studied. In the second step, the 
lyophilization process was optimized with respect to process time in order to reduce the energy 
costs of the company. For this purpose, the critical quality attribute was defined to be the final 
moisture content of the final product. 
4.4.1 Influence of Mannitol Grade 
4.4.1.1 Tested Formulations  
The placebo formulations of the Chapter 4.1.3.2.4 were used as a basis for the Paracetamol 
Lyoc® formulation. The quantity of paracetamol (i.e. 100 mg) replaced the corresponding 
quantity of mannitol. Paracetamol Lyocs® with Pearlitol® 160 C were not manufactured due 
to the gritty feeling in mouth observed in Section 4.1.3.2.4. The formulations are summarized 
below, in Table 4-40.  
 
F1: Paracetamol 100 mg Lyocs® with Pearlitol® 25 C. 
F2: Paracetamol 100 mg Lyocs® with Pearlitol® 50 C. 
F3: Paracetamol 100 mg Lyocs® with Pearlitol® 110 C. 
F4: Paracetamol 100 mg Lyocs® with a mixture of Pearlitol® 25 C and 160 C (1+1). 
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F5: Paracetamol 100 mg Lyocs® with a mixture of Pearlitol® 25 C and 160 C (3+1). 
F6: Paracetamol 100 mg Lyocs® with a mixture of Pearlitol® 25 C and 160 C (1+3). 
 
Table 4-40: Composition of the formulations tested. 
Substance mg / dose 
 
F1 F2 F3 F4 F5 F6 
Batch Nr 160284 160285 160283 160289 160290 160291 
Paracetamol 
SAP-Nr 251937 
100 100 100 100 100 100 
Mannitol 615 615 615 - - - 
Pearlitol® 
25 C 
- - - 307,5 410 205 
Pearlitol® 
160 C 
- - - 307,5 205 410 
Dextran 
SAP-Nr 236561 
25 25 25 25 25 25 
Water 
SAP-Nr 14022 
550 550 550 550 550 550 
Total 1290 1290 1290 1290 1290 1290 
 
IPCs are summarized in Table 4-41. 
Table 4-41: IPC results of the formulations F1-F6 ± SD. 
IPC results 
 F1 F2 F3 F4 F5 F6 
η [mPa.s] 221 152 83 158 154 93 
F 0,98 0,98 0,98 0,98 1 1 
Sedimentation 
in FD 
No No No No No No  
H [N], n=20 54±17 53±11 48±8 42±12 39±11 50±10 
D.T [s], n=6 18±4 8±2 5±1 9±3 11±2 8±2 
Appearance Good visual 
aspect. Do 
not break 
during 
unpacking. 
Not powdery 
Good visual 
aspect. Do 
not break 
during 
unpacking. 
Not 
powdery. 
Good visual 
aspect. Do 
not break 
during 
unpacking. 
Not 
powdery. 
Good 
visual 
aspect. Do 
not break 
during 
unpacking. 
Not 
powdery 
Good 
visual 
aspect. Do 
not break 
during 
unpacking. 
Not 
powdery. 
Good visual 
aspect. Do not 
break during 
unpacking. Not 
powdery. 
 
The IPCs obtained for each batch are very concluding (Table 4-41). As expected, D.T increases 
in the following order: F3 < F2 < F1. This is due to the particle size of mannitol (the smaller 
the particle size, the higher the cohesion within the Lyocs®). The same trend could be 
observed for the D.T of the formulations containing a mixture of Pearlitol® 25 C and 
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Pearlitol® 160 C. Indeed, D.T (F6) < D.T (F4) < D.T (F5). This result is coherent since the 
amount of Pearlitol® 25 in F6 is lower than in F4, which is itself also lower than in F5 (see 
Section 4.1.3.2.4 and the respective D.T results of F1, F2, F3). The visual aspect of the Lyocs® 
was the same for each formulation. The Lyocs® resulting from F1 to F6 were indeed all 
smooth, without visual defects, and were not powdery. The viscosity of F1 is like expected the 
highest one, due to the higher amount of small particle size of mannitol in the suspension. F2, 
F4 and F5 (where mannitol particle size is medium) have close viscosities between 152 and 
158 mPa.s. The same phenomenon can be observed for F3 and F6, where mannitol particle 
size is the bigger. As previously seen in Section 4.1.3.2.4, when two suspensions of a constant 
mass, the one containing small particles has more particles in its system, increasing the 
interactions between the particles and thus leading to an increase in the viscosity. Any real 
trend (i.e. any significant difference) could be detected for H in function of mannitol particle 
size for F1 to F6. The results obtained in this section are fully comparable to the one of the 
respective placebos (see Section 4.1.3.2.4). Paracetamol only has a marginal effect on the 
resulting Lyocs®. 
4.4.1.1.1 Microscopic Characteristic 
The first picture of each Lyoc® (see Figures 4-96, 4-99, 4-102, 4-105, 4-107 and 4-111) shows 
their entire microscopically structure. They are quite homogeneous, except for F5 (see Figure 
4-108), where agglomerates are observed. Those agglomerates could be due to a bad 
homogenization of the suspension during the mixing step, leading to remaining powder clumps 
in the suspension. A finer structure and a better homogeneity could be observed for F1 (Figure 
4-96) and F4 (Figure 4-105) than F2 (Figure 4-99), F3 (Figure 4-102), F5 (Figure 4-108) and 
F6 (Figure 4-111). Air bubbles are also observable on Figures 4-96, 4-98, 4-99, 4-101, 4-104, 
4-106,4-108, 4-110, 4-111 and 4-113 (see red marks on each Figure), which could have been 
incorporated through a too intense mixing of the suspension. The incorporation of air bubbles 
in the formulation might be nevertheless avoided by mixing the suspension in a closed 
container and by applying a vacuum in order to degas the suspension. Moreover, it was also 
observed that the microscopically structure of the placebos (see Figures of Paragraph 4.1.3.2.5) 
are very similar to the formulations containing paracetamol, which means that the API does 
not interfere the microscopically structure of the Lyocs®.  
   
By combining the microscopic analysis carried out by means of SEM with the IPC results 
(especially the D.T), it can be concluded that F2, F3, F4 and F6 are the most appropriated 
formulations. F4 and F6 could even bring a plus to the formulation, due to the cooling effect 
given through the Pearlitol® 25 C grade. 
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Figure 4-96: SEM picture of F1 (Entire structure),  
12x magnification. 
 
Figure 4-97: SEM picture of F1 (Surface),  
100x magnification. 
 
Figure 4-98: SEM picture of F1 (Center),  
100x magnification. 
 
 
  
 
Figure 4-99: SEM picture of F2 (Entire structure),  
12x magnification. 
 
Figure 4-100: SEM picture of F2 (Surface),  
100x magnification. 
 
Figure 4-101: SEM picture of F2 (Center),  
100x magnification. 
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Figure 4-102: SEM picture of F3 (Entire structure),  
12x magnification. 
 
Figure 4-103: SEM picture of F3 (Surface),  
500x magnification. 
 
Figure 4-104: SEM picture of F3 (Center),  
100x magnification. 
 
 
  
 
Figure 4-105: SEM picture of F4 (Entire structure),  
12x magnification. 
 
Figure 4-106: SEM picture of F4 (Surface),  
100x magnification. 
 
Figure 4-107: SEM picture of F4 (Center),  
100x magnification. 
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Figure 4-108: SEM picture of F5 (Entire structure),  
12x magnification. 
 
Figure 4-109: SEM picture of F5 (Surface),  
100x magnification. 
 
Figure 4-110: SEM picture of F5 (Center),  
100x magnification. 
 
 
  
 
Figure 4-111: SEM picture of F6 (Entire structure),  
12x magnification. 
 
Figure 4-112: SEM picture of F6 (Surface),  
100x magnification. 
 
Figure 4-113: SEM picture of F6 (Center),  
100x magnification. 
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4.4.1.1.2 Porosity of Lyocs® 
Table 4-42 summarizes the porosity results of the Lyoc® formulations F1-F6. Those porosity 
results vary between 57 % and 59 %. The results obtained are consistent with the ones obtained 
to the respective placebo formulations (see Table 4-20)   
The % error between the measured porosity and the calculated one is lower than 5 % for F1 
and F4.  
The % error of F2, F3, F5 and F6 is higher than 5 %, which could be explained by the presence 
of air bubbles in the Lyocs® (see Figures 4-99, 4-102, 4-108 and 4-111). Those air bubbles 
could have been incorporated in the formulation during the mixing step, due to a too high shear 
rate. The formula used to calculate the porosity of Lyocs® is still appropriated in order to 
quickly estimate the product porosity, even if a measurement might be more precise in the case 
of Lyocs®.  
Table 4-42: Porosity measurements of the different placebo Lyocs® (n=5). 
 Porosity measured 
[%] 
Porosity calculated 
[%] 
% error 
F1 56,9   55,0  3,3 
F2 58,2   55,0 5,5 
F3 58,7   55,0 6,3 
F4 56,8   55,0 3,2 
F5 58,6   55,0 6,1 
F6 58,5   55,0 6,0 
 
4.4.1.2 API Release  
The API release of the formulations F1-F6 was measured by means of UV-VIS spectroscopy 
according to the Ph.Eur. Paragraph 2.9.3, with a validated method of the Analytical 
Department of Teva Ulm. The measurement conditions are summarized in Annex (see Section 
6.3). API release is a primordial test to complete in formulation development, as it determines 
the percentage of API that has been released from the dosage form and has dissolved in the 
dissolution medium during the test period. It can provide an estimation on the matrix which 
releases the API faster for same measurement conditions.  
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Table 4-43: Paracetamol release of F1-F3 (n=6). 
F1 F2 F3 Paracetamol 1g Tablet 
Time [h:mm] Average % Min % Max % Time [h:mm] Average % Min % Max % Time [h:mm] Average % Min % Max % Time [h:mm] Average % Min % Max % 
0:00 0,00 0,00 0,00 0:00 0,00 0,00 0,00 0:00 0,00 0,00 0,00 0:00 0,00 0 0 
0:05 74,93 60,48 89,96 0:05 73,70 65,16 83,73 0:05 80,66 64,44 98,59 0:05 59,40 37,65 72,60 
0:10 91,95 82,27 98,90 0:10 91,57 82,33 99,19 0:10 91,77 79,99 97,77 0:10 87.39 85,34 91,99 
0:15 96,83 93,23 100,11 0:15 96,47 92,19 99,26 0:15 95,70 89,49 98,15 0:15 91,88 86,43 96,36 
0:20 98,25 97,09 100,09 0:20 97,42 96,15 98,95 0:20 96,86 93,79 98,12 0:20 95,14 90,00 98,24 
0:30 98,54 97,14 100,09 0:30 97,59 96,53 98,96 0:30 97,00 94,02 98,69 0:30 97,03 92,26 100,51 
0:45 98,47 97,13 100,05 0:45 97,61 96,60 98,96 0:45 96,93 94,00 98,35 0:45 98,11 95,16 101,31 
1:00 98,50 97,23 100,03 1:00 97,63 96,61 99,02 1:00 96,98 93,95 98,65 1:00 98,64 96,55 101,60 
 
 
Figure 4-114: In-Vitro-Dissolution of Paracetamol 100 mg Lyoc® F1-F3 (n=6), Paddle  /  Buffer pH 5.8  /  900 mL  /  50 rpm  /  GF 1µm  /  UV-Evaluation 
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Table 4-44: Paracetamol release of F4-F6 (n=6). 
F4 F5 F6 Paracetamol 1g Tablet 
Time [h:mm] Average % Min % Max % Time [h:mm] Average % Min % Max % Time [h:mm] Average % Min % Max % Time [h:mm] Average % Min % Max % 
0:00 0,00 0,00 0,00 0:00 0,00 0,00 0,00 0:00 0,00 0,00 0,00 0:00 0,00 0 0 
0:05 71,97 50,91 87,06 0:05 82,42 71,24 94,65 0:05 76,02 67,09 81,93 0:05 59,40 37,65 72,60 
0:10 87,32 71,41 96,35 0:10 95,23 88,34 98,75 0:10 92,89 86,58 97,26 0:10 87.39 85,34 91,99 
0:15 92,54 81,02 96,87 0:15 98,04 96,70 98,93 0:15 97,23 94,63 99,04 0:15 91,88 86,43 96,36 
0:20 94,30 85,75 96,86 0:20 98,30 97,97 98,93 0:20 98,55 97,65 99,76 0:20 95,14 90,00 98,24 
0:30 94,91 87,51 97,72 0:30 98,28 97,95 98,93 0:30 98,62 97,67 99,80 0:30 97,03 92,26 100,51 
0:45 93,54 87,34 98,42 0:45 98,30 97,97 98,95 0:45 98,64 97,67 99,81 0:45 98,11 95,16 101,31 
1:00 94,86 87,29 97,51 1:00 98,30 97,98 98,97 1:00 98,68 97,71 99,83 1:00 98,64 96,55 101,60 
 
 
Figure 4-115: In-Vitro-Dissolution of Paracetamol 100 mg Lyoc® F4-F6 (n=6), Paddle  /  Buffer pH 5.8  /  900 mL  /  50 rpm  /  GF 1µm  /  UV-Evaluation 
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Figure 4-114 shows that the API release in not influenced by the mannitol quality. Based on 
Table 4-43, between ca. 74 and 81 % of API is already released after 5 minutes from F1-F3, 
whereas only 59 % of API is released after 5 min from a conventional tablet. Ca. 96 % of API 
release is reached after 15 minutes for the Lyoc® formulations, whereas the normal tablet 
needs between 20 and 30 min to release this amount of API.  
Figure 4-115 did not show any statistical difference of API release between those 3 
formulations. Based on Table 4-44, between ca. 72 and 82 % of API is already released after 
5 minutes from F4-F6, whereas 59 % of API is released after 5 min from a conventional tablet. 
Ca. 96 % of API release is reached after 15 minutes for the Lyoc® formulations, whereas the 
normal tablet needs between 20 and 30 min to release this amount of API. 
The Lyoc® formulations thus allow a much faster release, since ca. 15 % more of the API is 
released 5 minutes after the intake of the drug than the conventional tablet. Lyocs® could thus 
give the API faster available in the body than a conventional tablet. This could lead to a faster 
action of the drug in the organism. 
A comparison of dissolution profile between the conventional tablet and the Lyocs® 
formulations (F1 to F6) was carried out by calculating both difference factor (f1) and similarity 
factor (f2). The results are summarized in Annex 6.3.2. It is to note that the f2 factors of F3 and 
F5 are very close to 50, meaning that a faster API release could be expected for both 
formulations rather than conventional tablets. For F1, F2, F4 and F6, f1 < 15 and f2 > 50, 
meaning that their dissolution profile are similar to the one of conventional tablets. The 
performance of Paracetamol Lyocs® is thus equivalent to the one of conventional tablets. 
Nevertheless, Lyocs® provide to the patient a better treatment comfort due to an easier and 
more discreet treatment, since no water is needed for the intake of the drug and the ODT 
disintegrates itself in the patient’s mouth.  
4.4.1.3 Content of Uniformity 
The content of uniformity of each batch was measured, in order to prove the homogeneity of 
API within the tablets. This test was made according to the Ph. Eur., paragraph 2.9.40 (EDQM, 
2014f). The measurement conditions are summarized in Annex (see Section 6.4.1) 
The statistical results such as the average content ?̅?, the sample standard deviation s, the 
relative standard deviation RSD were thus determined. 
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Figure 4-116: Absorption measurement of Placebo formulations, Reference solutions and F3. 
As shown on the placebo curves in the Figure 4-116, the excipients do not have any absorption 
at 243 nm, meaning that the absorption at 243 nm is directly correlated with the API content 
in the Lyocs®, and is not influenced through the excipients.  
Table 4-45: API content of Lyocs® with statistical values (n=10). 
 F1 F2 F3 F4 F5 F6 
?̅? [%] 97,12 98,60 97,41 94,32 101,64 105,35 
s 2,94 4,18 1,15 8,55 1,24 0,68 
RSD 3,03 4,24 1,18 9,06 1,22 0,65 
 
 
Figure 4-117: Content of uniformity in F1-F6 (n=10) ± SD. 
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The API content of F1, F2, F3 and F5 is good, as ?̅?.of those formulations stays in the interval 
100 ± 5%. Formulations having the bigger amount of Pearlitol® 160 C (i.e. F4 and F6) both 
have an API deviation greater than 5 %, meaning that the API homogeneity in those 
formulations is varying too much. The use of Pearlitol® 160C in proportion higher than 27,7 
% on the dried mass of the formulation is thus not appropriate for the Lyoc® technology. This 
deviation could be the result of a bad mixture between the two different grades of mannitol. 
The higher inhomogeneity of F4 could also be seen in the API release curve (see Figure 4.115), 
where the error indicator interval was quite higher than the one of other formulations, as on 
Figure 4-117 where the standard deviation is clearly bigger than for the other formulations. 
Since the suspension of F4 had the same characteristics as the other formulations, the API 
inhomogeneity could be explained by a bad manufacturing process (e.g. air inclusion during 
the mixing step due to a too high mixing rate or bad pipetting).  
A one-way ANOVA with a significance level α=0,05 and a Tukey Post hoc  statistical analysis 
were performed on the uniformity of content between all the groups F1 to F6. Based on the 
results summarized in Annex 6.4.2, a significant difference could be observed between [F1-
F6], [F2-F6], [F3-F6], [F4-F6] and [F4-F5]. Indeed, the two main anomalies are observed for 
F4 (too low mean value and too high standard deviation) and F6 (too high mean value). Those 
two formulations are containing the highest concentration of Pearlitol® 160 C in the mannitol 
grade mixture (Pearlitol® 25 C + Pearlitol® 160 C). The following proposition could be 
established: when Pearlitol® 160 C is present in too big proportions in the mixture Pearlitol® 
25 C + Pearlitol® 160 C, the mixture behavior with Pearlitol® 25 C may be bad, leading to an 
inhomogeneity of materials in the suspension. To confirm this hypothesis, the one-way 
ANOVA analysis should be carry out on 3 batches for each formulation and not 1. 
Unfortunately, due to lack of time and capacity, 3 batches per formulation could not be 
produced.  
4.4.1.4 Study of Sedimentation Within The Pipette 
The same analytical measurement system was used as in Chapter 4.4.1.3. F3 was produced 
with different pipette tip volumes, namely 10 mL, 25 mL and 50 mL in order to determine if 
sedimentation occurs within the pipette. 1 mL of suspension was poured in each blister cavity. 
For each pipette volume, 10 samples coming from the beginning of the pipetting and 10 
samples coming from the end of the pipetting were randomly picked up. 
Table 4-46: API content of Lyocs® with statistical values (n=10). 
 10 mL pipette 25 mL pipette 50 mL pipette 
Batch Nr 160302 160301 160303 
 Beginning End Beginning End Beginning End 
?̅? [%] 90,11 92,49 98,10 95,88 92,10 96,52 
s 0,59 0,90 1,54 1,70 3,61 3,24 
RSD 0,66 0,97 1,57 1,77 3,92 3,36 
 
The standard deviation of the 3 pipette volumes increased from 10 mL pipette to 50 mL pipette. 
It can be concluded that the 10 mL pipette gives a more precise dosage (0,59 < s < 0,90) than 
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a 25 mL (1,54 < s < 1,70) and a 50 mL pipette (3,24 < s < 3,61). Nevertheless, the s value of 
the 25 mL is still acceptable to be used in the development step, since s lies below 3.5. In 
comparison to the 10 mL pipette, a 25 mL pipette gives a faster dispensing time and offers 
more comfort to the worker by reducing the number of suspension sampling.    
The API content [%] ± SD was schematically represented in Figure 4-118 in order to determine 
if sedimentation occurred within the pipette tip.  
 
Figure 4-118: API content ± SD of Lyocs® at the Beginning and the End of pipetting (n=10). 
As shown on Figure 4-118, it could be supposed that the only statistical difference is observed 
for the 10 mL tip pipette, since the SD ranges for the beginning and the end of the pipetting 
are not overlapping. The SD ranges of the 25 mL and the one of the 50 mL are overlapping, 
which may mean that no statistical difference is observed between the API concentration at 
the beginning and at the end of the pipetting for those two pipette tips. A t-test analysis was 
carried on in the 3 pipette tips in order to study the statistical difference of API content between 
the beginning and the end of the pipetting step. Based on the results summarized in Annex 
6.5.1, the calculated t-value is for the 3 cases above t-critical value, meaning that a statistical 
difference is observable for all the 3 pipette tips.   
 
Figure 4-118 and the results summarized in Table 4-46 both show that the API content of the 
beginning of pipetting is lower than the end of pipetting for the 10 mL and 50 mL pipette tips. 
This phenomenon could be explained for the 10 mL pipette tip by the fact that the diameter of 
the dispensing hole of the 10 mL pipette tip (diameter = 0,8 mm) is the smaller than the one 
of 25 mL (diameter = 1,34 mm) and 50 mL (diameter = 1,92 mm) pipette tips. A possible 
reason for that can be that at the beginning of the pipetting, the API sticks to the pipette tip 
wall, giving a bad API repartition and disturbing the mean API value, as represented on Figure 
4-119. 
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Figure 4-119: Fluid behaviour in the pipette tips, Red Particles = API. 
For the 50 mL pipette tip, the lower API content at the beginning of the it could be due that  
The 25 mL is thus the best suitable pipette for the Lyoc® technique as it has smaller SD than 
the 50 mL pipette.  
4.4.1.5 Study of Sedimentation Within The Suspension Placed in The Blister 
Cavity 
The sedimentation within the Lyocs® of the 6 formulations of the chapter 4.4.1.1 was studied 
as described in Chapter 3.2.5.10.2.             
Table 4-47 summarizes the paracetamol content in mg/g per half Lyoc® ± SD.  
Table 4-47: API content [mg/g] in each half Lyoc® of the formulations F1-F6 (n=6) ± SD, where “Bottom” corresponds 
to the half part in contact with the PVC cavity whereas “Top” corresponds to the half part in contact with the 
aluminum foil. 
  F1 F2 F3 F4 F5 F6 
API 
conten
t  
Botto
m 
158,17±3,0
3 
158,76±4,7
8 
157,92±3,5
5 
159,07±4,6
9 
158,80±5,6
2 
159,13±5,4
8 
Top 153,89±5,0
9 
154,19±3,9
7 
152,91±3,0
2 
151,70±3,8
7 
153,23±4,4
2 
154,54±5,2
7 
A t-test analysis with a significance level α=0,05 was conducted on the results of Table 4-47 
in order to statistically conclude on the sedimentation of the API in the manufactured 
suspension during the lyophilization process. Indeed, this test allows to analyze the possible 
differences within the batch (i.e. interbatch variability) and the results are summarized in 
Annex (see Section 6.5.2).  
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Since the t-values of F1, F2, F5 and F6 is below t-critical, no statistical significant difference 
can be observed between the two half Lyocs® of those formulations. No significant 
sedimentation occurs during the lyophilization process for F1, F2, F5 and F6.  
However, t-value (F3) and t-value (F4) are bigger than the critical value. That is why it can be 
concluded that for F3 and F4, there is a statistical difference between the half Lyocs®. 
Therefore, sedimentation occurs within those two samples.  
It is to note that the particle size D50 of Paracetamol is 150 µm.   
This sedimentation occurring by can be due to the particle size of mannitol. F3 indeed contains 
Mannitol of 110 µm, whereas F4 contains 50% of Pearlitol® 25 C and 50 % of Pearlitol® 160 
C. For F4, maybe the two grades are not mixing well together (as already underlined in Section 
4.4.1.3) bringing an inhomogeneity within the Lyocs®. For F3, the lower particle size of 
Pearlitol® leads to faster sedimentation within the Lyocs® according to the Stock’s law, which 
is why a significant sedimentation may occur in this sample. 
 
 
Figure 4-120: Representation of the API content [mg/g] of each half Lyoc® contained in F1-F6 ± SD (n=6). 
After schematically representing the paracetamol content per half Lyoc® ± SD for F1-F6 (see 
Figure 4-120), a certain trend of API sedimentation within the Lyocs® can be observed, since 
a significant difference can be noticed for each formulation between the API content of the 
bottom and the top of each Lyoc®. It can thus be concluded at first sight, that sedimentation 
occurs thus whatever the mannitol grade, but a statistical difference between both Lyoc® 
halves could only be noticed for F3 and F4. 
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4.4.1.6 Conclusion 
After having conducted an analytical study on Paracetamol 100 mg Lyocs®, it could be 
noticed that API release is quite independent of the mannitol grade. A faster onset of action 
could have been expected for the Lyocs® than the conventional tablets, possibly due to a faster 
D.T of Lyocs® in comparison to the one of conventional tablets. Nevertheless, the API release 
of Lyocs® was equivalent to the one of conventional tablets, as shown by the statistical 
analysis based on both f1 and f2 factors.  
The Lyoc® formulations containing Pearlitol® 25 C, Pearlitol® 50 C, Pearlitol® 110 C and 
Pearlitol® 25 C/160 C (3+1) (i.e. F1, F2, F3 and F5) presented a more consistent API content 
than Lyoc® formulations with Pearlitol® 25 C/160 C (1+1) and (1+3) (i.e. F4 and F6). This 
could be explained by the too high concentration of Pearlitol® 160 C, which may cause a bad 
mixture between Pearlitol® 25 C and 160 C, causing an inhomogeneity in the suspension. This 
result should nevertheless be studied more in details, by increasing the number of tested 
samples (completion of 2 other batches, in order to have a significant ANOVA statistical 
study). 
A sedimentation trend could also be observed between the top and the bottom of each Lyocs®, 
as the API content was significantly different between both Lyocs® part. This trend is also 
notable with small Mannitol particle size. The use of a viscosity enhancer (such as xanthan 
gum) could prevent this sedimentation issue within the suspension and thus, provide more 
homogeneous tablets. 
4.4.2 Process Optimization 
In order to reduce the time and energy costs of the process, a process optimization was done 
on F1, F2 and F3. The product quality was then checked through IPCs and through a moisture 
content measurement by means of LoD. 
F1: Paracetamol 100 mg Lyocs® with Pearlitol® 25 C. 
F2: Paracetamol 100 mg Lyocs® with Pearlitol® 50 C. 
F3: Paracetamol 100 mg Lyocs® with Pearlitol® 110 C. 
 
In the production scale, the suspension is dispensed in blisters and cooled down at -40°C in a 
refrigerating chamber during one hour before being dried in the FD. That is why no changes 
were made on the freezing step in this study, in order to stay the closest to the production 
conditions. The studied parameters were thus Ts, p and process time of primary drying and 
secondary drying.  
4.4.2.1 Initial Process 
Table 4-48 summarizes the initial manufacturing process. The total duration is set at 15:25, 
almost twice as much as in the production scale. 
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Table 4-48: Initial manufacturing process of Lyocs®. 
Step Time [hh:mm] T [°C] Vacuum [mbar] T ramp [°C/min] 
Loading 00:00 -40 1000 - 
Freezing 02:15 -40 1000 - 
P.D 00:35 -40 0,2 - 
01:35 45 0,2 0,89 
06:00 45 0,2 - 
S.D 04:00 45 0,2 - 
00:30 25 0,2 0,67 
00:30 25 0,2 - 
Total duration 15:25    
 
Figure 4-122 shows the monitoring process during the initial lyophilization cycle. The first 
observation that can be made is that the three products are behaving the same during the 
lyophilization cycle. Therefore, the mannitol grade does not seem to have any influence on the 
sublimation rate occurring in the product.  
The process time lasts longer than the 8 hours predetermined from the production scale. 
Nevertheless, the freeze-dryer characteristics of the production are different, especially the 
maximum shelf temperature. The shelves can reach up to 80°C in the production compared to 
45°C in our case. As this process is quite gentle for the Lyoc® technology, it can be used at 
first for each type of formulation.  
The process will be optimized step by step, in order to see the influences of every change on 
the product. The first step to be changed is thus the freezing one. It can be seen that the freezing 
process could be shortened by one hour, as the product temperature does not evolve after 2 
hours (see Figure 4-122). As the product is not sensitive to temperature (even with a high 
increase of T after the freezing step, the product is not deteriorated), the first increase of T 
ramp could also be increased without any influences on the product quality, accelerating the 
sublimation rate and so decreasing the process duration.  
The “Eiskond” curve (see black line on Figure 4-122) represents the Tcc during the process. A 
peak can be observed at the beginning of the P.D (at t=5:00 hours) when Pc is decreasing, 
reflecting the brutal entrapment of water molecule present in the chamber (such as surrounding 
humidity added during the loading step, frost accumulated on the chamber wall, and beginning 
of sublimation) (Le Floch, 2008). Tcc is slightly decreasing at 13:00, meaning the end of the 
sublimation step and that no water molecules are being entrapped on the condenser anymore 
(Le Floch, 2008). This is confirmed with Tp, as it can be noticed on Figure 4-122 that when 
Tcc  decreases, Tp=Ts designating the end of the P.D step. 
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Figure 4-122: Temperature and pressure evolution during the initial lyophilization process, white=loading step, 
green=freezing step, red=P.D, blue=S.D. 
A further evaluation can be done on the freezing step of Figure 4-122. A zoomed picture was 
created and represented on Figure 4-123. With Figure 4-123, two main characteristics can be 
determined, namely the ice formation where a plateau on the product temperature can be 
observed at -5 °C, and the solidification point (at around -20 °C) where the LyoRx curve does 
not change anymore as this sensor measures the electrical resistance present in the product 
(ChristMartin, 2015). The freezing step could thus be considerably decreased, at least 1 hour. 
139 
 
 
Figure 4-123: Representation of the zoomed zone of the freezing step in order to determine the Ice formation and the 
Solidification point of the product. 
 
Table 4-49: IPC results of F1-F3 ± SD. 
IPC results 
 F1 F2 F3 
Batch Nr 160284 160285 160283 
LoD 
[%], n=2 
0,41 0,44 0,43 
H [N], 
n=20 
54±17 53±11 48±8 
D.T [s], 
n=6 
18±4 8±2 5±1 
Aspect Good visual aspect. Do not 
break during unpacking. Not 
powdery 
Good visual aspect. Do not 
break during unpacking. Not 
powdery. 
Good visual aspect. Do not 
break during unpacking. Not 
powdery. 
Ice formation (Daniels, 2014). 
Solidifaction point (Christ). 
Tcc 
Ts 
LyoRx curve (crystallization %) 
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The IPCs obtained with the initial process in Table 4-49 will be taken as reference for the 
optimization study. The LoD value will be carefully observed. It can be firstly noticed that 
whatever the mannitol grade, the LoD values are similar, meaning that the LoD is not 
influenced by structural aspects of Lyocs®. 
4.4.2.2 Optimization 1 
Table 4-50 summarizes the first optimization of the manufacturing process. The total duration 
is decreased down to 13:20 (2 hours less than the initial process). For this, as explained in 
Section 4.4.2.1, the freezing step was reduced from 2:15 to 1:00 and the T ramp at the 
beginning of the P.D was considerably accelerated from 1:35 to 00:45.  
Table 4-50: First optimization of the manufacturing process of Lyocs®, the parameters which were changed are 
marked in green. 
Step Time [hh:mm] T [°C] Vacuum [mbar] T ramp [°C/min] 
Loading 00:00 -40 1000 - 
Freezing 01:00 -40 1000 - 
P.D 00:35 -40 0,2 - 
00:45 45 0,2 1,89 
06:00 45 0,2 - 
S.D 04:00 45 0,2 - 
00:30 25 0,2 0,67 
00:30 25 0,2 - 
Total duration 13:20    
Figure 4-124 shows the monitoring process during the first optimized lyophilization cycle. It 
can be seen that the freezing step was shortened correctly, as the beginning of the freezing 
plateau is still visible at the end of the freezing step. The T ramp increase at the beginning of 
P.D was divided by two, bringing no changes to the visual aspect of the product (no exploded 
Lyocs® were obtained, meaning that the Lyoc® products could bear the high T increase).  
What role does the p exactly play? Indeed, the faster sublimation rate occurs when 𝑃𝑐ℎ𝑎𝑚𝑏𝑒𝑟 =
 
𝑃𝑖𝑐𝑒 𝑜𝑣𝑒𝑟 𝑡ℎ𝑒 𝑝𝑟𝑜𝑑𝑢𝑐𝑡
2
. At the end of the freezing step, Tp = -35°C, which corresponds to an ice 
pressure of 0,220 mbar (ChristMartin, 2015). Pc could be thus set at 0,110 mbar during the 
P.D. It can also be observed on Figure 4-124 that the end of the P.D is not reached at 10:30 
(end of the red area), as Tp ≠ Ts. The P.D should thus last until 12:00 in order to have Tp=Ts. 
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Figure 4-124: Temperature and pressure evolution during the first optimized lyophilization process, white=loading 
step, green=freezing step, red=P.D, blue=S.D. 
Table 4-51: IPC results of F1-F3 ± SD. 
IPC results 
 F1 F2 F3 
Batch Nr 160305 160306 160304 
LoD 
[%], n=2 
0,29 0,30 0,30 
H [N], 
n=20 
53±13 57±11 46±10 
D.T [s], 
n=6 
16±3 10±2 5±2 
Aspect Good visual aspect. Do not 
break during unpacking. 
Not powdery 
Good visual aspect. Do not 
break during unpacking. Not 
powdery. 
Good visual aspect. Do not 
break during unpacking. Not 
powdery. 
 
Table 4-51 summarizes the IPC results of the Lyocs® resulting from optimization 1. 
It can be noticed that the D.T and H stay approximately the same between the initial process 
(see table 4-49) and the first optimization process (see table 4-51). The lower LoD observed 
for the first optimization process (LoD ≈ 0,4 % for the products manufactured with the initial 
process, whereas LoD ≈ 0,3 % for the products manufactured with the first optimization 
process) could be explained by the fact that the higher T ramp of the beginning of P.D extracts 
more molecules of water, leading to a measurable decrease of the LoD. 
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4.4.2.3 Optimization 2 
In the second optimization, the pressure in the chamber was decreased from 0,2 mbar to 0,11 
mbar in order to see the influence of the pressure on the Lyocs®, as explained in paragraph 
4.4.2.2. Table 4-52 summarizes the second optimization of the manufacturing process used. 
The entire process lasts 13:20. 
Table 4-52: Second optimization of the manufacturing process of Lyocs®, the parameters which were changed are 
marked in green. 
Step Time [hh:mm] T [°C] Vacuum [mbar] T ramp [°C/min] 
Loading 00:00 -40 1000 - 
Freezing 01:00 -40 1000 - 
P.D 00:35 -40 0,11 - 
00:45 45 0,11 1,89 
06:00 45 0,11 - 
S.D 04:00 45 0,11 - 
00:30 25 0,11 0,67 
00:30 25 0,11 - 
Total Duration 13:20    
 
Figure 4-125 represents the lyophilization cycle of the second optimization. It looks like the 
frozen products need 7 hours to be completely sublimated, as Tp reaches the Ts 7 hours after 
the beginning of the T ramp increase (see Figure 4-125). In the case of optimization 1, Tp 
reaches the Ts 7:45 hours after the end of the T ramp increase (see Figure 4-125). Therefore, 
the decrease in pressure allowed shortening the process by another one hour. The long plateau 
observed at the beginning of the S.D (excess of over 3 hours) can also be shortened in order to 
decrease the cycle duration. This last change will be applied to finally optimize the process.  
Moreover, during the S.D, all the adsorbed molecules of water have to be removed by 
decreasing Pc down to 1 µbar. This P change will also be applied to the final optimized process.   
 
Figure 4-125: Temperature and pressure evolution during the second optimized lyophilization process, white=loading 
step, green=freezing step, red=P.D, blue=S.D. 
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Table 4-53: IPC results of F1-F2 ± SD. 
IPC results 
 F1 F2 F3 
Batch Nr 160308 160309 160307 
LoD [%], 
n=2 
0,30 0,33 0,30 
H [N], 
n=20 
69±13 56±11 49±8 
D.T [s], 
n=6 
20±6 13±5 5±1 
Aspect Good visual aspect. Do not 
break during unpacking. Not 
powdery 
Good visual aspect. Do not 
break during unpacking. Not 
powdery. 
Good visual aspect. Do not 
break during unpacking. Not 
powdery. 
Table 4-53 summarizes the IPC results of the Lyocs® resulting from optimization 2. 
The IPC results summarized in Table 4-53 are similar to the one of optimization 1 (see Table 
4-51), meaning that the new parameters applied to this second optimized process do not have 
any negative impacts on the product quality. However, the lower P at the beginning of P.D in 
comparison with optimization 1, allowed to shorten the process (45 min shorter with P=0,11 
mbar as with P=0,2 mbar). 
4.4.2.4 Final Process Optimization 
Table 4-54 summarizes the initial manufacturing process used. As explained in Section 4.4.2.3, 
the P.D was extended by 1 hour, in order to reach Tp=Ts. The long plateau between P.D and 
S.D was also clearly shortened by 3 hours in order to shorten the process time. The influence 
of Pc was also studied, by decreasing Pc from 0,11 to 0,001 mbar during the S.D in order to 
remove the adsorbed molecules of water. The final total duration is thus set at 11:50. 
Table 4-54: Final optimization of the manufacturing process of Lyocs®, the parameters which were changed are 
marked in green. 
Step Time [hh:mm] T 
[°C] 
Vacuum [mbar] T ramp [°C/min] 
Loading 00:00 -40 1000 - 
Freezing 01:00 -40 1000 - 
P.D 00:35 -40 0,11 - 
00:45 45 0,11 1,89 
07:00 45 0,11 - 
S.D 00:30 45 0,001 - Pressure rise test  - 
01:00 45 0,001 - 
00:30 25 0,001 0,67 
00:30 25 0,001 - 
Total duration  11:50    
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Figure 4-126 represents the lyophilization cycle of the ultimately finally optimized process. 
The process duration could be successfully shortened by 3:35. A pressure rise test was also 
performed at the end of the P.D (see decrease of P on the yellow curve of Figure 4-126). During 
this test, the valve separating the chamber and the condenser was closed, in order to ensure 
that the product was completely dried. As shown in the Figure 4-126, Pc did not increase during 
this pressure rise test, meaning that the P.D is finished and that the product is correctly dried. 
Moreover, the decrease of Pc from 0,11 to 0,001 mbar during S.D shows a slight decrease of 
Tcc at 12:00. This shows that no adsorbed water molecules are being entrapped on the 
condenser anymore (Le Floch, 2008). 
 
Figure 4-126: Temperature and pressure evolution during the final optimized lyophilization process, white=loading 
step, green=freezing step, red=P.D, blue=S.D. 
Table 4-55: IPC results of F1-F3 ± SD. 
IPC results 
 F1 F2 F3 
Batch Nr 160311 160312 160310 
LoD [%], 
n=2 
0,33 0,31 0,30 
H [N], 
n=20 
55±14 55±12 45±10 
D.T [s], 
n=6 
15±4 10±2 6±1 
Aspect Good visual aspect. Do not 
break during unpacking. Not 
powdery 
Good visual aspect. Do not 
break during unpacking. Not 
powdery. 
Good visual aspect. Do not 
break during unpacking. Not 
powdery. 
The IPC results summarized in Table 4-55 are similar to the one of optimization 1 (see Table 
4-51) and optimization 2 (see Table 4-53), meaning that the new parameters applied to this 
final process do not have any negative impact on the product quality. 
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The lyophilization process was thus completed successfully, as the process time was reduced 
from 15:25 to 11:50, without any significant changes in the product quality.   
4.4.2.5 Conclusion 
The D.T and the LoD of the 3 products manufactured with the different processes are very 
similar, such as the H and the visual aspect of the product. It means that the process duration 
could successfully be shortened from 15:30 to 11:50 without any influences on the product 
quality. The characteristics of the Ts of the laboratory scale freeze-dryer and the production 
machine are very different. Indeed, Ts max of the development machine is maximum 45°C, 
whereas Ts max of the production machine is 80°C, allowing to impose higher T during the 
primary drying step, which decreases a lot the process duration through a faster sublimation 
rate. This T characteristic will have to be taken into considerations later on, when scale-up 
studies are performed on the process. Indeed, a pilot scale-equipment with a larger production 
capacity than in the lab scale has to be used in order to produce 1/10 of the total production. 
This pilot scale instrument can have characteristics that are more closely to the production 
scale than the lab scale could. This is especially the case for the Ts characteristics. A further 
study can then be carried out in detail in order to evaluate the influence of higher Ts on the 
product quality, in order to attempt to reach the 8 hours of process duration of the production.     
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5 Summary 
The goal of this doctoral thesis was to characterize and optimize the formulation of lyophilized 
ODTs, by using more specifically the patented Lyoc® technology. ODTs have several 
advantages in comparison to conventional tablets, since they allow the patient to have a 
convenient administration (no need of water, discreet treatment, does not leave any residue in 
the mouth after administration). This dosage form is thus adapted for patients who have 
swallowing difficulties (such as pediatric use, geriatric use, and patients suffering from 
dysphagia), and might be particularly advantageous for the treatment of psychiatric patients. 
A Lyoc® formulation is based on a suspension system containing mainly a diluent, a binder, 
API, and water which is subsequently lyophilized. 
Using a lyophilization technology in the manufacturing of ODTs presents the advantage of 
rapidly disintegrating solid dosage forms. However, it is more expensive than the 
manufacturing of conventional tablets. Not only is the formulation of Lyoc® hard to develop 
and optimize, but the process optimization of the multiple critical parameters is also complex 
to complete. 
In this thesis, firstly an excipient screening was performed in order to limit the possible usable 
excipients in the formulation of Lyocs® and their range of use. This study showed that 
crystalline mannitol with a particle size lower than 160 µm was the most appropriate diluent 
due to: 
-  its good ability to crystallize during the freezing step, 
- its sweetening properties and cooling effect, 
- its ability to allow fast sublimation leading to a high water loss at the beginning of the 
drying process.  
 
Mixing the two mannitol grades Pearlitol® 25 C (D50 = 25 µm) and 160 C (D50 = 160 µm), 
also brought convincing improvements to the formulation concerning the suspension 
properties and the taste of the resulting Lyocs®.   
Regarding binders, diverse water-soluble polymers were found to be appropriate for the 
Lyoc® technology, namely dextran, dextrates, and povidone with a maximum ratio of 
Diluent/Binder up to 90 %/10 % w/w of the dried mass in lyophilized tablets. Beyond 10 %, 
the lyophilized tablets are too hard because of the cohesion caused by the binding agent within 
the particles, leading to an unacceptable high disintegration time. 
Further optimization of base formulations consisting of Mannitol as diluent and either 
Hypromellose or dextran as binder was performed by means of a DoE study. This served to 
investigate if the high multi-variable system could be successfully optimized by using a tailor-
made design (“Custom Design” tool in the JMP® software). Indeed, the amount of diluent, 
binder and water had to be optimally determined in order to obtain optimum physical 
properties of the product (i.e. F, viscosity, D.T, H). Despite the multiple responses, the large 
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factors variability and the broad range of IPCs, an optimum could be identified for both 
placebo systems.  
A further issue was to study the influence of the API solubility used in Lyoc® formulation. In 
the context of this study, two crystalline very soluble APIs (metoclopramide HCl monohydrate 
and metamizol Na) and two crystalline sparingly or slightly soluble APIs (paracetamol and 
sildenafil citrate) were used to identify the solid state of the API after lyophilization. XRPD 
and Raman mapping were conducted on the resulting Lyocs®, allowing the determination of 
the solid state. Regarding the very soluble APIs, both remain partially or completely 
amorphous after the lyophilization process. Due to this API amorphization, Lyocs® tend to 
lose their structures during the lyophilization process. The loading limit of soluble API was 
estimated at 16 % of the total dried mass of the Lyoc®. Regarding the less-soluble APIs, 
XRPD study proved that both APIs recrystallize during lyophilization. This crystallinity 
imparts elegance to the Lyoc® structure.  
Finally, a systematic study was undertaken on Paracetamol Lyocs®. First, the influence of the 
mannitol grade on the IPC results, on the API release and on the API sedimentation during 
lyophilization was specifically studied. In the second step, the lyophilization process was 
optimized with respect to the required processing time.  
By combining microscopic analysis with the IPC results (especially D.T), it can be concluded 
that Paracetamol 100 mg Lyocs® with Pearlitol® 25 C, 50 C, 110 C, 25 C / 160 C (3+1) are 
an adequate option for the Lyocs® formulations.  
The Paracetamol release was independent of the used mannitol grade. A faster onset of action 
might be expected for the Lyocs® (ca. 96 % of API release is reached after 15 minutes) 
compared to conventional tablets (ca. 90 % of API release is reached after 15 minutes), due to 
a shorter disintegration time of Lyocs® in comparison to the conventional tablets, and 
therefore a faster release of API out of the Lyoc® matrix. Nevertheless, the calculation of the 
difference factor (f1) and the similarity factor (f2) showed that Lyocs® and conventional 
tablets have both similar dissolution profiles, since f1 < 15 and f2 > 50 for all formulations. 
However, the f2 factor of Paracetamol 100 mg Lyoc® with Pearlitol® 100 C and of 
Paracetamol 100 mg Lyoc® with a mixture of Pearlitol® 25 C and 160 C (3+1) were very 
close to 50, meaning that a faster API release could be expected for these formulations in 
comparison to the conventional tablets.  
Based on IPC and API release results, the most appropriate formulations are therefore 
Paracetamol 100 mg Lyocs® with Pearlitol® 100 C and with Pearlitol® 25 C / 160 C (3+1). 
The mixture of Pearlitol® 25 C with 160 C showed an additional benefit due to the cooling 
effect related to Pearlitol® 25 C. 
Independent from the used grade of mannitol, sedimentation occurred in the suspension after 
dispensing and before the freezing step. This resulted in significantly different API contents 
in the top and bottom parts of theLyocs®. The use of a viscosity enhancer (such as xanthan 
gum) should prevent this sedimentation issue within the suspension and thus, provide 
homogeneous tablets. 
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Regarding the process optimization, no significant differences in the freeze-drying behavior 
of the formulations using the several mannitol grades were detected (no collapsed Lyocs® 
were obtained). 
The initial lyophilization process which lasted 15:25 h could be reduced by 3.5 h with the same 
lab scale equipment, thanks to a faster T ramp during P.D and a lower Pc during P.D and S.D 
without generating a negative impact on the product quality.  
To conclude, the following main points summarized in Table 5-1 need to be carefully studied 
during the development steps of freeze-dried tablets. 
Table 5-1: Summary of formulation and process parameters to take into consideration during galenic and process 
development. 
Formulation Process 
Collapse temperature of the suspension is of 
paramount importance and has to be 
determined (by means of DSC) for 
suspension characterization and for process 
optimization. 
Influence of critical process parameters (Pc, 
Ts) on the product quality should be evaluated 
preferably by means of a Quality by Design 
(QbD) approach.  
Viscosity and degree of sedimentation 
needs to be carefully studied in order to 
allow pipetting and to avoid sedimentation 
in the FD. 
Scale-up activities on dispensing are 
necessary in order to determine the influence 
of suspension viscosity on the suspension 
dispersion.   
Study on API solubility and on API load 
within Lyocs® need to be performed. 
XRPD characterization on Lyocs® may be 
helpful to determine the solid state of API 
after lyophilization. 
Scale-up activities on freeze-dried process 
should be performed in order to optimize and 
shorten the process duration. 
Combination of Pearlitol® 25 C and 160 C 
grades brings a cooling effect to the drug 
product  advantageous for bitter APIs. 
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6 Annex 
6.1 DSC Measurements 
6.1.1 DSC Measurements of Diluent/Water Suspensions 
 
Lactose 
 
Maltitol 
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Maltose 
 
Mannitol 
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Sorbitol 
 
Xylitol 
Figure 6-1: DSC thermogram of Diluent/Water suspensions. 
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6.1.2 DSC Measurements of Mannitol/Binder Suspensions 
 
Figure 6-2: DSC thermogram of the suspensions Mannitol/Binder. 
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6.2 TGA Measurements 
6.2.1 Metoclopramide HCl 
 
Figure 6-3: TGA thermogram of Metoclopramid HCl. 
Metoclopramide HCl = C14H22ClN3O2, x H2O 
M(C14H22ClN3O2) = 299 g/mol 
M(H2O) = 18 g/mol 
The mass loss notable between 60 °C and 100 °C of 3,1 % :  
𝑀(H2O)
𝑀(C14H22ClN3O2)+𝑀(H2O)
=
18
299+18
= 5,68 % 
5,68%
2
 = 2,84 %, corresponding to a half 
molecule of water  x=1/2. 
6.2.2 Metamizol Na 
 
Figure 6-4: TGA thermogram of Metamizol Na. 
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Metamizol Na = C13H16N3NaO2S, x H2O 
M(C13H16N3NaO2S) = 333 g/mol 
M(H2O) = 18 g/mol 
The mass loss notable between 80 °C and 120 °C of 5,0 % :  
𝑀(H2O)
𝑀(C13H16N3NaO2S)+𝑀(H2O)
=
18
333+18
= 5,1 %, corresponding to a half molecule of water. 
The API used is thus a monohydrate  x=1 
6.3 API Release 
6.3.1 Measurement 
The choice of the size of the quartz cell was made by measuring the absorbance (A) of two 
reference solutions containing different concentrations C of pure paracetamol (i.e. CRef 
1=111,56 mg/L and CRef 2=56,05 mg/L). Ref 1 will set the size of the cell and Ref 2 will play 
the role of measurement verification by calculating the standard comparison value (SV), where 
± 2 % is allowed. 
 
Figure 6-5: Absorbance of Ref 1 and Ref 2 with a 1 cm cuvette and a 1 mm cuvette 
According to the Beer-Lambert equation, A has to be below 1. On Figure 6-5, the absorption 
curve of the 1 cm quartz cell is too high, meaning that the cell size needs to be lowered. Aλmax 
of Ref 1 with the 1 mm cuvette is 0,72607 which is below 1. Aλmax of the Ref 2 with the 1 mm 
cuvette equals 0,36569.  
SV =
𝐴𝑅𝑒𝑓 2 𝐶𝑅𝑒𝑓 1 
𝐴𝑅𝑒𝑓 1 𝐶𝑅𝑒𝑓2
100 = 100,2 % < 2 %. 
The measurement method is thus approved and a 1 mm quartz cell is used for the measurement 
of the API release. As shown on the Figure 6-5, the maximum wavelength (λ) of paracetamol 
is at 243 nm. That is why the measuring λ is set at 243 nm.  
The A was then converted into % of API released using the formula: 
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𝑃𝑎𝑟𝑎𝑐𝑒𝑡𝑎𝑚𝑜𝑙 𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 (%) =
𝐴𝑇𝑠𝑡 𝐶𝑅𝑒𝑓 𝑉1 100%
𝐴𝑅𝑒𝑓 𝑉𝑅𝑒𝑓 𝐺
 
ATst = Absorption of the test solution at λmax (i.e. 243 ± 2 nm) 
CRef = Concentration of paracetamol (mg) in the reference solution 
V1 = Volume (mL) of test batch 
ARef = Absorption of the reference at λmax (i.e. 243 ± 2 nm) 
VRef = Volume (mL) of reference solution 
G = Content of paracetamol (mg/tablet) 
6.3.2 Dissolution Profile Comparison 
 f1 f2 
F1 4.81 82.80 
F2 4.37 60.89 
F3 5.43 53.65 
F4 3.92 63.29 
F5 6.69 50.84 
F6 5.27 57.32 
 
6.4 Content of Uniformity 
6.4.1 Measurement conditions 
The measurement conditions such as λmax, the sample concentration and the size of the cell 
were firstly determined by means of a preliminary test. 1 tablet was firstly dissolved in 50 mL 
of solvent (i.e. Csolution = 2 mg/mL). According to the Beer-Lambert equation, the absorbance 
A has to be below 1. Aλmax of the 0,2 mm cuvette is 2,50, which is too high. Aλmax of the 0,1 
mm cuvette is 1,27.  
 
 
Figure 6-6: Absorption measurement for the choice of the cuvette size. 
That is why the system of measurement is set as: 
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- 10 tablets were randomly picked up in each batch and each tablet was separately 
dissolved in 100 mL of the solvent, i.e. csolution = 1 mg/mL, 
- 0,1 mm cuvette, 
- λmeasurement = [200-500]. 
Two standard solutions with different concentration of pure paracetamol were also measured 
(CRef 1 = 0,99 mg/mL, and CRef 2 = 0,87 mg/mL), in order to calculate the concentration of the 
samples from the A value with the following formula: 
  
𝑃𝑎𝑟𝑎𝑐𝑒𝑡𝑎𝑚𝑜𝑙 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 (𝑚𝑔/𝑚𝐿) =
 𝐶𝑅𝑒𝑓 1 𝐴𝑇𝑠𝑡 
𝐴𝑅𝑒𝑓1 
 
A linearity study was also carried out, to ensure that the measurements are within the linearity 
area. For this step, the absorbance of 8 parent solutions of paracetamol with concentrations 
ranging from 0,20 mg/mL to 2 mg/mL were measured (see Figure 6.7).  
 
Figure 6-7: Absorption measurement of the solvent and of the parent solution having different concentrations. 
As shown on Figure 6-8, R²=0,9999 which means that all Paracetamol concentration between 
0,20 mg/mL to 2 mg/mL is within the linear area. 
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Figure 6-8: Linearity range of the measurement method. 
6.4.2 Statistical Analysis 
A one-way ANOVA with a significance level α=0,05 and a Tukey Post hoc were performed 
in order to study the statistical difference of content of uniformity between the 6 formulations 
F1 to F6. 
Anova: Single Factor    
     
SUMMARY    
Groups Count Sum Arith. Mean Variance 
F1 10 971,202556 97,1202556 8,659769279 
F2 10 985,9546705 98,59546705 17,47546405 
F3 10 974,1390779 97,41390779 1,313036403 
F4 10 943,2125779 94,32125779 73,09354891 
F5 10 1016,437991 101,6437991 1,537917813 
F6 10 1053,528631 105,3528631 0,463464134 
     
ANOVA       
Source of 
Variation 
Square Sum 
(SS) 
Degrees of 
Freedom (df) 
Mean Suare sum 
(MS) 
Test Value 
(F) P-Value F crit. 
Between 
Groups 754,1856317 5 150,8371263 8,825770532 
3,602E-
06 2,38606986 
Within Groups 922,8888053 54 17,09053343    
       
Total 1677,074437 59         
 
P-value << α, that is why a difference of content of uniformity can be statistically noticed 
between the 6 formulations F1 to F6. In order to detect between which groups exactly a 
statistical difference exists, a Tukey post hoc test was carried out. 
Honnest Significant Difference (HSD) qα /(MSE/n)1/2 5.4384 
Multiplier qα read in the table “Critical Values for the Tukey Q Test” 4.16  
Mean Squared Error (MSE) SS/df (within groups) 17.09053 
N Count 10 
y = 0.6723x + 0.0013
R² = 0.9999
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0.00 0.50 1.00 1.50 2.00 2.50
A
b
so
rp
ti
o
n
Concentration (mg/mL)
Linearity
Paracetamol
Linear (Linearity
Paracetamol)
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The difference between the arithmetical means of each batch was then calculated.  
 F1 F2 F3 F4 F5 F6 
F1 0 -1,48 -0,29 2,8 -4,55 -8,23 
F2     1,19 4,28 -3,07 -6,75 
F3       3,09 -4,26 -7,94 
F4         -7,35 -11,03 
F5           -3,68 
F6             
 
As the absolute value of the yellow marked values is above HSD, it can be concluded that 
there is a statistical difference in the content of uniformity between F1-F6, F2-F6, F3-F6, F4-
F6 and F4-F5.  
6.5 Sedimentation Study  
6.5.1 Sedimentation Within The Pipette 
Formulation t-value Critical t-value Conclusion 
10 mL 
pipette 
7.000 
2,101 
Read in the t-table 
(SanJoséStateUniversity, 
2007). 
t-value > critical t-value, hence 
significant difference between the 
beginning and the end of pipetting. 
25 mL 
pipette 
3.061 t-value > critical t-value, hence 
significant difference between the 
beginning and the end of pipetting. 
50 mL 
pipette 
2,890 t-value > critical t-value, hence 
significant difference between the 
beginning and the end of pipetting. 
6.5.2 Sedimentation Within The Lyocs® 
Formulation t-value Critical t-value Conclusion 
F1 1,771 
2,228 
Read in the t-
table 
(SanJoséState
University, 
2007). 
t-value < critical t-value, hence no significant 
difference between the top and the bottom of the 
Lyoc®. 
F2 1,802 t-value < critical t-value, hence no significant 
difference between the top and the bottom of the 
Lyoc®. 
F3 2,635 t-value > critical t-value, hence significant difference 
between the top and the bottom of the Lyoc®. 
F4 2,970 t-value > critical t-value, hence significant difference 
between the top and the bottom of the Lyoc®. 
F5 1,909 t-value < critical t-value, hence no significant 
difference between the top and the bottom of the 
Lyoc®. 
F6 1,476 t-value < critical t-value, hence no significant 
difference between the top and the bottom of the 
Lyoc®. 
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